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ABSTRACT 
 
 
 
 
FROM DIATOMS TO MALARIA: SYNTHESIS AND APPLICATION OF 
FUNCTIONAL MATERIALS 
 
 
JOSHUA DAVID SWARTZ 
 
Dissertation under the direction of David Wilson Wright 
 
This dissertation focuses on two unique projects that attempt to solve two unique 
challenges. Biomimetic syntheses provide scientists the opportunity to develop functional 
materials that aren’t available with traditional synthetic processes. Diatoms, for example, 
are capable of designing intricate silica structures under mild reaction conditions using 
amine-terminated polymeric organic compounds and post-translationally modified 
peptides. The goal of this half of the thesis was to capitalize on the simplicity and ease of 
morphological control to encapsulate functional enzymes such as nitrilase and -
glucosidase within the growing silica matrix. This matrix serves to protect the enzymes 
from degradation and enhances their shelf-lives. Also, piezoelectric inkjet printing 
techniques were utilized to pattern these enzyme-encapsulated substrates onto reactive 
surfaces toward the design of functional materials. The second half of this thesis focuses 
on developing alternative strategies for malarial diagnostics. Malaria is a tropical disease 
caused by the Plasmodium parasite. Its prevalence in most developing countries creates a 
financial burden on both the residents of these regions, as well as the health organizations 
trying to eradicate the disease. With the development of antimalarial drugs such as 
 xiii 
chloroquine, malaria was nearly eliminated in the middle half of the 20
th
 century. With 
the development of parasitic resistance, malaria has reemerged as one of the most 
dangerous diseases in the developing world. Paramount to effective treatment is accurate 
and efficient diagnosis of patients in low resource settings. Although significant progress 
has been made toward diagnostic strategies in these settings, the current “gold standards” 
still are not capable of being effective in the most remote regions, due to their reliance on 
electricity or sensitive reagents. The second half of this thesis is focused on 
circumventing the challenges of low resource diagnostics through alternative diagnostic 
strategies and novel sample processing technologies. Using surface tension valving to 
separate aqueous processing chambers, complex biological samples can be processed to 
collect, purify, and concentrate biomarkers for malaria diagnosis. Capitalizing on the high 
affinity of the malarial protein Histidine-Rich Protein II (pfHRP-II) towards Ni(II)NTA 
chelation, this sample processing technology has been demonstrated to collect and isolate 
this protein from human whole blood and plasma with modest yields. To circumvent the 
challenges associated with current diagnostic strategies, a novel coffee ring diagnostic 
has been developed that captures the biomarker of interest and processes it within the 
drying drop. Utilizing radial flow, this assay is capable of concentrating a signal into a 
small ring visible by the naked eye. This is the first time that this phenomenon has been 
used as a diagnostic platform. Whether it is for improving enzyme longevity or 
diagnosing malaria in the field, these functional materials serve to improve the overall 
wellbeing of mankind.      
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CHAPTER I 
 
BIOMIMETIC SYNTHESIS OF SILICA NANOMATERIALS 
 
Introduction 
 Traditionally, synthetic approaches for the production of functional metal oxide 
materials such as silicon dioxide (silica; SiO2) have involved high-temperature reaction 
environments with energy intensive techniques such as laser ablation, ion implantation, 
chemical vapor deposition (CVD), photolithography, or thermal decomposition.
4
 The 
incorporation of these techniques provided a rapid prototyping technique, essential for the 
commercial development of current minimum-feature sized semiconducting integrated 
circuits. However, the production of these devices has come at a major price. Some of the 
primary challenges currently faced by high-throughput fabrication laboratories include 
the high cost of laborers and instruments, high temperature reaction conditions, and a 
surplus in generated waste.
4
 In fact, the cost of fabrication facilities are estimated to reach 
an outstanding $100 billion dollars per facility by the year 2020, as the demand for 
smaller, lighter, and faster materials continues to grow.
4
 Additionally, manufacturers are 
progressing in this manner at the expense of the environment, as they accumulate 
hazardous chemical wastes.
22
 For decades, researchers have been searching for 
alternative methods to passivate the rate of waste production and the cost of spending in 
the semiconductor industry.  
 The most accessible resource for the synthesis of functional materials under ambient 
conditions is found in biology. From highly ordered nanostructures to genetically 
2 
 
controlled reactive surfaces, systems in biology perpetually demonstrate their ability to 
find effective solutions to multifaceted, real world problems using a rigorous process of 
natural selection.
23-27
 The versatility of biology’s incredible portfolio encourages 
researchers to develop modified syntheses derived from nature. Their findings have been 
successfully organized into the field of biomimetics, or bio-inspired research, which 
encompasses alternative approaches towards developing nonmaterial’s with technological 
applications.
28
 Based primarily on the designs, mechanisms, and processes found in 
nature, biomimetics encompasses the field of structural biology while interfacing 
engineering, materials science, physics, and chemistry.
24,28
  
 Biomimetics infers manipulating and mimicking the natural architectures and 
processes of biologically produced minerals, or biominerals, to direct the synthesis of 
non-natural materials. For instance, the architecture of one of the most abundant 
biological species on the planet, the virus, has recently been manipulated to serve as 
containers for the synthesis of a variety of functional molecular cargoes.
29,30
 In particular, 
the positively charged interior of the cowpea chlorotic mottle virus (CCMV) has been 
used as a container for the nucleation of spatially confined metal oxide nanomaterials.
30
 
On a larger and more complex scale, versatile strategies for substrate modification have 
been developed directly, through inspiration from surface mediated mineralization of 
biological organisms.
23
 The eggshell matrix proteins from the Chinese soft-shelled turtle 
(composed primarily of aragonite, CaCO3) were isolated and revealed properties that are 
necessary for embryonic survival.
23
 It was suggested that the matrix proteins contained 
pelovaterin peptides as their major unit that self-assembled into micelles, altering the 
interfacial energy of the eggshell.
31
 Applications of such controlled mineralization could 
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be applied to the successful construction of functional two-dimensional (2D) reactive 
surfaces, with reduced nonspecific adsorption.
32-35
  
As mentioned above, bio-inspired research is based on identifying and emulating the 
principles of biomineralization in natural systems instead of copying them directly. In 
fact, most strategies incorporated by natural systems are not directly applicable to 
engineered materials, so the need for alternative synthetic routes are required for the 
incorporation of non-natural elements, such as barium, nickel, copper, or aluminum, with 
functional nanoscale properties.
4,28
 From a materials perspective, highly intact biological 
structures such as diatoms, bacteria, proteins, or butterfly wings provide an excellent 
source of inspiration for their synthesis.   
 
Metal Oxides in Nature 
There have been as many as 60 identified biominerals that are necessary for the 
proper function of organisms, and more than 60% of them are reported to be coordinated 
to either hydroxyl moieties or water molecules, enabling the rapid release of ions in 
solution.
27
 Metal oxides, in particular, provide a fundamental stepping-stone for the 
development of functional nanomaterials. In the oxidative environment of the atmosphere 
of the Earth, oxides are the lowest free energy states for most metals in the periodic table 
and have applications ranging from semiconductors to insulators.
36
 As insulators, SiO2 
and Al2O3 are the two most commonly used supports for catalysis, as they are non-
reducible oxides.
36
 Semiconductors, such as ZnO and SnO2, have high electrical 
resistivities that provide alternative templates for  gas sensors.
36
 Currently, 
microelectronics rely on bulk silica as an important dielectric material that is often used 
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as an insulating template for further reactivity. On the nanoscale, silica can be 
synthesized by polymerizing silicic acid in an aqueous system or through hydrolysis and 
condensation of silicon alkoxides in the Stöber synthesis.
37
 The mechanism of these two 
methods is unique. The first method is dominated by monomers and tetra-functionalized 
species. The resultant silicate sols are uniform, meaning that they are fully hydrolyzed 
and grow by monomer addition. On the other hand, di- and tri-functionalized species are 
dominant for alkoxides. Regardless of the synthesis used, these particles induce a fractal 
interior with minimal morphological control due to their common template, ammonium 
hydroxide.
37
   
Surprisingly, the properties associated with metal oxides in technology are not so far 
removed from what is observed in natural systems. Through precisely tuned processes, 
Nature is able to synthesize a variety of metal oxide nanomaterials under ambient 
conditions. The magnetic navigation device found in magnetotactic bacteria (MTB) is 
one such example.
38
  Magnetite (Fe3O4) nanocrystals are aligned with the Earth’s 
geomagnetic field and are contained within specific organelles known as 
magnetosomes.
38
 Fresh water salmon, for example, utilize these magnetic nanoparticles 
in the nasal cavities of their forehead as a biomagnetic compass during migration.
39
  
 
Diatoms 
Diatoms are one of the largest groups and perhaps one of the most studied single-
celled eukaryotic micro algae found in almost every sea- and freshwater habitat. These 
microorganisms have silica-based cell walls, which range in size from ~50 to 500nm 
(Figure 1).
40
 Although diatom silica is X-ray amorphous, they still exhibit highly regular 
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and rather exquisite patterns of pores, ridges, or tubular structures that are formed under 
genetically controlled processes. Studies using electron microscopy have revealed that 
the valves and girdle bands associated with silica formation are formed inside the cell 
within highly specialized membrane-bound compartments called silica deposition 
vesicles (SDVs).
32
 After morphogenesis is completed, these silica species are deposited 
on the cell surface using SDV exocytosis. 
 
 
Biological Synthesis of Silica Nanoparticles 
Specific silicon transport proteins (SITs) produced by diatoms are responsible for the 
uptake and delivery of orthosilicic acid (Si(OH)4, pKa = 9.8) to the diatom. Within the 
cell, orthosilicic acid is then concentrated up to 1000-fold, resulting in the condensation 
of amorphous, hydrated silica.
5
 Strikingly, poly-condensation of silica occurs in neutral to 
slightly acidic pH conditions under ambient temperatures and pressures. Although these 
conditions are considered mild, diatoms still have control over the product morphology. It 
Figure 1. Scanning electron microscopy images of the cell walls of a variety of diatom species.
5
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is understood that the patterns created by diatoms are species specific, so their directed 
grown process must be regulated by transcription.
37
 
Significant effort has been devoted to determining the specific templates used by 
different species of diatoms in silica formation. Although diatom cell walls consist 
primarily of silica doped (~97%) with trace amounts of aluminum and iron, they also 
contain a wide variety of incorporated organic molecules and proteins.
41
 In fact, solid-
state nuclear magnetic resonance (NMR) spectroscopy revealed that some these 
molecules and coat proteins are encapsulated within the silica matrix.
42,43
 Two main 
templates for silica growth were identified after dissolution of the silica cell wall with 
hydrogen fluoride (HF) or ammonium fluoride. 
Extracted and purified from up to three species of diatoms (C. fusiformis, T. 
pseudonana, and E. zoodiacus), silaffins are polypeptides (4-17kDa) with a variety of 
posttranslational modifications, including propylamino-functionalized lysine side chains 
(Figure 2).
40
 Currently, there have been four silaffin genes identified (one from C. 
fusiformis (sil1) and three from T. pseudonana (tpSil1, tpSil2, and tpSil3)), which encode 
for eight known polypeptides. Of these four genes, only tpSil1 and tpSil2 have shown 
sequence similarities, likely from gene duplication; however, the overall lack of sequence 
similarity strongly suggests that the posttranslational modifications of silaffins are critical 
to their function. These posttranslational modifications include mono-hydroxylation of 
lysine and proline, di-hydroxylation of proline, o-phosphorylation of serine, threonine, 
hydroxyproline and hydroxylysine, glycosylation, sulfation of carbohydrate moieties, and 
alkylation of -amino groups of lysine.41,44 These modifications are charged and 
stabilized through electrostatic interactions between the phosphate groups on one silaffin 
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to the charged amines of another, inducing a self-assembled template available for further 
reactivity.  
 
 
The different structures associated with different species of diatoms are directly 
related to the silaffin being studied. For instance, spheres (silaffin-1/2L mixture from T. 
pseudonana
45
), dense plates (silaffin-3 from T. pseudonana
45
), or porous sheets (silaffin-
1/2H mixture from T. pseudonana
45
 or natSil-2 from C. fusiformis
46
) are all a function of 
a precursor template. While silaffins are responsible for controlling which shapes formed 
in the SDV, positively charged long-chain polyamines (LCPAs) are an integral part of 
silica condensation.
5
 The silaffins that are negatively charged must be stabilized by the 
LCPAs, or the recently discovered silacidins
47
 (in T. pseudonana), to complete silica 
condensation. 
LCPAs are non-protein components (>3.5kDa) that were found encapsulated in the 
silica matrix of the diatom and were isolated through a series of HF extractions.
48
 Unlike 
silaffins, which utilize a peptide backbone, these polyamines consist of linear chains of 
C-N linked propyleneimine units that are bonded to a putrescine or putrescine derivative 
Figure 2. Chemical structure of silaffin-1 A1 from C. fusiformis.
20 
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backbone. The chemical composition of these long-chain polyamines is unique for each 
diatom species, with variable repetitions and degrees of methylation.  
Similar to reactivity of silaffins, silica production in the presence of LCPA and silicic 
acid requires an addition of counter anion in the form of phosphate, sulfate, or citrate 
ions. This electrostatic matrix is projected to induce the formation of silica by 
microscopic aggregation of LCPAs and subsequent phase separation into a LCPA-anion-
rich microdroplet.
32
 In his 2002 theory of cell wall morphogenesis, Manfred Sumper 
suggested that the formation of secondary patterns, as seen on the diatom cell wall, is 
related to the wall-to-wall distance of the areolae, hexagonally packed polyamine 
monolayers and the polyanion concentration, on the surface of the SDV.
32
 For example, a 
size-control experiment using LCPAs from S. turris has shown that the size of  
nanoparticles was dependant not only on the phosphate concentration, but also whether 
orthophosphate or a more highly charged pyrophosphate was used.
49
  
 
Biomimetic Synthesis of Silica Nanoparticles 
The biological mechanism of diatom silica formation has been demonstrated as a 
valuable source for bioinspired templates for non-natural metal oxide synthesis at 
ambient temperatures and near-neutral pH. Moreover, silica nanostructures can be tuned 
according to a specific template, providing functional properties that can be directly 
applied in designing nanomaterials. These syntheses have integrated moieties that are 
tuned for a specific function, such as encapsulation of functional enzymes
9,50
  and 
controlled construction of nanomaterials through nanoscale building blocks.
15,17,51
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Mimicking the nanopatterns of the diatom cell wall still remains a great challenge for 
materials scientists because the natural reaction mechanism still unknown, as many 
essential components to silica precipitation have yet to be discovered. However, it is well 
known that the terminal amine templates interact with monosilicic acid to induce the 
specific morphology of the resultant silica. A variety of different silica pre-cursors have 
been used with a number of templates, including tetramethyl orthosilicate 
(TMOS),
6,7,9,14,52-56
 tetraethyl orthosilicate (TEOS),
10,17,57
 tetrakis(2-hydroxyethyl) 
orthosilicate (THEOS),
10
 sodium silicate,
51
 a silicon-catecholate complex,
15,58
 and 
dipotassium Tris(1,2-benzenediolato-O,O’) silicate.11 In addition, a variety of bio-
inspired templates have been used, including synthetic and natural polypeptides,
17,52,57
 
polyamines,
6,56,58
 and even modified organic materials, including cellulose
59
 and 
chitosan.
60
 
Recently, synthetic or natural polypeptides have been created or modified to serve as 
silica condensation templates. Many examples of these polypeptides include the 
poly(amino acids),
61
 the diatom-derived R5-peptide,
52
 chimeric polypeptides,
14,15
 block 
co-polypeptides,
54,55,57,62
 lanreotide,
17
 and even the naturally occurring protamine.
51
 
These polypeptides have been used to produce a variety of silica shapes and sizes, which 
can be tuned to perform a variety of applications, including transport and separation of 
encapsulated materials
9
, or potentially for drug delivery.
56
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Peptide and Peptide Derivatives 
R5 Peptide 
The R5 peptide (H2N-SSKKSGSYSGSKGSKRRIL-CO2H) is an unmodified 
biomimetic analog of the silaffin precursor peptide (sil1p) in C. fusiformis that exhibits 
silica condensation activity at neutral pH in a buffered phosphate-citrate solution.
34
 These 
peptides self-assemble into an ordered matrix through electrostatic interactions facilitated 
by the cationic lysine and arginine residues and the anionic citrate and phosphate ions, 
providing an ordered template for silica condensation. Capitalizing on the high charge 
associated with this peptide-salt complex, several enzymes have been encapsulated 
within the silica matrix with the R5-peptide as the silica template, including catalyase, 
horseradish peroxidase, and butyrylcholinesterase.
50,52
 The silica matrix provides an inert 
cage around the enzyme which not only protects it from the surrounding environment and 
increases its shelf life but it could also provide the basis for biosensors and catalysts. In 
addition, CoPt, CdSe and ZnS nanoparticles were also successfully encapsulated into the 
silica matrix.
50
 These magnetic nanoparticles could serve a wide variety of applications, 
including catalysis, biological labeling and detection, and electronics.
7
 In addition, these 
encapsulated magnetic particles have potential use in enzyme encapsulation because they 
could provide a physical means to separate the enzyme from the reaction mixture.      
Chimeric (fusion) proteins that incorporate the R5 peptide have also been synthesized 
to control and precipitate silica nanoparticles. Po Foo and coworkers have utilized a two 
component chimeric protein consisting of the R5 polypeptide (from C. fusiformis) and the 
self-assembling domain based on the consensus repeat in the major ampullate spidroin 
protein 1 (MaSp1) of N. clavipes spider dragline silk.
15
 MaSp1 forms highly stable -
11 
 
sheet secondary structures that can be spun into intricate fibers, which when fused with 
the silica-templating R5-peptide, allow for the formation of film-like and fibrous silica 
structures (Figure 3). 
 
 
Two different silk motifs were investigated, one with and one without a CRGD cell-
binding motif. When silica precipitation was conducted under ambient temperatures and 
near-neutral pH with ratios of Si:N = 22:1 in solution, silica nanospheres with >1µm 
diameter were synthesized for both fusion proteins. Thermal analysis determined that 
~90% of the material was the templating protein and the remaining 10% was silica. 
Nitrogen absorption analysis indicated a pore radii <10 angstroms and a low surface area 
(~10m
2
/g), which are smaller than the R5-peptide templated silica nanospheres (pore 
radii = 35 angstroms and surface area = 600m
2
/g). Although silica precipitation was 
Figure 3. Schematic representation of the fusion protein and its use in controlled silica nanomaterial 
formation. A.) Schematic of the chimeric polypeptide consisting of the R5 and silk polypeptides. B.) 
Model of R5-silk polypeptide processing into films and fibers and subsequent silification reactions.
15
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successfully conducted with the free R5-silk peptide in solution, the silk moiety provides 
a means for size and shape control for the growing silica nanocomposite. When these 
chimeric proteins were spun into fibers via electrospinning, silica nanospheres were 
formed with much smaller diameters (200-400 nm). In addition, when the chimera 
CRGD15mer + R5 was electrospun concurrently with the silica condensation reaction, 
silica was deposited in and on the fibers, resulting in elliptically shaped silica particles 
that were fused to the fibers. As a result, processing modifications can be tailored to 
structural templates, inducing silica nanoparticles of specific sizes and morphologies. 
Most importantly, since this reaction is conducted under mild conditions, these fibers 
have a variety of potential applications in specialty materials, including those used in the 
biomedical field.
15
  
Another chimeric polypeptide consisting of the R5-peptide and a self-assembling 
hydrophobic-phobic (HP) protein monomer capable of self-assembly was also used to 
direct silica precipitation in vitro at neutral pH and ambient temperatures.
14
 The HP 
monomer consists of an n-AEAEAKAKAEAEAKAK-c sequence, called EAK1. These 
monomers self-assemble into stable -sheet supramolecular structures due to their binary 
patterns. This leads to hydrophobic and hydrophilic faces, where favorable side-chain 
interactions result in aggregation through hydrophobic and electrostatic interactions, 
respectively. Thus, an EAK1–R5 chimeric polypeptide assembles into fibrous aggregated 
hydrogels and precipitates silica nanospheres with sizes dependant on the reaction 
temperature (Figure 4).  
13 
 
 
 
The size distribution of the control R5 template for silica formation produced a 
distribution of nanoparticles in the diameter range of 402-530 nm, as opposed to the R5-
EAK templates, which showed a bimodal range of diameters from 63-103 nm and 385-
541 nm respectively. However, at higher temperatures, the R5-EAK1 peptide promotes 
rapid nucleation, resulting in a loss of bimodal character and subsequently the production 
of smaller silica nanoparticles (64-116 nm in diameter). Not only does the change in 
diameter size with different temperatures allow for the production of size-specific 
tailored silica nanocomposites, but also the loss of bimodal character at higher 
temperature allows for an even tighter control of silica structure under these conditions. 
By adjusting this morphology under mild reaction conditions, biologically active matrices 
can be synthesized, and could be used in solid-state enzymatic catalysis, physiologically 
active biomatrix implants, and potentially biosensors.
14
  
 
 
 
Figure 4. Sphere diameter distribution for silica particles precipitated using R5 peptide (black, left) and 
R5-EAK1 (white, left) and the sphere size distribution for silica particles formed with R5-EAK1 at 
different temperatures (right).
14
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Poly-L-Lysine 
Poly-L-lysine (PLL) has been implicated in silica formation because of its ability to 
adopt a -helix, -sheet, or random coil conformation under controlled conditions. For 
example, PLL is a random coil at neutral pH, but at high pH (~11) the polymer assumes a 
-helical shape. Hawkins and coworkers have shown that silica pore sizes could be 
modified by changing the secondary structure of the polyamine.
63
 For example, silica 
composites that are formed by -helix PLL under basic conditions (pH 11.2) produced 
1.5 nm pore sizes; on the other hand, silica formed using PLL -sheets (heated to ~52oC) 
resulted in larger pore sizes (~1.5-8 nm). In both cases, silica formation was dependant 
on the PLL concentration and reaction conditions.  
More recently, Tomczak and coworkers have shown that hexagonal silica platelets 
can be synthesized using PLL as a precursor.
18
 The morphology of silica species is highly 
specific to the size of the PLL polymer used. Larger molecular weight PLLs (>100 
lysines) produced hexagonal silica platelets, while lower molecular weight PLLs afforded 
silica nanospheres. Although PLL is a random coil at near-neutral pH (7.5), electrostatic 
interactions between the larger PLL templates and the silica promotes a -helical 
structure formation during condensation, resulting in hexagonal plates (Figure 5).  
 
Figure 5. Proposed model of PLL induced condensation of silica platelets.
18
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Gautier and coworkers have also utilized PLL by incorporating the template into the 
pores of polycarbonate membranes to further control the silica size and morphology.
13
 
Silica formation within confined spaces is important for a variety of materials 
applications. For example, silica encapsulated enzymes integrated into a micro or nano 
filter could be used in catalysis, where the substrate would pass through the membrane, 
interact with the enzyme, and pass through the filter as the product.   
Rod-like silica tubes were synthesized once PLL was integrated into polycarbonate 
membrane pores (sizes ranging from 1200 nm, 400 nm, and 200 nm) (Figure 6). Multiple 
successive impregnations (5 times) of the pores with sodium silicate resulted in the 
formation of a silica-filled pore. The thickness of the silica wall decreased as its pore size 
decreased. In addition, TEM analysis determined that the primary particle diameter was 
independent of the pore size (~9 nm). However, this primary pore diameter was smaller 
than for silica formed on the surface (~11 nm), which is likely the result of PLL 
localization in the pore rather than silicate-PLL interactions.  
 
 
Figure 6. Schematic of silica tube formation. (a) PLL is first integrated onto the surface of the pore. (b) 
Addition of silicates initially results in the formation of a silica shell. (c) Multiple additions of silicates 
thicken the silica shell. (d) Further addition of silicates results in core particle growth.
13
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Block Co-Polypeptides 
Block co-polypeptides have also been used as templates for controlled silica 
formation.
54,55,57,62
 These polypeptides consist of covalently linked domains (domains) of 
hydrophilic and hydrophobic polypeptides. Due to their unique polarities, these block 
segments induce an amphiphilic character, resulting in self-assembled vesicles in aqueous 
solution.
57
 For example, a co-polypeptide consisting of polymers of linked lysine and 
glycine residues (Lys-b-Gly), was used as a silica template in the presence of orthosilicic 
acid and phosphate buffer at pH 7.2.
55
 Different methods of silica precipitation were 
tested by changing the amount of silica pre-cursor or the amount of phosphate present 
during precipitation. Method I used 6 mmol of silica pre-cursor, while Methods II & III 
used 30 mmol. In addition, Method III had 7.5 mmol more phosphate buffer than the 
other two methods (0.1 M). An increase in phosphate buffer (Method III) resulted in a 
spherical morphology (40-120 nm in diameter) while the other two methods either 
produced mostly platelets for the Lys-b-Gly block copolypeptides (Table 1).  
 
 
The formation of platelets or spheres with the Lys-b-Gly copolypeptide suggested 
that there was a morphological dependence on the phosphate concentration and the 
solubility of the hydrophobic block. As a result, by optimizing the hydrophobicity of the 
Table 1. Silica morphology for each copolypeptide at different synthesis conditions.
8 
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template and the phosphate concentration, specific morphologies can be obtained. As the 
relative hydrophobicity was increased though the addition of glycine residues, 
substitution of the glycine block with the more hydrophobic alanine block, or the loss of 
lysine residues, the solubility of the copolypeptide was decreased, making it more 
susceptible to phase separation. The hydrophobic block was more energetically stable 
when it was associated rather than by being free in solution. Aggregation of this region 
was induced and spherical silica condensation was promoted instead of platelets. In 
addition, an increase in phosphate ions (Method III) had a similar effect by 
electrostatically interacting with the hydrophilic lysine block and promoted silica spheres. 
Platelets from Method II are smaller than those from Method I, caused by the higher 
concentration of silica pre-cursor and subsequent increase in the rate of nucleation 
(Figure 7).  
 
Figure 7. Field-emission scanning electron microscopy (FE-SEM) images of silica nanoparticles 
synthesized using (left) Lys340-b-Gly85 and (right) Lys320-b-Gly160 using (top to bottom) Methods I, II, 
and III respectively.
8 
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Lanreotide 
Cyclic lanreotide is a dicationic octapeptide that self-assembles into nanotubes in 
water with a monodispersed diameter of 24.4 nm and a wall thickness of 1.8 nm.
17
 This 
polypeptide has two exposed protonable amine groups that can be used as catalytic sites 
for silica condensation (Figure 8). By exposing the nanotubes to a TEOS-derived 
Si(OR)3O
-
 precursor, silica was deposited and bundles of silica nanofibers were formed 
with a total length as long as 7 µm. Each nanotube extended as long as 3 µm.  
 
Figure 8. Synthesis of lanreotide-templated silica nanotubes. A.) Structure of lanreotide showing the 
two charged amine sites responsible for silica condensation. B.) Dynamic templating model for the 
mechanism of silica condensation into nanofibers. The cationic lanreotide nanotube surface utilizes 
electrostatic attraction to catalyze silica condensation (step C) and the anionic silica deposit promotes 
additional lanreotide assembly (step Ton) through neutralization of the system.
17
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TEM analysis determined that the dried fibers consisted of bundles of aligned nanotubes 
with homogeneous inner and outer diameters of 14-16 nm and 28-30 nm respectively. In 
addition, the two concentric tubes were both 1.4 nm thick, and were separated by 2 nm, 
which is the approximate width of the lanreotide molecule. The proposed dynamic 
templating mechanism suggested that the cationic lanreotide nanotube surface catalyzed 
the silica condensation by electrostatic forces, and the consequent anionic silica deposits 
promoted additional lanreotide assembly through synergetic neutralization of the entire 
system. Not only does this templating mechanism provide insight into the potential 
fundamental mechanisms used in biological systems, it also allows for the production of 
superstructures that greatly exceed the size of the original template.
64
 Consequently, a 
variety of new silica structures could be synthesized that maintain nanoscale properties 
even in the microscale or larger.        
 
Polyamines 
 Non-peptide biomimetic analogs to silica precipitating peptides are inspired from the 
isolated LCPAs found on the cell walls of diatoms. Some of these polyamines include 
poly(allylamine) (PAA),
61
 poly(ethyleneimine) (PEI),
56
 N-methylpropylamine (PA),
58
 
and amine-terminated dendrimers.
6,7,9,53
 Each of these classes of compounds represents a 
different structural aspect to silica templating, including the number of amines, the 
number of spacer atoms between the amines, its relative degree of methylation, and the 
presence and number of branching elements. All of these factors alter the resultant 
physical properties and subsequent reactivity of the silica nanoparticle produced.  
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Poly(ethyleneimine) 
Poly(ethyleneimine) (PEI) is a branched polyamine (Mw = 1800) consisting of a 1:2:1 
ratio of primary, secondary, and tertiary amines that makes it structurally similar to 
polyamines isolated from S. turnis and C. fusiformis.
65
 These PEIs were integrated as 
spherical reverse micelles (RMs) made from bis(2-ethylhexyl) sulfosuccinate sodium salt 
(AOT) in isooctane, providing a constrained environment for silica precipitation. These 
RMs exchanged their contents quickly through fusion and redispersion processes (106-
108 m
-1
s
-1
). Consequently, PEIs reacted with silicic acid from a tetramethylorthosilicate 
(TMOS) precursor produced silica nanoparticles with size and structure control 
dependant on the size of the RM.
56
 Before testing silica precipitation in the RM, 
condensation of silica was investigated at a variety of pH values (6.3-11.2) in water. 
Instantaneous precipitation occurred at basic pH (9-11), slow deposition of amorphous 
silica matrix occurred at near-neutral pH, and no precipitation occurred for acidic pH 
(Figure 9). This lack of activity is likely caused by the absence of anionic constituents 
(ions or polymers) in neutral or acidic solutions, which are critical for the self-assembly 
of the amine-functionalized template.  
 
Figure 9. Diameter and dispersity of silica particles formed in aqueous PEI solutions at 0.05M primary-
amine concentration and 1M silicic acid in a 4:1 volume ratio at pH 9, 10, and 11. SEM images of the 
nanoparticles are provided as inserts, and the silica formed in pH 7 and pH 8 is provided on the left.
12
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Consequently, it was expected that PEI would provoke similar pH dependence once 
reacted with the RM. However, when PEI and silicic acid were incorporated into the RMs 
prepared in isooctane, the initial pH of the amine solution was negligible in terms of 
controlled silica growth. This was confirmed by testing the AOT pH w/ 8-
hydroxypyrene-1,3,6-trisulfonic acid (HPTS). It was determined that the local pH stays 
consistent (>= 9), independent of the pH of the inserted PEI. In addition, alterations of 
the size of the water pool wo = 5-40 (wo = [H2O]/[AOT]), produced a variety of particle 
sizes. The smallest RMs (wo = 5) fashioned very small amounts of silica due to the tight 
interactions between the water molecules, the anionic sulfonate groups of the AOT, and 
cationic sodium ions. Larger RMs (wo = 10) resulted hollow silica shells, with diameters 
on the order of 1m. In this case, the RM remained stable during the reaction, and the 
silica units only interacted by micellular exchange. For the largest reverse-micelle sizes 
wo >= 20, destabilization of the RM occurred because of the addition of additional water 
molecules in the RM from the condensation of silanol groups, thus increasing the w0 
during the reaction. 
Initial w0 = 20 RMs became unstable as soon as the reaction was initiated, resulting in 
tri-modal nanosphere diameter distributions (56+-6 nm, 172+-31 nm, and >200 nm 
respectively). This suggested multiple destabilization pathways of the RMs during the 
condensation, resulting in different silica sizes. Moreover, the morphology of the silica 
was determined by the size of the RM, as well as its stability during the condensation 
reaction. By understanding the mechanism of this reaction, the sizes and shapes of silica 
were tuned to serve a variety of functions, including an inert matrix for catalysis, drug 
delivery, and transport.
66
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Other Unbranched Polyamines 
To assess the role of polyamine structure in controlling the morphology of silica 
nanoparticles, Belton and coworkers utilized several polyamines with different degrees of 
polymerization, different levels of amine methylation, and different lengths of amine 
chain spacers (Figure 10).
11
 The degree of polymerization was evaluated by comparing 
two naturally occurring polyamines, spermidine and spermine, to the other synthetic 
polyamines. Amine methylation was investigated through a set of N,N’-(bis-3-
aminopropyl)-1-3-diaminopropanes with levels of methylation from 0 to 4. For each 
experiment, dipotassium Tris(1,2-benzenediolato-O,O’)silicate served as the silica 
precursor. 
 
  
 For all of investigated samples, there were mixtures of solid and hollow particles 
associated with the number of amines per molecule, the amine-amine separation, and the 
size of the polyamine. The larger propylamines, which are the most hydrophobic and 
most readily form microemulsions, were the most efficient in generating hollow silica 
nanoparticles. Hollow silica nanoparticles are of particular interest due to their potential 
Figure 10. Structures of unbranched polyamines. a.) Ethyleneamines. b.) Propylamines. c.) Natural 
amines spermine and spermidine. d.) C3N3 with varying degrees of methylation.
11
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applications in adsorptive filters, ultrasound imaging, photonic band gap materials, and 
catalysis.
67
 
Two critical factors were identified for controlling the nature of the resultant silica 
composite in this reaction. First, the template’s ability to produce microemulsions 
determined whether solid or hollow silica was formed (Figure 11).
11
 Second, the reaction 
kinetics of the composite was shown to increase according to the degree of charge 
associated with the microemulsions. A positively charged microemulsion introduced a 
water-free microenvironment, where water removal promoted the condensation of 
controllable silica.  
 
  
 The kinetics of each silica condensation reaction was quantified using the 
molybdenum blue method, which is sensitive to mono- and dimeric- silicic acid. Within 
the initial condensation time, there is a third-order linear relationship between [Si(OH)4]
2-
 
and time. As a result, it was concluded that polyamines with a three-fold increase in their 
third-order rate constant were kinetically active. All of the propylamines and longer chain 
ethyleneamines significantly influenced condensation rates, with C3N7 having a 14-fold 
increase in catalytic activity. C2N2-4 and the naturally occurring polyamines spermidine 
Figure 11. Schematic representation of the microemulsion formation leading to hollow silica 
structures.
11
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and spermine observed no rate enhancement. These results suggest that there is a direct 
correlation between template size and its ability to catalyze silica formation. In addition, 
increasing the methylation levels in the C3N3 species also increased the third-order rate 
constant. For all of the kinetically active species, the silica nanoparticles produced were 
nonporous, which is likely due to rapid nucleation. Thus, by modifying the composition 
of the polyamine, the ability to produce microemulsions which lead to hollow silica and 
the porosity of the silica can be tailored, leading to the production of a variety of potential 
nanomaterials.
11
  
 
Dendrimers 
Amine terminated dendrimers are unique, uni-molecular polymer templates with 
defined reactivity as a function generation size (the number of branching elements). 
Dendrimers have been utilized as a template capable of localizing a high concentration of 
biomimetic moieties, including silica.
6
 Not only have dendrimers been used as stabilizing 
templates for sol-gel composites
6
, but amine terminated polypropylenimine (PPI) and 
polyamidoamine (PAMAM) dendrimers have also been used as non-peptide mimics to 
the silaffin peptides for the controlled formation of silica nanospheres (Figure 12).
6,7,9,53
  
 
Figure 12. Chemical structure of the G-3 PPI dendrimer (left) and G-1 PAMAM dendrimer (right).
6
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Positively charged dendrimers only produce silica nanospheres in the presence of an 
anion, such as phosphate, sulfate, or acetate at neutral pH. The size of silica produced is 
dependent on the generation size of the dendrimer, where larger generations produce 
larger silica nanospheres. Comparisons between the PPI and PAMAM dendrimers have 
revealed that the PPI dendrimer has reduced specific activity because it precipitates silica 
much faster than the PAMAM dendrimer of similar generation size.
6
 
Incorporating known concentrations of dendrimers into the silica matrix has enabled 
specific morphological control over the nanoparticles under mild conditions. This control 
could be modified and applied directly to the encapsulation of functional components that 
are necessary for catalysis, biological labeling and detection, and electronic devices.
7,9
 
Generation 4 (G4) PAMAM dendrimers have been used to catalyze the encapsulation of 
gold nanoparticles and CdSe and ZnS core shell AMP Quantum Dots.
7
 In this reaction, 
cationic gold (Au
3+
) is coordinated to the amine groups of the G4 PAMAM dendrimer, 
where it is reduced to Au
0
 by NaBH4. After lyopholization, energy dispersive X-ray 
spectrometry (EDS) analysis determined that the gold was either surface passivated or 
incorporated with within the dendrimer matrix (Figure 13).  
 
Figure 13. Schematic silica encapsulation of Au
0
 nanoparticles (left) and CdSe/ZnS core shell AMP 
quantum dots (right).
7
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 Although many of the surface dendrimer amines are occluded by the gold or quantum 
dot nanoparticles, silica condensation still occurs. In fact, the CdSe/ZnS core shell 
Quantum Dots with negatively charged surface carboxylates were encapsulated with 99% 
efficiency, which suggests that the electrostatic attraction between the quantum dots and 
the templates was sufficient for encapsulation of these materials.
7
   
Enzymes have also been incorporated into the PAMAM dendrimer to produce silica 
nanoparticles. At physiological pH, the interaction between an enzyme and the cationic 
surface of the PAMAM dendrimer plays an important role in forming supramolecular 
complexes. As a result, the cationic dendrimer (pKa ~9.5) interacts with low pI enzymes. 
For example, glucose oxidase (GOx, pI ~4.2) was encapsulated in water with a 
quantitative yield. Since phosphate ions compete with the enzyme, GOx was poorly 
encapsulated as phosphate buffer concentrations increased because the phosphate ions 
significantly reduce the electrostatic interactions between the enzyme and dendrimer 
(Figure 14).  
 
  
Figure 14. Effect of increasing the phosphate buffer concentration on GOx encapsulation. Note: initial 
reactions contained 400µg of GOx.
9
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 A loss of half of the enzymatic activity under optimal conditions was likely due to 
unfavorable orientations in the silica framework or alterations in steady-state conditions 
due to a local increase of enzyme concentration in the silica. Long term storage effects 
were examined and enzymatic activity was consistent after 30 days of storage at room 
temperature in buffered solutions. The silica framework provides a structural matrix 
around the enzyme, which physically block much of the natural degradation of the 
enzyme, as well as provides a physical barrier from invading species, such as bacteria.
9
    
 
Other Biomimetic Templates 
Other natural biomimetic templates that utilize amines as the catalytic sites for silica 
precipitation have also been reported.
59,60
 Cellulose was recently used as a rigid backbone 
for silica nanotube formation by introducing oligopropylamido side chains derived from 
dipropylenetriamine (DPTA) to the C6 position of almost all of the anhydroglucose units 
(AGUs) (Figure 15).
59
 
 
 
These silica nanotubes are of technologically significant because they could be used 
as a non-conductive substitute for carbon nanotubes and as templates for further 
Figure 15. Structure of DPTA cellulose tosylate. Note that some tosylate residues are present at the C2 
and C6 positions during the synthesis, as indicated by 
13
NMR spectroscopy.
10
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reactivity. The rigidity of the cellulose backbone exposes its surface amines in water, 
inducing a hydrogen bonded amine-silica network (Figure 16).  
 
 
The resultant nanotubes exhibited diameters of 10-30 nm, inner core diameters of ~3 
nm, and lengths of up to 500 nm. The proposed mechanism of condensation shows that 
the silica monomers are interacting with two amino groups on the DPTA through 
hydrogen bonding. This localization of silica precursor along the catalytic amine sites of 
cellulose induces a lateral growth of nanotubes. After the initial silica growth, 
condensation repeats but in a disordered fashion, resulting in a tubular coating of 
amorphous silica.
59
  
 
Conclusion 
As scientists discover more and more about the biological mechanisms that drives 
silica formation of diatoms, they produce more evolved biomimics that continually 
Figure 16. Silica nanotubes. a.) Schematic representation of the formation of silica nanotubes from a 
functionalized biopolymer. b.) TEM images of silica nanotubes formed using the DPTA cellulose 
tosylate template.
10
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expose applications beyond catalysis, biosensing, and drug delivery. Through all of the 
templates examined in this section, one thing is clear: templates strongly influence the 
size and morphology of the silica nanoparticle. For example, the recent discovery of 
silacidins, which are polyanions required for silica formation in vivo, suggest that the 
anion may have an effect on the size and morphology of silica nanoparticles produced. 
As a result, understanding the effect of all of the factors, including the structure of the 
template and the conditions of the reaction (i.e. pH, temperature, and anion 
concentration) will influence the sizes and shapes of silica nanoparticles that material 
scientists will develop.      
 
Dissertation Aims Using Biomimetic Syntheses  
 In the next two chapters, the topics presented will be focused on using biomimetic 
processes to develop silica materials containing functional enzymes. These materials are 
designed to capitalize on the stability of the silica matrix, which prevents enzymatic 
degradation and provides a facile method for biocatalyst recyclability. The focus of 
Chapter II is the in-solution silica encapsulation of two enzymes (nitrilase and -
glucosidase), which are responsible for the conversion of synthetic intermediates to 
industrially relevant products. Chapter III focuses on capitalizing on piezoelectric inkjet 
printing technologies to deposit functional inks used to synthesize enzyme containing 
silica patterns.  
 
 
 
30 
 
CHAPTER II 
 
BIOMIMETIC SYNTHESIS OF ENZYME-CONTAINING SILICA 
NANOPARTICLES 
 
Introduction 
Enzyme catalysis of industrially relevant chemicals provides a green alternative to 
traditional synthetic processes. They are biodegradable biomaterials that perform their 
chemistry in environmentally friendly solvents (i.e. water) at or near physiological pH 
and mild temperatures.
68
 In addition, enzymatic processes provide unique reaction 
chemistries that cannot be efficiently mimicked by traditional synthetic strategies. 
Enzymes however, are more expensive than many reagents, are not easily recycled after 
use, and may have poor shelf lives if they are not stored frozen or as lyophilized powders. 
To circumvent these challenges, several immobilization strategies have been developed 
to improve the stability of the enzyme and allow for simple separation from reaction 
mixtures. Three general methods have been developed: covalent enzyme attachment to a 
substrate, enzymatic crosslinking into reactive aggregates, and encapsulation of enzymes 
into an organic or inorganic polymeric matrix.
69
 Previous work has shown that enzymes 
immobilized within silica sol-gel matrices have improved stability over time and are 
more easily separated from complex reaction solutions.
70
 However, these processes are 
hindered by their inefficient loading yields and are prone to denaturation.
71-74
 Biomimetic 
silica formation however, has been successfully used as an alternative encapsulation 
method that has shown modest enzyme yield and comparable activity.
75-77
 As noted in 
Chapter I, our lab has successfully encapsulated glucose oxidase (GOx) and horseradish 
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peroxidase (HRP) within silica nanoparticles templated by the generation 4 PAMAM 
dendrimer. The following chapter highlights two additional enzymes encapsulated into 
silica matrices (nitrilase and -glucosidase) using a generation 4 PAMAM dendrimer as a 
silica template. 
   
Nitrilase 
Nitrile compounds are simple aliphatic and aromatic metabolites, cyanoglucosides, 
and cyanolipids serving as key compounds and intermediates in a myriad of biochemical 
pathways.
78
  The common biochemical transformation of organonitrile hydrolysis to 
higher value amide and carboxylic acid groups is often inaccessible to organic synthetic 
strategies due to the harsh conditions required for hydrolysis.
79-82
  Synthetically, 
organonitriles are easily produced via the addition of cyanide to alkyl halides, the 
Strecker reaction,
83-86
 reaction of aryl halides with copper cyanide,
87
 and the dehydration 
of amides.
88
  However, the strong acids and bases, often in conjunction with reflux 
conditions required to achieve nitrile hydrolysis prove impractical during the synthesis of 
sensitive and complex molecules. 
Microbial organonitrile transformations are achieved biochemically in ambient, 
aqueous environments by either a combination of nitrile hydratase and nitrile amidase 
enzymes or by members of the nitrilase superfamily.
89
  There are at least nine identified 
families within the nitrilase superfamily.  One well studied gene-cluster from the nitrilase 
superfamily is the NIT1-3 cluster from Arabidopsis thaliana.
90
  These enzymes utilize an 
active site cysteine residue to catalyze the direct conversion of aliphatic and aromatic 
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nitriles into carboxylic acids coupled with ammonia liberation and accept a wide array of 
substrates (Figure 17). 
 
 
While nitrilase containing cell farms have found a foothold in the commercial 
production of some high-value fine chemicals,
91
 they are not commonly employed in 
synthetic strategies due to traditional barriers of enzymatic catalysis.  In general, enzymes 
are more expensive than many reagents, are not easily recycled after use, and may have 
poor shelf lives if they are not capable of activity following lyophilization or freezing.  
These limitations have limited the large scale industrial use of nitrilase to maintaining 
various microbes expressing high levels of nitrilase, such as with acrylamide production 
(~ 6000 tons per year).
92,93
  Herein we report the encapsulation of a cysteine active, 
recombinant nitrilase inside silica nanoparticles.  The reaction is performed in an aqueous 
buffer and mediated by a water soluble PAMAM dendrimer to yield a nitrilase-containing 
silica nanocomposite capable of enzymatic conversion of nitriles, easy separation from 
product, and reusability. 
 
 
Figure 17. Enzymatic conversion of nitriles to carboxylic acids. 
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Experimental 
Enzymes and Reagents: Nitrilase-102 (recombinant from Arabidopsis Thaliana) was 
purchased from Codexis.  All other reagents were purchased from Sigma-Aldrich (U.S.A) 
and used as delivered.  
Nitrilase Encapsulation: Nitrilase was suspended at 2 mg/mL in water or phosphate 
buffer (8, 17, and 25 mM respectively) at pH 7.8.  An aliquot of 200 L was charged 
with enough generation 4 PAMAM dendrimer (Sigma; 10 wt.-% in MeOH) to afford a 
primary amine concentration of 20 mM.  Tetramethylorthosilicate (Aldrich; 1 M; TMOS) 
hydrolyzed by 1 mM HCl (aq.) was then added (20 µL) to achieve rapid precipitation of 
white silica nanoparticles.  The nanoparticles were collected by centrifugation at 10,000 
RPM and washed threefold with 25 mM phosphate buffer.  General protein content was 
quantitated with the Bradford assay from a standard curve of nitrilase. 
PPN Activity Assay:  Encapsulated nitrilase specific activity was compared to free 
nitrilase by a fluorometric assay previously described.
94
  Briefly, nitrilase was reacted 
with a 10 mM solution of PPN (Sigma) at 30
o
C for 10 minutes.  The reaction was stopped 
upon addition of an equal volume of 0.1 M HCl. Next, the amount of ammonia produced 
was assayed by adding a 10 L aliquot of the reaction solution to a 290 L solution 
containing alcoholic o-phthaldialdehyde (Fluka) (3.75 mM) and 2-mercaptoethanol 
(Sigma; 3.6 mM) in 0.2 M phosphate buffer pH 7.4.  This solution stood for 35 minutes, 
followed by excitation at 407 nm and monitored emission at 460 nm (Bio-Tek Synergy 
HT multi-detection microplate reader).  A standard curve of NH3 was produced for the 
range of 10 M and 1000 M. One unit of nitrilase activity was defined as the amount 
able to release 1 mol of NH3/min per mg of nitrilase under the assay conditions.  
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Kinetic parameters were obtained by varying the PPN concentrations and collecting 
several time points to acquire reaction rates. 
3-Cyanopyridine Activity Assay:  Specific activity of encapsulated and free nitrilase 
toward the conversion of 3-cyanopyridine (Sigma) to nicotinic acid was determined by 
reacting the enzyme with a 10 mM solution of 3-cyanopyridine at 30
o
C for 1 hour.  The 
reaction was quenched upon addition of an equal volume of 0.1 M HCl (aq.). The amount 
of ammonia released during the reaction was assayed using the same fluorometric assay 
used for the conversion of PPN. For kinetic experiments, 3-cyanopyridine concentrations 
were varied and several time points were obtained to acquire rates. 
Nitrilase Reusability: Reusability of the nanoparticles was assessed by resuspension in 
200 L of phosphate buffer and transferred to centrifuge filters (Millipore Ultrafree-MC 
centrifugal filter devices with a Durapore 0.1 m pore size PVDF filter).  Before the 
substrate was added, the extra solvent was removed by centrifugation (Beckman Coulter 
Allegra X-22R) at 2500 RPM for 1 min.  The reaction was initiated by the addition of 
200 L of a 5 mM 3-cyanopyridine solution in 25 mM phosphate buffer at pH 7.8 and 
incubated for 1 hr at room temperature.  The reaction was terminated by centrifugation of 
the supernatant at 2500 RPM for 1 min.  The nitrilase-containing nanoparticles were then 
washed with 5 portions of 300 L of phosphate buffer to ensure that all substrate was 
removed before the next experiment.  This reaction was repeated a total of ten successive 
times and the reactant and product concentrations were determined by the HPLC and the 
fluorometric assays.  
Batch Preparation of Nicotinic Acid: Multiple batches of nitrilase-silica nanoparticles 
were prepared in water as described above.  Two reaction vessels were prepared by 
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combining reaction batches (10 per reaction vessel) and a 500 L solution of 200 mM 3-
cyanopyridine in 25 mM phosphate buffer pH 7.8 was added and allowed to convert for 
12 hours at 30
o
C.  Additional aliquots of 3-cyanopyridine were added after the prior 
reaction solution was removed by centrifugation (10 mL total).  The amount of 
synthesized nicotinic acid was quantified by HPLC. 
HPLC Quantification: HPLC analysis was performed on the supernatant with a Waters 
600E Multisolvent Delivery System equipped with a Nova Pak C18 column (reversed-
phase column, 3.9 x 150 mm) at a flow rate of 0.5 mL/min.  A 90:10 mixture of 
water:acetonitrile with 0.1% trifluoroacetic acid was used as the mobile phase.  The A218 
and A261 were measured for 3-cyanopyridine and nicotinic acid respectively.  A standard 
curve for 3-cyanopyridine and nicotinic acid was produced from 5 M to 400 M and 25 
M to 500 M respectively. 
Bradford Assay: Protein mass quantification was performed by adding 160 μL of test 
solution to 40 μL of Bio-Rad Protein Assay solution concentrate and mixing for 5 min.  
The change in color was monitored via UV-Vis (Bio-Tek Synergy HT multi-detection 
microplate reader) at 595 nm.  A calibration curve was produced for nitrilase between the 
range 0.8 μg/mL and 80 μg/mL.   
NMR Analysis: NMR analysis was performed on a Bruker DPX-300 at room 
temperature.  Samples were prepared by performing encapsulation and enzymatic activity 
assay in deuterated 25 mM phosphate buffer.  Samples tested were collected by aspirating 
the supernatant following centrifugation of the reaction mixture. 
Silica Quantification: Silica nanoparticles were quantified following the ß-
Silicomolybdate method described by Iler.
95
  Samples were dissolved in 0.5 M NaOH 
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and incubated at 95°C for at least 30 minutes.  Following incubation, the liberated 
dendrimers were separated from solution by Centricon filtration (American Centricon 
filtration devices, Millipore Inc.).  Molybdate reagent was added (1:4 silicic 
acid/molybdate) to the filtered solutions to initiate the formation of the bright yellow 
product monitored by UV-Vis spectrophotometry at 410 nm and quantitated from a 
standard curve of silicate standards.   
Scanning Electron Microscopy: Silica samples were resuspended in ethanol and placed 
on an aluminum surface SEM sample stage (Ted Pella Inc.) to dry.  Samples were 
sputter-coated with a thin layer of gold via a Pelco Model 3 Sputter Coater (Ted Pella 
Inc.).  Thereafter, samples were imaged on a Hitachi S4200 scanning electron microscope 
operated at variable voltage. 
 
Results 
In order to improve upon the implementation and recycling of nitrilase for large scale 
production and small scale research and development, we encased a commercially 
available nitrilase within silica nanospheres using a biomimetic template.  Previous 
studies of oceanic diatoms have isolated a class of proteins, called silaffins, that catalyze 
the condensation of silicic acid into intricate exoskeletons.
96
  This process is amplified by 
polycationic lysine modifications containing many secondary and primary amines along 
the Sil-1A peptide.
97
  Subsequent reports indicated that similar condensation chemistry 
could be achieved using a variety of amine sources.
76,98-101
  Previously, we reported a 
rapid and efficient benchtop method for the immobilization of the model enzymes 
glucose oxidase and horseradish peroxidase.
77
  Briefly, the enzyme is exposed to a water 
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miscible PAMAM dendrimer which functions as a biomimetic template providing 
sufficient primary amine concentrations ( > 20 mM) to condense silicic acid.
98
  The 
resulting silica flocculates and precipitates within seconds trapping both the dendrimer
102
 
and enzyme within the particles.
99
  The efficiency of enzyme entrapment can be enhanced 
via manipulation of electrostatic attraction between the desired enzyme and cationic 
dendrimer surface.
77
  Compared to other enzyme immobilization strategies such as 
sodium silicates,
103
 the dendrimer based methodology offers a significant advantage in 
both time and processing required to produce the immobilized biocatalysts.
70,71
  The 
recombinant nitrilase (Codexis) for this study has a theoretical pI between 5 and 7 and 
utilizes an active site cysteine similar to the NIT1-3 cluster of Arabidopsis thaliana. 
Nitrilase-containing silica nanoparticles were initially synthesized in water by adding 
20 L of 1 M hydrolyzed tetramethyl orthosilicate (TMOS) to a 200 L solution 
containing nitrilase (0.400 mg) and generation 4 PAMAM dendrimer (20 mM primary 
amine concentration) at pH 7.8. Silica quantification of the rapidly precipitated 
nanocomposite (191 nm + 44 average particle diameters (Figures 18 & 19, Table 2)) 
using the -silicomolybdate assay method95 showed 0.43 mg + 0.1 (7.16 moles) of silica 
produced for each reaction, consistent with previously published yields.
77,98
 The 
efficiency of enzyme encapsulation quantified by the Bradford assay was rated 92.3 % + 
0.5 (0.3692 mg) of the starting enzyme. The remaining unencapsulated enzyme (0.0308 
mg) was found in subsequent supernatant washes. The enzyme to silica mass ratio for 
these reaction conditions is 0.37:0.43, or 0.86:1. The specific activity of the encapsulated 
nitrilase was determined using a previously described fluorometric assay.
94
  Activity of 
the nanocomposite toward 3-phenylpropionitrile (PPN) in 25 mM phosphate buffer (pH 
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7.8, 30
o
C) revealed a specific activity 59.2 % + 5.8 that of an equal amount of enzyme 
free in solution (Table 3).  
Previously, we reported that the electrostatic attraction between the cationic 
dendrimer and surface charge of the enzyme could be tuned as a function of the ionic 
strength of the buffer.
77
  When nitrilase was encapsulated over a range of phosphate 
buffer concentrations, the amount of total enzyme within the silica matrix increased as 
the buffer concentration decreased.  In addition, the particle diameter size decreased as a 
function of decreasing ionic strength, consistent with previously published results.
77
  
Since nitrilase has a slightly acidic pI (~5-7), it will be slightly anionic at neutral pH.  It is 
electrostatically attracted to the cationic dendrimer and would be in close proximity to the 
silica condensation event, resulting it its subsequent entrapment within the growing 
nanoparticle.  As the ionic strength of the buffered solution is increased, the interaction 
between the dendrimer and enzyme is diminished, resulting in reduced encapsulation 
efficiency.  Concurrently, the ions serve to maintain the solubility of the growing 
nanoparticle.  As the buffer concentration is increased, the critical size for particle 
precipitation is increased, resulting in larger nanoparticles.  It should also be noted that 
the absolute amount of silica produced for all of the conditions is the same regardless of 
the reaction conditions, suggesting that silica condensation occurs until the entire 
precursor is completely consumed.   
Although an unbuffered solution yields optimal enzyme loading and the smallest 
particle diameters, it is not clear whether these conditions affect nitrilase’s specific 
activity.  Nanoparticles synthesized under each buffer condition (8, 17, and 25 mM 
phosphate buffer; pH 7.8) were compared to the samples prepared in water.  All particles 
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showed a similar specific activity toward PPN, suggesting that the buffer concentration 
during encapsulation doesn’t have a significant effect on the activity of nitrilase.  
Consequently, the increase in particle size seen in the buffered samples doesn’t have a 
noticeable effect on activity, suggesting that the silica shell doesn’t create a diffusion 
barrier between the enzyme and substrate.  Therefore, the samples prepared in water, 
which had the highest enzyme yield, contain more total active enzyme per reaction batch. 
 
 
Figure 18. SEM images of nitrilase-containing silica nanoparticles formed in water (top left), 8 mM (top 
right), 17 mM (bottom left) and 25 mM phosphate buffer (bottom right). 
40 
 
 
 
 
Encapsulation 
Conditions 
Particle 
Diameters 
(nm) 
Silica Yield       
Per Batch 
(mg) 
Enzyme Yield 
Per Batch 
(mg) 
Enzyme 
to Silica 
Ratio 
Enzyme 
Yield (%) 
Water 191 + 44 0.430 + 0.100 0.369 + 0.002 0.858 92.3 + 0.5 
8 mM 331 + 83 0.442 + 0.041 0.331 + 0.020 0.749 82.8 + 5.0 
17 mM 353 + 88 0.419 + 0.026 0.290 + 0.001 0.692 72.5 + 0.3 
25 mM 376 + 94 0.433 + 0.030 0.275 + 0.017 0.635 67.8 + 4.3 
 
Figure 19. Size distribution graphs of the nitrilase-containing silica nanoparticles reacted in A.) water, 
B.) 8 mM, C.) 17 mM, and D.) 25 mM phosphate buffer. 
Table 2. Physical properties of nitrilase-containing silica nanoparticles. 
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To further investigate the utility of the nitrilase nanocomposite, we chose to examine 
nitrilase’s ability to convert 3-cyanopyridine to biologically active 3-carboxypyridine 
(nicotinic acid; niacin) (Scheme 1).  Previous reports have indicated that this niacin 
precursor is significantly less labile to nitrilase conversion as compared to PPN due to 
polarity and steric concerns, making it a more rigorous test for this system.
90,104
  Specific 
activity testing of the nanocomposite with a 10 mM solution of 3-cyanopyridine revealed 
that the nanoparticles have nearly identical specific activity relative to the free enzyme, 
regardless of particle size, again suggesting that the silica matrix doesn’t create a 
diffusion barrier between the substrate and enzyme. 
 
 
Kinetic parameters of encapsulated nitrilase for both substrates were compared to that 
of free enzyme (Table 3). The apparent Km value increased by ~60% for both substrates 
when compared to nitrilase free in solution, regardless of the encapsulation conditions.  A 
difference in Km within one-fold suggests that the enzyme is behaving kinetically similar 
to the free enzyme. Previous studies have reported changes of Km values for 
biomimetically synthesized silica-enzyme nanoparticles anywhere from a one-fold 
decrease to a three-fold increase.
77,105
  Changes in the Km in these systems have been 
attributed to a variety of factors, including limited substrate access into the silica matrix 
and occlusion of the enzyme active site.  Since there is little control over the orientation 
of the enzyme within the silica, and there is no apparent kinetic variation with different 
Scheme 1. Hydrolysis of 3-cyanopyridine with nitrilase. 
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sized particles, it is likely that the active site of some of the enzyme is occluded by the 
silica at any given time.     
 
Encapsulation 
Conditions 
Km PPN (mM) 
Specific 
Activity PPN 
(U / mg) 
Km 3-
Cyanopyridine 
(mM) 
Specific Activity 
3-Cyanopyridine 
(U / mg) 
Free Enzyme 2.02 + 0.27 2.47 + 0.15 0.57 + 0.07 0.0514 + 0.0036 
Water 3.38 + 0.63 1.47 + 0.19 0.90 + 0.11 0.0489 + 0.0045 
8 mM 3.18 + 0.69 1.81 + 0.25 0.71 + 0.10 0.0549 + 0.0028 
17 mM 3.37 + 0.72 1.35 + 0.20 0.80 + 0.13 0.0566 + 0.0038 
25 mM 3.14 + 0.88 1.67 + 0.24 1.12 + 0.16 0.0352 + 0.0017 
 
 
To evaluate the applicability of these nanocomposites for the industrial synthesis of 
niacin, a single reaction batch of encapsulated nitrilase was used to drive the conversion 
of 3-cyanopyridine.  The overall conversion rate was compared between the free and 
encapsulated conditions (Figure 20).  The conversion was verified by HPLC and 
characterized by NMR (NMR data not shown).  It should be noted that no enzymatic 
activity was observed in the supernatant, confirming that the enzyme wasn’t simply 
absorbed onto the silica surface or isn’t leeching out of the silica framework.  This 
combined with the ease of product separation from the biocatalyst makes the silica-
enzyme nanocomposites attractive for large scale use.  
Table 3. Kinetic parameters and specific activity of nitrilase-containing silica nanoparticles. 
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Since the nanocomposite can be separated from the reaction media by centrifugation, 
it is of interest whether the material can be used multiple times.  Thus, we examined the 
biocomposites ability to convert multiple doses of 3-cyanopyridine.  A single preparation 
of encapsulated nitrilase (same as above) was used to convert a 5 mM solution 3-
cyanopyridine ten successive times.  However, loss of silica to the multiple handling 
procedures reduced the amount of biocatalyst present, which has a significant impact for 
repeated usage.  Recently, a histidine-tagged R5 peptide linked to cobalt-coated agarose 
beads in a flow reactor was used to immobilize silica encapsulated equine 
butyrylcholinesterase.
75
  Although this process is an effective method for screening 
cholinesterase inhibitors, synthesizing a histidine-modified peptide can be expensive and 
time-consuming, especially at the large scale.  Alternatively, inspired by a bed flow 
Figure 20.  HPLC spectra following the conversion of a 50 mM solution of 3-cyanopyridine to nicotinic 
acid with nitrilase-containing nanoparticles. Time points are initial (top left), 3 hours (top right), and 22 
hours (bottom left).  (bottom right) Fluorometric comparison of the conversion of 50 mM 3-
cyanopyridine with free and silica encapsulated nitrilase. 
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reactor design of PEI-templated nitrobenzene nitroreductase silica nanoparticles,
105
 the 
effective, repeated separation of water-soluble nicotinic acid from the nitrilase-containing 
nanospheres was achieved by performing the reaction in centrifuge filters (Millipore 
Ultrafree-MC centrifugal filter devices with a Durapore 0.1 m pore size PVDF filter).  
Even after 10 consecutive experiments, only a 10% loss of activity was observed (Figure 
21).  Also, no detectable activity was observed in the supernatant after filtration.  Much 
like the frit filters used in the nitrobenzene nitroreductase study, the centrifuge filters 
served as a physical barrier between the nitrilase-containing silica nanoparticles and the 
desired product after conversion and centrifugation, which allows for their more efficient 
recyclability. 
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A scaled preparation of niacin was produced by combining 20 batches of nitrilase-
containing nanoparticles (7.4 mg of total enzyme; 8.6 mg of silica) synthesized in water.  
A 200 mM solution of 3-cyanopyridine was then added and allowed to convert for 12 
Figure 21. Consecutive experiments performed on a single triplicate batch of nitrilase-containing silica.  
A 5 mM 3-cyanopyridine solution was added and incubated at RT for one hour before being removed 
by centrifugation.  Activity of the enzyme was only diminished by 10% at reaction # 10. 
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hours at 30
o
C.  Upon centrifugation, the supernatant was readily collected and 9 
additional aliquots of 3-cyanopyridine were added.  After HPLC quantification of the 
product (10 mL total), it was determined that this system was capable of synthesizing 
1.75 mg of nicotinic acid/hr throughout 10 reaction cycles.   
Nitrilase containing silica particles can be utilized as a viable immobilized biocatalyst 
that is both rapidly produced and quickly reclaimed for use in the synthesis of nicotinic 
acid without loss of significant activity or need for cumbersome separation steps.  
Additionally, the reported long term storage of enzymes within nanoparticles with little 
loss in activity adds another cost effective benefit likely to be attractive for scale-up 
chemoenzymatic processes.
76,77
   Although there may be many challenges involved with 
commercializing this technology, these characteristics will greatly reduce time and costs 
that traditionally hinder widespread use of enzymes in pharmaceutical and fine chemical 
production. 
 
-Glucosidase 
Cellulose is a polysaccharide that comprises ~40% of plant tissue that can be 
hydrolyzed into D-glucose, which is widely used as a feedstock for production of 
ethanol.
106
 As a renewable resource, ethanol is widely considered as a viable alternative 
to fossil fuels that could potentially reduce the amount of imported oil, reduce air 
pollution, and facilitate economic development in rural areas. Traditionally, ethanol 
production from cellulose was achieved through the breakdown of pure cellulose powder 
or ball-milled cellulose.
107
 However, in 1993, it was shown that paper mill waste fiber 
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and spent liquor from an ammonium-sulfite pulp process can be used as a cheaper 
alternative source.
108
 Using a P. decumbens JU-A10 culture broth as a source of crude 
cellulase and Aspergillus niger L22 culture broth as a source of -glucosidase, fine fibers 
from paper mills can be hydrolyzed to glucose. The supplementation of -glucosidase 
increased the overall ethanol yield by 42.1% when compared to the activity of the P. 
decumbens JU-A10 culture broth alone.
108
  
In general, -glucosidases are enzymes responsible for the hydrolysis of glycosidic 
bonds, releasing non-reducing terminal glucosyl residues from glycosides and 
oligosaccharides (Figure 22).
1
 They are found most organisms are commonly used in the 
breakdown of glycolipids and exogenous glucosides in amimals, biomass conversion in 
microorganisms, and catabolism of cell wall oligosaccharides.
1
 Mechanistically, 
conversion occurs for the 240 kDa dimer of Aspergillus niger -glucosidase first by the 
donation of a proton from the one of the two carboxylic acids to the leaving group while 
the other deprotonated carboxylate nucleophile attacks from the opposite side to form an 
-linked intermediate. Next, the conjugate base of the catalytic acid extracts a proton 
from an adjacent water molecule, improving its ability to nucleophilically attack the 
anomeric carbon and release the products from the enzyme.  
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Although utilized in large scale industrial applications, the cost of maintaining a 
constant source of enzyme can be expensive and time-consuming. In addition, enzymes 
free in solution are susceptible to proteolytic degradation and can be thermally unstable. 
To circumvent these challenges, encapsulation methods to shield these enzymes from 
proteases have been developed. The purpose of this section is to investigate the effect of 
encapsulating -glucosidase from Aspergillus niger into generation 4 PAMAM 
dendrimer-templated silica nanoparticles. 
 
Experimental 
Reagents: All reagents were purchased from Sigma-Aldrich (U.S.A) and used as 
delivered.  
-Glucosidase Encapsulation: All silica precipitation experiments were performed by 
first creating a stock solution consisting of 160 L of -glucosidase at variable 
concentrations in 0.25 mM phosphate buffer pH 7.0 and 40 L of a 100 mM primary 
Figure 22. Catalytic mechanism found in the hydrolysis of oligosaccharides to glucose by Aspergillus 
niger -glucosidase.1 
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amine solution of generation 4 PAMAM dendrimer. Tetramethylorthosilicate hydrolyzed 
by 1 mM HCl (aq.) was then added (20 µL) and incubated for 5 minutes. After 
precipitation of silica was achieved, the particles were isolated by centrifugation (5 min, 
7.2 x g). The supernatant was collected and this process was repeated three times with a 
200 L aliquot of a 200 mM acetate buffer (pH 5.0) wash solution. Next, the particles 
were washed three times with 200 L of water and resuspended in water. General protein 
content in the supernatant and washes was quantitated with the Bradford assay against a 
standard curve of -glucosidase. 
Specific Activity Assay:  Specific activity of the encapsulated enzyme was determined 
through the hydrolysis of pNpp-b-glucopyranoside (pNPG). Briefly, a 25 L aliquot of 
silica encapsulated -glucosidase (0.1 mg/mL protein) was heated to 50oC for 10 minutes 
and subsequently added to a 125 L solution containing 6.0 mM pNPG in 50 mM acetate 
buffer pH 5.0 and incubated for 5 minutes. The reaction was then quenched with 150 L 
of 1M sodium carbonate. The resulting yellow product was then measured 
spectrophotometrically at 405 nm. One unit of -glucosidase activity was defined as the 
amount able to release 1 mol of pNPG/min per mg of -glucosidase under the assay 
conditions. 
Activity Studies: The activity of the encapsulated enzyme was evaluated by varying the 
reaction pH and temperature. For the pH study, the particles were dissolved in water as 
noted above and incubated with 6 mM pNPG in 0.1 M KCl/HCl buffer pH 1-2, 0.1 M 
acetate/phosphate buffer pH 3-3.4, 0.1 M acetate buffer pH 4-5.5, and 0.1 M phosphate 
buffer pH 6-8, respectively. The temperature study was performed the same as the 
standard activity assay except that the reaction temperature was varied from 30-80
o
C. For 
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the pH stability studies, the particles were incubated for 24 hrs at 4
o
C under different pH 
conditions. After incubation, the particles were washed with water prior to addition to the 
activity assay. The free enzyme was incubated at variable at high concentration and 
diluted down into the assay conditions with water. The thermal stability assay was 
conducted by incubating the particles at variable temperatures for 1 hr, cooled to room 
temperature, and then tested for activity using the standard activity assay.  
Bradford Assay: Protein mass quantification was performed by adding 160 μL of test 
solution to 40 μL of Bio-Rad Protein Assay solution concentrate and mixing for 5 min.  
The change in color was monitored via UV-Vis (Bio-Tek Synergy HT multi-detection 
microplate reader) at 595 nm. A calibration curve was produced for -glucosidase 
between the range 0.8 μg/mL and 80 μg/mL.   
Silica Quantification: Silica nanoparticles were quantified following the ß-
Silicomolybdate method described by Iler.
95
  Samples were dissolved in 0.5 M NaOH 
and incubated at 95°C for at least 30 minutes.  Following incubation, the liberated 
dendrimers were separated from solution by Centricon filtration (American Centricon 
filtration devices, Millipore Inc.). Molybdate reagent was added (1:4 silicic 
acid/molybdate) to the filtered solutions to initiate the formation of the bright yellow 
product monitored by UV-Vis spectrophotometry at 410 nm and quantitated from a 
standard curve of silicate standards.   
Scanning Electron Microscopy: Silica samples were resuspended in ethanol and placed 
on an aluminum surface SEM sample stage (Ted Pella Inc.) to dry. Samples were sputter-
coated with a thin layer of gold via a Pelco Model 3 Sputter Coater (Ted Pella Inc.).  
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Thereafter, samples were imaged on a Hitachi S4200 scanning electron microscope 
operated at variable voltage. 
 
Results 
-glucosidase from Aspergillus niger was chosen for silica encapsulation due to its 
low isoelectric point (~4.0).
109
 The difference in overall charge between the PAMAM 
dendrimer and -glucosidase at neutral pH allows for an electrostatic interaction between 
the two molecules. This creates a protein-polymer conjugate that is isolated within the 
growing silica matrix during amine-catalyzed precipitation. -glucosidase-containing 
silica nanoparticles were synthesized in 0.25 mM phosphate buffer pH 7.0 by adding 20 
L of 1 M hydrolyzed tetramethyl orthosilicate (TMOS) to a 200 L solution containing 
varying amounts of -glucosidase and generation 4 PAMAM dendrimer (20 mM primary 
amine concentration). The efficiency of enzyme encapsulation quantified by the Bradford 
assay determined an enzyme encapsulation yield of ~80% irregardless of starting protein 
concentration (Figure 23). This suggests that the loading capacity of the silica 
nanoparticles has not yet been reached under the reaction conditions tested. 
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The specific activity of the encapsulated protein was determined by monitoring the 
conversion of 6.0 mM pNPG in 50 mM acetate buffer at pH 5.0 for 5 minutes. A trend 
towards higher specific activity at the higher protein loading concentrations was 
observed. For example, the specific activity for the highest protein loading condition (10 
mg/mL) was experimentally determined to be 1.74 + 0.28 U/mg, which is 48.9 + 10.1% 
of the activity found with the enzyme free in solution. SEM characterization of selected 
samples revealed a change in particle size as a function of starting enzyme concentration 
(Figure 24). In fact, particles synthesized with 10 mg/mL protein were 5x smaller than 
those with 1 mg/mL -glucosidase. In general, smaller particles imply a shorter distance 
between the substrate in solution and the protein inside the silica matrix which may 
explain why the higher loading conditions had ~1.75x higher specific activity. 
Figure 23. Loading efficiency (left) and specific activity (right) of -glucosidase-containing silica 
nanoparticles. 
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Figure 24. SEM images and particle size distributions of -glucosidase containing silica nanoparticles. 
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Using the highest loading condition particles, kinetic parameters of encapsulated -
glucosidase for pNPG were compared to that of the free enzyme (Figure 25). The 
apparent Km for the encapsulated enzyme was within 20% of the free enzyme in solution. 
In addition, the calculated Vmax indicated that the encapsulated enzyme can turnover 
~70% of what the free enzyme can in solution. A difference in Km within one-fold 
suggests that the enzyme is behaving kinetically similar to the free enzyme. As noted 
above, changes of Km in biomimetically synthesized silica-enzyme nanoparticles have 
ranged anywhere from a one-fold decrease to a three-fold increase.
77,105
  Given the fact 
that the Km for -glucosidase is nearly identical under both conditions, it is likely that the 
loss of specific activity in the silica nanoparticles is caused by the occlusion of the active 
site of some of the enzyme by the silica at any given time. 
 
 
Figure 25. Kinetic parameters of free and silica encapsulated -glucosidase. Michaelis-Menten (top) 
and Lineweaver-Burke (center) graphs.  
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One advantage of silica encapsulation is that the inorganic matrix serves as a cage 
around the enzyme which can serve to stabilize the enzyme at elevated temperatures and 
variable pH. For example, the specific activity of the nanoparticles was highest at pH 4, 
whereas the free enzyme was the most robust at pH 5 (Figure 26, top left). Interestingly, 
the encapsulated enzyme maintains >50% of the overall activity as low as pH 2.5 and as 
high as pH 6. Conversely, the free enzyme shows an activity window between pH 3.5-7, 
with maximum activity at pH 5. Silica is negatively charged, so the local pH found within 
the silica nanoparticles may actually be higher than the solution pH, which could account 
for the relative shift in activity. This phenomenon is not present when the particles are 
stored overnight at variable pH (Figure 26, bottom left). In fact, the trend in activity 
when the particles were is similar for both the free and encapsulated conditions. 
When the reaction temperature was assayed, the free enzyme demonstrated optimal 
specific activity at 50
o
C and drastically decreased at elevated temperatures, likely caused 
by the denaturation of the protein (Figure 26, top right). Strikingly, the encapsulated 
protein was not only highly active at 50
o
C, but it also exhibited a three-fold increase in 
specific activity at 70
o
C. In addition, when the protein was heated for an hour at variable 
temperatures and tested for activity, the encapsulated enzyme maintained its activity even 
at 60
o
C (Figure 26, bottom right). The free enzyme begins to lose activity at 50
o
C, and 
has less than half of its activity at 60
o
C. It is likely that the silica matrix serves to stabilize 
the protein by reducing the number of potential inactive conformations and thereby 
constraining the protein into an active state. 
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Conclusions 
Dendrimer-mediated enzyme encapsulation into silica matrices has many advantages 
in the context of industrial biotransformations. The silica matrix serves as a protective 
cage that prevents enzymatic proteolysis while still allowing free diffusion of substrates 
and products to and from the active site. These biocatalysts are easily recovered and 
purified from reaction mixtures by filtration or decantation with minimal loss of 
enzymatic activity. Also, the silica matrix has been shown in the case of -glucosidase to 
improve the specific activity of the enzyme by stabilizing the enzyme at elevated 
Figure 26. Thermal and pH stability of -glucosidase encapsulated within silica nanoparticles. A.) 
Specific activity as a function of pH. B.) Specific activity as a function of reaction temperature. C.) 
Stability of encapsulated -glucosidase after being stored at different pH’s overnight. D.) Thermal 
stability of -glucosidase upon incubation at variable temperatures for 1 hr. 
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temperatures. One potential application of this technology is a combinatorial approach to 
ligand synthesis by encapsulating several enzymes from the same pathway, thereby 
creating a synthesis cascade that could overcome limitations that unstable enzymes 
provide. Another potential application is to incorporate this technology with other 
immobilization strategies (i.e. cross-linked enzyme aggregates) to encapsulate enzymes 
that are inactivated during the crosslinking process.  
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CHAPTER III 
 
BOTTOM-UP SYNTHESIS OF BIOLOGICALLY ACTIVE MULTILAYER FILMS 
USING INKJET PRINTED TEMPLATES 
 
Introduction  
One essential characteristic of 2D bioanalytical systems is their ability to rapidly 
detect a panel of drugs, pathogens, or biomolecules from selectively functionalized 
surfaces. From point of care (POC) diagnostics to electrochemical sensing, localized 
areas of biologically active films serve to support and to protect a functional material, 
while offering higher sensitivity and increased resolution during product analysis.
110-113
 
With the advent of recent, low temperature, micron-scale deposition techniques such as 
direct ink writing (DIW), screen-printing, or ink-jet printing (IJP), there has been 
considerable interest in modifying solid surfaces with biologically active functional 
materials.
114-118
 In fact, enzymes have been printed using various biomaterial deposition 
methods;
 119-121
 however, real-time analysis of reaction products detected along a 
patterned 2D interface still remains an obstacle for functional adaptation because of the 
unpredictable nature of such chemically responsive surfaces.
122
  
While the structure and property relationships of 2D-active surfaces are not well 
understood, solution phase bio-compatible systems have been studied extensively.
52,122,123
 
Previously, enzyme-containing silica particles have been synthesized via sol-gel or 
biomimetic encapsulation strategies, producing localized nano-environments for the 
soluble enzyme.
113,124-129
 When compared to the reactivity of the enzyme in solution, free 
diffusion of small molecules within these constrained, three-dimensional (3D) porous 
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silica matrices offer cheaper product separation and purification strategies and enhanced 
biological life-spans. Unlike traditional sol-gel methods that often incorporate multiple 
steps under high-temperature reaction conditions, biomimetic approaches for enzyme 
encapsulation have been reported to be faster and more efficient under mild reaction 
conditions (>30 min at room temperature compared to 32 h at variable temperatures for 
sol-gel formation).
125,128,129 
 
As demonstrated in Chapter II, amine-terminated PAMAM dendrimers have been 
shown to direct the encapsulation of enzymes within silica nanospheres with high loading 
efficiency and excellent long term stability.
123,130
 This strategy utilizes the electrostatic 
attraction between the cationic dendrimer and anionic enzyme, creating a supramolecular 
complex that simultaneously polymerizes silica while immobilizing the active enzyme. 
More importantly, this confinement strategy does not significantly inhibit the active 
conformation of the enzyme, as same-fold enzymatic activity is reported when compared 
to the soluble enzyme in solution. 
52,118,122,123
 Although these strategies are used to create 
highly efficient bed reactors and reaction columns in solution phase reactions,
130
 the 
application of this approach as a 2D film has not been investigated.  
In this chapter, inkjet printing, using the Dimatix Materials Printer (DMP), is used to 
template the 2D encapsulation of enzymes, where encapsulation efficiency and activity is 
studied as a function of the degree of enzyme loading. Unlike other commercially 
available biomaterial deposition techniques, the DMP offers non-invasive rapid 
prototyping (8 m*s
-1
), where an applied voltage, controlled through the DMP software,  
induces a fluctuation in pressure within the printhead nozzles (16 nozzles, spaced 256 
µm); once the pressure reaches a critical point, a droplet (< 12 pL) is released.
114,131
 The 
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very nature of the DMP provides a tunable printing environment, where any ink that is 
synthesized within a jettable range (viscosity of 8-15 cPs and surface tensions of 25 
dynes cm
-1
) can be optimized for uniform printing.  Combining the versatility of the 
DMP with a previously established biomimetic dendrimer ink,
132
 a platform is developed 
for the efficient, bottom-up synthesis of a biologically active enzyme film.   
 
Experimental 
Materials: All reagents/compounds were purchased from Sigma-Aldrich and used with 
no modifications. 
Pre-Preparation of the Gold Substrate: All gold substrates used for printing were 
cleaned in piranha solution (3:1 H2SO4:H2O2) for at least 30 min, washed with copious 
amounts of water and dried with nitrogen before use. Warning: Piranha solution should 
be handled with extreme caution.  
Printing of Dendrimer Ink: An ink consisting of 8.6 wt% PAMAM generation 4 
dendrimer and 25% w/v polyethylene glycol (PEG, Aldrich Chemical Co.) in 100 mM 
phosphate buffer pH 7.5 was printed using a Dimatix Materials Printer (DMP). The ink 
was printed with 2x coverage on either gold substrates or into the wells of a 96-well 
Immulon 2-HB plate. During printing, the maximum voltage pulse was 24 V, and the 
pulse frequency was maintained at 1.0 kHz.   
Glucose Oxidase (GOx) Silica Encapsulation on Gold:  
Method 1: A gold substrate containing the printed dendrimer ink was inverted and 
lowered into a solution containing 500 L of 0.1 mg/mL GOx (in 0.25 mM phosphate 
buffer pH 7.0) and incubated for 10 minutes. Next, 50 L of 1 M silicic acid was added 
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and the reaction was allowed to react for varied times (1-20 min). The reaction was 
terminated by removing the substrate from the reaction solution and washing it copiously 
with water. The substrates were then dried under a gentile stream of N2. Controls were 
also prepared with the same method, except the reaction solution didn’t contain any GOx.  
Method 2: Instead of allowing for interaction between the printed spot and GOx, the 
printed substrate was inverted and lowered into a solution containing 500 L of 0.1 
mg/mL GOx (in 0.25 mM phosphate buffer pH 7.0) and 50 L of 1 M silicic acid. Upon 
addition, the reaction was allowed to proceed for 20 min. The reaction was similarly 
terminated by removing the substrate, washed with water, and dried with N2. Controls 
without GOx were also prepared using the same method.  
Glucose Oxidase (GOx) Encapsulation in 96-well Plates:  
Method 1: A 200 L solution of GOx in 0.25 mM phosphate buffer pH 7.0 was added to 
each printed well and allowed to incubate for 10 minutes. Next, 20 L of 1 M silicic acid 
was added and the reaction was allowed to proceed for 20 minutes. The reaction was 
terminated upon centrifugation at 3000k for five minutes and the supernatant was 
removed. The wells were then washed three-fold with 200 L of 0.1 M phosphate buffer 
pH 6.0 to remove any unused reactants.  
Method 2: A solution containing 200 L of GOx in 0.25 mM phosphate buffer pH 7.0 and 
20 L of 1 M silicic acid was added to each printed well and allowed to react for 20 
minutes. The reaction was terminated upon centrifugation at 3000k for five minutes and 
the supernatant was removed. The wells were then washed three-fold with 200 L of 0.1 
M phosphate buffer pH 6.0 to remove any unused reactants. 
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Glucose Oxidase Activity: Activity of the encapsulated enzyme was determined by the 
glucose oxidase activity assay (Worthington Biochemical Corporation) with slight 
modifications. First, an O-dianisidine dye reagent was prepared by adding 100 L of 1% 
O-dianisidine solution to 12 mL of 0.1M potassium phosphate buffer at pH 6. After 
purging this solution with oxygen for at least 10 minutes, an aliquot of 192 L was added 
to a solution containing 25 L of -D-glucose (concentrations of glucose reflect 
consideration of mutarotation in solution) and 8.35 L of a 0.2 mg/mL solution of 
horseradish peroxidase (HRP). Next, this solution was added to a 25 L solution of 
appropriately diluted GOx in H2O or added to the printed wells containing 25 L of 
water, and the change in color was observed for 5 min at 460 nm. Reusability of the wells 
was assayed by reacting for 5 min and then washing 3 times with buffer before reuse. The 
reaction was repeated a total of 10 times. Storage stability of the printed wells was 
assayed after storage at 4
o
C in 0.1 M phosphate buffer for multiple days. 
Profiliometry: Height profiles of the printed composite for each reaction condition were 
analyzed using a VEECO profilometer with a 12.5 m stylus. The scan rate was 10 
m/sec and the stylus was maintained at 3.00 mg.  
Scanning Electron Microscopy: Scanning electron microscopy (SEM) was conducted 
using a Hitachi S4200 microscope operating at variable voltages. Samples were prepared 
by sputter-coating them with a thin layer of gold using a Pelco Model 3 Sputter 
Instrument (Ted Pella Inc.) to prevent substrate charging during analysis. 
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Results  
Given its capability to be encapsulated using previously established biomimetic 
strategies,
123
 its low cost, and its commercial availability.
123,133  
the enzyme, glucose 
oxidase (GOx), is used as a robust model enzyme in these 2D encapsulation studies. 
Initially, the microstructure of a dendrimer patterns interfaced with GOx is investigated 
using two methods of synthesis. In each method, a 48 mm
2
 array, containing 
approximately 20 pL of dendrimer ink per spot (spots spaced at 96 µm, printed 2x), is 
patterned onto gold coated silicon nitride chips.  The first method (Method I) applied in 
this study represents a layer-by-layer approach to encapsulate GOx within an individual 
spot. The patterned substrates are first submerged in a solution of GOx. Then, without 
directly disturbing the chip in solution, the silica precursor, monosilicic acid, is directly 
added. The resulting film is then studied as a function of reaction time. Once the reaction 
is completed, the patterns are washed extensively in DI-water, dried under Nitrogen, and 
analyzed using SEM and height profilometry (Figure 27).  
 
      
Figure 27. The change in morphology of a printed spot as a function of reaction time with monosilicic 
acid using Method I. A. Printed spot reacted first with GOx (10 min), followed by silica encapsulation. 
B. Printed spot in the absence of GOx as a function of silica formation.  
63 
 
Given the previously observed interactions between the dendrimer and enzyme in 
bulk solution,
123
 it is initially anticipated that the enzyme would electrostatically adhere 
to the surface of the printed spot during the first incubation, essentially creating a printed 
anion exchange surface. Because the patterns are exposed to a locally high concentration 
of enzyme, silica is expected to form during the second incubation period, resulting in the 
effective encapsulation of the enzyme film. Analysis of the resulting composite films, 
however, revealed that the morphology of a spot is severely disrupted after 5 minutes of 
development when compared to the control conditions without enzyme. In fact, the 
control patterns indicate that spot morphology is sustained over the reaction period. The 
initial incubation period of the patterns with GOx is observed to cause a significant 
morphological disruption. When the final reaction solution is assayed for enzyme activity 
after the chip is removed, nearly 100% of the enzyme is detected, inferring that GOx has 
aggressively reacted with the printed dendrimer, solubilizing the film as a dendrimer-
enzyme aggregate.  
This reaction is documented over time using profilometry. When the spot is reacted 
with monosilicic during the second incubation period, silica is formed only along the 
remaining fragments of the spots but is not retained over time. Morphology is initially 
preserved at 5 min of reaction time (2.6 ± 0.9 µm, Figure 28). After 10 min of reaction 
time, however, over 50 % of the physical spot dimensions are lost when compared to the 
control pattern, suggesting a differential disruption of the dendrimer layer at the spot 
interface.  
64 
 
 
 
To eradicate impending pattern destruction witnessed in the Method I synthesis, a 
necessary alternative, Method II, was developed. Method II is premised on the 
simultaneously reaction of both GOx and monosilicic acid with the printed chip. Since 
monosilicic acid is available to the patterns as the enzyme is introduced, the differential 
disruption observed in Method I should be eliminated. In fact, SEM and profilometry 
analysis confirms that uniform silica films are formed, during the simultaneous 
encapsulation of the enzyme (Figure 29). 
Figure 28. Height profiles of the two methods used in multicomposite formation. A. Profiles of spot 
height using Method I with and without GOx. B. Profiles of spot height using Method II with and 
without GOx. Time points are determined upon addition of monosilicic acid. 
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When compared against the control patterns, examination of the enzyme-reacted 
spots using SEM revealed only a slight disruption in the surface morphology using the 
Method II synthesis; however, the overall quality and uniformity of the film is 
significantly improved, undoubtedly due to the immediate order of reactants. 
Profilometry measurements verified the integrity of the enzyme encapsulated patterns. 
Spot height initially increases (4.3 ± 0.6 µm) after 5 min of reaction time and stabilizes at 
20 min (4.4 ± 1.1 µm). The decrease in spot height observed between 5-15 minutes of 
reaction time is likely due to the nature of the dendrimer-silica interaction.
132
 Because of 
the nature of this 2D reaction,
134
 the original spot is understood to open up in the 
presence of multiple reactants, producing a metastable environment necessary for 
complete encapsulation. Control patterns in the absence of enzyme behaved similarly as 
documented in its analogous back-filling behavior, where the reacted spots varied in 
height again from 5 min (4.7 ± 1.0 µm), 15 min (2.0 ± 0.5 µm), and 20 min (3.4 ± 0.7 
µm).  
 
Figure 29. The change in morphology of a printed spot as a function of reaction time with monosilicic 
acid using Method II. A. Printed spot reacted with GOx as a function of silica formation. B. Printed spot 
in the absence of GOx as a function of silica formation. 
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In order to explain the morphological differences witnessed between the two methods 
of synthesis, both the composition of the ink and the reaction solution must be 
considered. The ink, itself, consisted of three main components: 113 mM phosphate 
buffer, 8.6 wt % dendrimer, and 25 wt % poly-(ethylene) glycol (PEG). Once printed 
onto the substrate, each pattern was submitted to control reaction conditions without 
enzyme. During this reaction time, it is predicted that the smaller components of the ink, 
such as the buffer ions and water, are exchanged with the reaction solution until 
equilibrium is achieved. Since the ink localized within the spot is much more 
concentrated than the surrounding solution (0.25 mM), water is diffused into the spot, 
causing it to swell and expand as silica is precipitated at the interface, which is 
comparable to what has previously been observed under similar reaction conditions.
132 
 
When the enzyme is incorporated within the reaction mixture, the variation in spot 
morphology is dependent on the method of synthesis, likely due to a competing 
mechanism of spot disruption. As water from the far more dilute reaction solution 
diffuses into the patterns, the concentrated buffer within each spot begins to diffuse 
outward. The significant disruption of the formed spot observed during the first synthesis 
is likely due to the decrease in the local ionic strength of the spot during this interfacial 
diffusion. The high concentrations of buffer (with both anions and cations) are not 
reaching the spot during the Method I synthesis because of the initial GOx (0.1 mg mL
-1
) 
incubation period. The enzyme is acting as the complementary charge for the 
supramolecular aggregation of the dendrimer template, depleting the region of reactive 
products before monosilicic acid is added. This is not observed in the Method II synthesis 
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because the two reaction components are added simultaneously, eliminating the initial 
incubation, or reaction, time.  
With the physical properties of the enzyme encapsulated film optimized, the activity 
of the constrained enzyme was examined. To test the enzyme activity, arrays (24 mm
2
 
area, cycled 2x) are printed directly into each well of a polymer coated 96-well plate to 
template enzyme encapsulation, and the wells are reacted using Method II synthesis 
(Figure 30). Note that the patterning in the 96-well plate are much more scattered. This is 
caused by the fact that printer cartridge is much farther away from the surface due to the 
depth (~1 cm) of the plate. Patterning within the plates however, provided a direct 
method for the rapid detection of enzymatic activity using a modified version of a GOx 
activity assay.
123
 In this assay, the encapsulated GOx patterns were reacted with substrate, 
-D-glucose, and molecular oxygen to produce -gluconolactone and hydrogen peroxide 
products, with the latter being easily detected through a coupled horseradish peroxidase 
colorimetric assay.  
 
 
With the ink patterned into the wells, each well are reacted for 20 min, according to 
the Method II synthesis, and the resulting patterns were purified through a series of 
Figure 30. Images of the patterned inks on gold (left) and a 96-well plate (right) 
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centrifugation and wash cycles. At the end of the third wash, the supernatant was 
extracted, and the encapsulated patterns were assayed for enzyme activity. The starting 
enzyme concentration within each reaction mixture was varied to determine the 
maximum loading capacity and encapsulation efficiency of the patterns (Table 4).  
 
 
Starting Enzyme 
Concentration [µg/ mL] 
Amount of Active 
Enzyme per Well [ ng] 
Reaction Velocity 
[nmoles/min] 
Relative Activity to 
soluble GOx [%] 
0.6 31.1 ± 0.1 1.6 ± 0.3 25.9 ± 4.5 
3 80.4  ± 15.1 4.2 ± 0.8 13.4 ± 2.5 
6 106.8 ± 16.8 5.6 ± 0.9 8.9 ± 1.4 
12 117.6  ± 26.4 6.2 ± 1.4 4.9 ± 1.1 
 
The most robust encapsulation parameters (0.6 g mL-1, 200 L) offered the 
highest % activity when compared to free GOx in solution (25.9 ± 4.5 % of the starting 
enzyme activity). Enzyme saturation is observed at concentrations higher than 3 g mL-1, 
corresponding to a maximum loading of ~120 ng of enzyme per reaction well. In fact, 
incorporating the higher starting enzyme concentrations (3, 6, and 12 g mL-1) is reported 
to decrease the % of enzymatic activity within the patterns at a rate of ~6 nmoles/min.  
Even the minimal fraction of activity (~5%) observed for the 0.6 g mL-1conditions 
infers that there is a trade-off between maximizing the enzymatic activity of the 
encapsulated patterns and optimizing the loading efficiency of the samples.  
Table 4. Activity of the enzyme as a function of starting enzyme concentration. 
69 
 
To determine whether enzyme confinement within the 2D microenvironment has 
affected its functionality, kinetic parameters were determined for patterned GOx at the 
optimal concentration (0.6 g mL-1). When compared to GOx free in solution, the 
immobilized enzyme exhibited a near two-fold decrease in Km (24.47 + 2.81 for soluble 
GOx compared to 9.31 + 1.37 for 2D GOx), suggesting that restricting the enzyme to the 
2D surface effectively reduces its access to the substrate.  Compared to the solution-phase 
enzyme encapsulated nanoparticles, which exhibited 50% relative activity when 
compared to soluble GOx,
123
 the activity of the enzyme immobilized within the patterned 
surface demonstrated a one-fold decrease in activity. By restricting the enzyme to the 2D 
surface, many of the nanopores that were available during the solution phase synthesis 
are blocked by the substrate, and the film is restricted from diffusing through the solution. 
Therefore, the overall activity of the 2D phase composite is expected to be slower than 
the encapsulated enzyme in solution.  For all of the restrictions placed on the enzyme 
within the pattern, however, its overall activity is still robust enough for many 
applications.     
With the enzyme film still active on the 2D surface, their storage stability and 
reusability are investigated. In these studies, the encapsulated enzyme spots are initially 
assayed for repeated use. After 10 reaction uses over two weeks, the enzyme film 
demonstrated minimal degradation and remained ~98% active when compared to the 
initial reaction activity. (Figure 31).  
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Similarly, the stability of the enzyme (stored at 4
o
C in a phosphate buffered solution) is 
investigated, again over a period of two weeks (Figure 32). When the patterns are stored 
in air, nearly 75 % of the activity is lost over time; however, when the patterns are stored 
at 4
o
C, enzyme activity is essentially maintained with only slight loss of activity (25 ± 
1%) at the end of the two weeks. This trend holds true for solution phase enzyme 
nanoparticles, as well.
123 
 
Figure 31. The calculated reusability of the enzyme encapsulated patterns as a function of time. The 
patterns retained near optimal activity after multiple reactions and washing steps. 
 
Figure 32. Storage stability of active printed patterns. The patterns were stored at 4
o
C in 0.1 M 
phosphate buffer and tested for activity after several days. 
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Conclusions 
This chapter highlights the bottom-up synthesis of an enzyme containing film, with 
specific emphasis on the physical and chemical properties of the immobilized enzyme. In 
general, enzyme confinement within the patterns reduced the overall reactivity, reaction 
rate, and product yield of the enzyme when compared to solution-phase reactions. 
However, this loss in activity is considered negligible when compared to the overall 
impact of the functionally active template. Localizing the enzyme to a 2D pattered 
surface not only minimized the amount of reactants used during the study, but also 
enabled the patterns to be  reused over extended periods of time without substantial loss 
in activity. The impact of such biologically active films can be translated into larger scale 
applications, serving a variety of functions, including biosensing and catalysis. 
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CHAPTER IV 
 
CURRENT STRATEGIES IN MALARIA DIAGNOSTICS 
 
Introduction 
 Although nearly eradicated, malaria has reemerged as one of the most prevalent 
diseases in the third world. Malaria is a tropical infectious disease caused by the 
protozoan parasites of the genus Plasmodium. Approximately half of the world’s 
population is at risk for malarial infection, with 108 countries and territories reporting 
nearly 250 million cases (of which ~1 million were fatal) in 2008 (Figure 33).
135
 The 
most susceptible population groups are young children, non-immune or semi-immune 
pregnant women, HIV infected individuals, and travelers/immigrants. One in five 
childhood deaths in Africa, occurring roughly every 45 seconds, can be attributed to 
malarial illness. In addition, current estimates suggest that an African child has on 
average between one and five episodes of malarial fever per year.
136
 It also contributes to 
30-50% of inpatient hospital admissions and up to 60% of outpatient health clinic visits 
in Africa. In countries with high infectivity rates, it is estimated that the GDP can be 
lessened by as much as 1.3%, placing malaria as the primary cause to the economic 
disparities between the infected countries and the rest of the world.
137
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 There are 5 types of known human malarial species: falciparum (by far the most 
common and most deadly), vivax, malariae, ovale, and some cases have been reported in 
southeast Asia with the monkey malaria parasite P. knowlesi.
135
 Transmission of malaria 
into the human host is achieved exclusively through the bites of Anopheles mosquitoes. 
Typically, these mosquitoes breed in shallow collections of water which are prevalent in 
humid climates. In Africa, the high infection rates can be partially attributed to the 
African Anopheles mosquito, which has a relatively long lifespan that allows for the 
parasite to fully develop, and is highly attracted to humans.  
 The life cycle of the malaria parasite is shared between the human host and the 
Anopheles mosquito vector. As a sporozoite, the parasite is transmitted to humans from 
the Anopheles mosquito during a blood meal (Figure 34).
19
 Within an hour, the 
sporozoites are transported to the liver, where they develop into schizonts. After 1-2 
weeks, the schizonts rupture, each releasing several thousand merozoites into the blood 
Figure 33. Estimated incidence of malaria per 1000 population, 2006.
3
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stream. There, they invade healthy red blood cells (RBCs). Within the RBC, the 
merozoite matures into a schizont containing several merozoites, eventually rupturing to 
release these merozoites. Some merozoites differentiate into gametocytes, which are 
transported to the mosquito during a blood meal with an infected host. Here, they mature 
into sporozoites, and can be reinjected into a human host. The cycle continues as these 
sporozoites infect additional RBCs. Further details of the parasite’s life cycle remain 
unclear. 
 
 
 The rupture of RBC’s marks the onset of visible symptoms of illness, including 
headaches, chills, and vomiting. If treatment is not administered within 24 hours of the 
Figure 34. Life cycle of the malarial parasite.
19
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onset of symptoms, the infection will become severe, likely resulting in death. A major 
challenge in diagnosing malarial infections is that the clinical presentation of malaria is 
highly variable and overlaps with other common febrile illnesses, including pneumonia, 
sleeping sickness, and tuberculosis.
138,139
 Without effective diagnostic technologies in 
low resource regions, early health care workers had to rely on their ability to diagnose 
symptoms rather than identify biomarkers of a disease, as is the case today. In addition, 
of the diseases mentioned above, only malaria has traditionally been treated effectively 
due to the availability of cheap and effective antimalarials, including quinine from 
Cinchona bark and more recently synthetic chloroquine. As a result, in endemic regions, 
most illnesses expressing malaria-like symptoms were treated as malarial illness. For 
many years, the medical community essentially forwent the diagnostic process and even 
recommended in training manuals for health workers to treat all fevers in children with 
cholroquine.
140
 In fact, it was reported that less than 20% of suspected malarial cases in 
75% of African countries receive a confirmatory diagnosis before treatment.
141
  
 Although many lives have been saved by this “fever equals malaria unless proven 
otherwise” mentality, in many settings, especially where malaria is seasonal or where 
intensive disease controls are implemented, only a small minority of febrile patients may 
be parasitaemic.
142
 In addition, over the last few decades, overuse of chloroquine has led 
to parasitic resistance toward the drug, rendering it ineffective against most P. falciparum 
infections. In general, monotherapies are the cause for drug resistance because in many 
instances people that have been treated still have an asymptomatic parasite load capable 
of being transmitted back into the mosquito vector. These setbacks in malarial treatment 
have led to the development of a new group of highly effective, fast-acting antimalarials 
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known as artemisinin-based combination therapies (ACT).
143
 Although highly effective, 
ACT incur more than 10 times the treatment costs of chloroquine, placing a severe 
economic burden on malaria-stricken countries.
144
 In many Sub-Saharan African 
countries, as much as 40% of all health care costs being attributed to malarial treatment. 
In addition, a report was published in 2010 indicating that P. falciparum parasites in the 
border region of western Cambodia and eastern Thailand have shown evidence of 
resistance to artemisinins.
145
 Without a current alternative treatment for malaria, accurate 
and efficient diagnosis and treatment of malarial infected patients is essential to suppress 
the spreading of resistant strains of malaria.  
 Malaria misdiagnosis and mismanagement also has individual and societal 
implications. At the individual level, misdiagnosis leads to costly drug purchases, which 
can also result in unwanted side effects. In addition, misdiagnosis implies that the 
individual is never treated for the true illness, which in many instances is potentially fatal. 
At a societal level, consistent mismanagement leads to a significant loss in consumer 
confidence in the health system. One major consequence is that the true infection rates of 
each disease are unknown, making it difficult for health officials to develop targeted 
regional strategies for each disease. To overcome these challenges, it is essential that 
efficient diagnostic strategies are developed and/or implemented so that both the patient 
and the healthcare provider have accurate information about the disease state of both the 
patient and of others in the region.  
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Healthcare in the Developing World 
 Of the ~7 billion people in the world, 3 billion lack basic sanitation, 2 billion do not 
have access to electricity, and more than 1 billion lack basic healthcare services and clean 
drinking water.
146
 In addition, approximately half of the world’s children live below the 
poverty line. More than half of the deaths in the poorest countries are the result of 
infectious diseases, compared to less than 5% in the richest countries.
147,148
 In developed 
countries, healthcare is provided through a centralized laboratory system that is capable 
of effective diagnosis and treatment even at the local level. In the few instances where a 
centralized laboratory system is available in developing countries, only the affluent upper 
class has access to their facilities. In general, healthcare in developing countries is 
divided into three classes: capital or major city level hospitals (high level); district-level 
healthcare providers (mid-level), and village-level healthcare workers (low-level).
16
 Of 
these three classes, diagnosis and treatment is performed primarily at the mid and local 
levels. 
 Mid-level healthcare facilities in the developing world look drastically different than 
those found in the U.S. Running water and electricity may or may not be available, and 
power is at best intermittent with wide fluctuations in voltage. Without air conditioning, 
the ambient temperature at such facilities can vary from 10-40
o
C. Dust, wind, and 
contaminating pathogens are very common as well. High risk human samples containing 
potential biosafety level 2 and 3 pathogens are typically handled with no more than 
gloves for protection. Maintaining and calibrating moderately advanced equipment is 
highly sporadic, questioning the validity of their output (Figure 35). Furthermore, at the 
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township and village level, power, running water, and refrigeration are highly intermittent 
or absent.
149
 
 
 
 Resource limitations in the low-level and to some extent the mid-level facilities 
require that diagnostics performed in these settings must be self-contained. If devices 
have a power requirement, it must come from battery power. It needs to require little or 
no maintenance or calibration, be dust-proof, be easily secured at night, and operate 
under variable environmental conditions. In addition, healthcare workers at this level are 
typically capable of only performing rudimentary dipstick or test strips. Also, test results 
must be easy to interpret so that misdiagnosis is avoided. In general, factors typically 
involved in influencing adoption of a diagnostic technology in low resource settings 
include
150
:  
 Cost of the device 
 Degree of sensitivity and specificity 
 Availability and cost of related equipment and supplies 
 Level of user training needed for implementation 
Figure 35. Typical laboratory conditions at mid-level healthcare facilities in the developing world.
16
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 Total time from sample collection to diagnosis 
 Sample collection and processing requirements 
 Equipment maintenance needs 
 Infrastructure requirements (i.e. electricity and water) 
 Performance under harsh environmental conditions 
 Availability of effective therapies 
 Management of hazardous waste 
Although these factors are not limiting, a diagnostic that sufficiently addresses these 
factors will most likely perform well in low-resource settings. 
 
Current Malaria Diagnostic Strategies 
 Traditionally, the “gold standard” for malarial detection has been microscopic 
examination of thick and/or thin blood films, where an experienced microscopist 
manually counts the number of parasites found per unit volume of blood (Figure 36).
151
 
When performed at a “high standard”, light microscopy is capable of accurately 
identifying and quantifying Plasmodium parasites within a timely manner in a clinical 
setting.
152
 Unfortunately, the quality of light microscopy is often limited in the clinical 
setting due to the difficult preparation of Romanowsky-based stains, poorly maintained 
equipment, and undertrained personnel.
153,154
 Ultimately, the reliance on electricity and a 
skilled technician limit the utility of microscopy to only high and some mid-level health 
care facilities in developing countries. For example, a 2006 study in Kenya showed that 
routine microscopy by local health workers was 69% sensitive and 62% specific when 
compared to expert microscopy.
155
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 Other diagnostic methods have also been developed, including fluorescence 
staining
156-158
, amperometric immunosensing
159
, single and multiplexed PCR 
techniques
160
, and enzyme-linked immunosorbent assays (ELISA) (Table 5).
161,162
 Each 
of these techniques is capable of either quantifying the parasite load or biomarker 
concentration with limits of detection below the WHO’s recommended parasite load of < 
100-200 parasites/L. They are however, limited primarily to the laboratory due to their 
sensitivity to environmental changes, requirements for specialized reagents, slow 
developing time, reliance on sophisticated equipment for an interpretable readout, and the 
necessity of a skilled workforce to administer and interpret the diagnostic. 
 
 
 
 
 
 
Figure 36. General light microscopy for Plasmodium detection. Left: A thin blood smear stained with 
Giemsa. Right: A thick blood smear. Images courtesy of the CDC.  
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 Technique Limit of Detection 
(parasites/L) 
References 
Microscopy Thick Film 5-20 
151
 
Thin Smear 50-200 
151
 
Fluorescent 
Microscopy 
Acridine Orange 100 
156
 
Quantitative Buffy Coat 100 
157
 
Electrochemical 
Detection 
Amperometric Immunosensor < 100 
159
 
PCR 18S rRNA and 
Circumsporozoite 
< 5  
160
 
ELISA pfHRP-II 12 
161
 
Unified LDH and pfHRP-II 2 
162
 
RDT pfHRP-II 100 
21
 
 
 
 Immunochromatographic rapid diagnostic tests (RDTs) have been developed for the 
detection of malarial infection in low-resource setting over the last two decades.
21,163,164
 It 
is estimated that approximately 25 million malarial RDT’s were produced globally in 
2005.
137
 These devices rely on detecting the Plasmodium antigens aldolase, lactate 
dehydrogenase (LDH) or P. falciparum specific Histidine-Rich Protein-II (pfHRP2) in 
blood obtained from a finger prick. This strategy generally works well for P. falciparum 
infection because ~97% of pfHRP-II is secreted as a soluble protein in the periphery of 
the red blood cell at picomolar to nanomolar concentrations during infection.
165
 These 
devices operate by labeling the target antigen from patient blood with monoclonal 
antibodies conjugated with a liposome containing selenium dye or gold nanoparticles. A 
Table 5. Limits of detection for current malarial diagnostic strategies. 
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nitrocellulose membrane strip coated with capture antibodies is then dipped into the 
sample solution. As the liquid travels up the test strip, the antibody-conjugated enzyme is 
captured by the antibodies on the strip, resulting in the formation of a visible band 
(Figure 37).
21
 The inclusion of a goat anti-mouse antibody on the test strip provides a 
positive band that ensures that lateral flow is achieved on the test strip. 
 
 
 Although these techniques have performed at the same limits of detection as 
microscopy in laboratory testing (> 100 parasites/L), these techniques have not 
performed well when tested by the World Health Organization under high temperature 
(40
o
C) and humidity conditions (Figure 38).
166
 In fact, of the 50 RDTs that qualified for 
Figure 37. Dipstick malarial RDT mechanism of action.
21
 A.) The RDT is dipped into a solution 
containing a patient sample with gold conjugated monoclonal antibodies. The solution travels up the 
dipstick and passes over HRP2-specific antibodies, localizing the HRP-antibody-gold conjugate B.) A 
buffered solution is used to wash away any excess reaction solution. C.) The dipsticks are assessed for 
positive detection.   
A.) 
C.) 
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the study, only four had detection rates above 90% for the WHO recommended lower 
limit of detection of 200 parasites/L. This loss of sensitivity is likely due to the thermal 
instability of the antibodies under these conditions. In addition, many of the RDT 
manufactures are small companies and have traditionally had difficulty obtaining 
reference materials with well-characterized malarial patients and biological standards.
149
 
As a result, their ability to optimize their product and evaluate lot variability during 
manufacturing has been limited. One side effect of RDT variability is that health care 
workers at the mid and low-level health care facilities frequently ignore RDT results. 
This lack of confidence in the RDTs is further enhanced by ingrained treatment habits 
and pressure from patients and family members to treat sick patients.
142
 Without 
consistency, current RDTs will continue to be questioned by those who use them most 
prevalently in the field.  
 
Figure 38. Malarial RDT detection rates as reported in the WHO’s Malaria Rapid Diagnostic Test 
Performance study of 2008-2009.
2
 Each brand of RDT that qualified for the study was subjected to a 
high thermal (40
o
C) and high humidity (95%) incubations (2 months) prior to product testing. The 
RDTs were then tested against patients with low and high parasitemia (200 and 2000 parasites L) 
respectively.  
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The Future of Malarial Low-Resource Diagnostics 
 Despite all of the challenges with drug and pesticide resistance
135
, malaria 
transmission is generally declining for many of the affected regions of the world.
167
 
Because of these findings, the WHO is now recommending that all patients with 
symptomatic malarial infections be confirmed by parasite-based diagnosis before 
treatment is given. Accurate diagnosis of symptomatic patients is important to rule out 
those with other non-malarial febrile infections and reduce the rate of misdiagnosis. In 
addition, it is becoming more generally accepted by world health leaders that for malaria 
elimination to be achieved, identification and treatment of asymptomatic carriers of the 
parasite is essential.
152
 Current antigen-detecting RDTs are likely to miss a significant 
portion of asymptomatic cases in low-transmission settings.
168
 To achieve these goals, 
new diagnostic strategies are needed that can detect very low levels of Plasmodium 
biomarkers in asymptomatic patients.  
 In addition, alternative patient sampling procedures may be needed for asymptomatic 
patients who won’t be as willing to provide a blood sample for testing. Many societies 
have blood taboos that limit access to blood sampling as well.
169
 Alternative sources of 
non-invasive patient sample will be required such as saliva, urine, or feces. For example, 
pfHRP-II has been detected in saliva and urine of infected patients, albeit at lower 
concentrations.
169,170
 One potential way to circumvent this challenge is to design a sample 
processing device that could purify and concentrate a large volume of patient sample (i.e. 
1 mL) into a much smaller volume (i.e. 10 L) for diagnosis. 
 Considerable effort has also been put into designing portable battery operated 
microscopy techniques that utilize the camera capabilities of most current cellular 
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phones.
171-173
 These devices could serve two purposes; (1) they could save diagnostic 
information, which could be collected and used in creating databases to determine where 
infections are most prevalent and (2) allow for the use of alternative diagnostic strategies 
that rely on complex analysis techniques (i.e. through the use of Smartphone 
applications) in places where it may have not been possible in the past. Despite their 
sophisticated hardware and software capabilities, the rapidly growing consumer use of 
cell phones is driving down the cost of their manufacture and implementation, making 
them an attractive potential component to low-resource diagnostic strategies in the next 
decade.   
  
Dissertation Aims for the Development of Malaria Diagnostics 
 The following chapters highlight our efforts towards designing reagents to assist in 
improving malaria diagnosis in the field. Chapter V highlights a malarial sample 
processing technology that utilizes surface tension valuing capable of purifying and 
concentrating pfHRP-II from plasma and whole blood, which could lower the limits of 
detection into the asymptomatic regime necessary for malarial elimination strategies. 
Chapter VI introduces a novel coffee-ring based diagnostic platform that utilizes an 
antibody-free ELISA-inspired capture strategy for the detection of pfHRP-II.   
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CHAPTER V 
 
DEVELOPMENT OF A LOW RESOURCE PURIFICATION PLATFORM FOR 
PLASMODIUM FALCIPARUM HISTIDINE-RICH PROTIEN-II USING SURFACE 
TENSION VALVES 
 
Introduction 
 As global health organizations begin to focus on worldwide malarial elimination, 
diagnostic strategies need to be able to not only accurately diagnose symptomatic patients 
in low resource settings, but also be able to identify asymptomatic carriers as well. With 
limits of detection > 100 parasites/L, current lateral flow RDTs are fundamentally 
limited to detecting only symptomatic cases. Two possible solutions arise: (1) design a 
novel diagnostic platform that has lower limits of detection and/or (2) design a sample 
processing device capable of concentrating and purifying the biomarker of interest. 
Ideally, a novel platform would be capable of achieving both goals, while maintaining the 
simplicity of use and relative ease of interpretation seen with the current diagnostic 
strategies. 
 When considering a novel diagnostic strategy, it is important to consider the 
limitations faced in low resource settings. For example, complex biological media 
contains high concentrations of solutes (i.e. salts and proteins) that can specifically or 
non-specifically interfere with diagnostic reagents. For example, human whole blood 
consists of 45% erythrocytes and 3.5-4.5% soluble protein. If red blood cells lysis is 
necessary to collect more biomarker (as is the case for malarial detection using pfHRP-
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II), then ~5 mM hemoglobin is released into the biological solution. Hemoglobin has a 
strong visible absorption at 414 nm from the Soret band of heme, giving blood its dark 
red color. If a colorimetric readout is desired for accurate detection, such as in the 
commercially available malaria RDTs, then elimination of biological noise is desired. 
These RDTs remove biological noise by continuous lateral flow, where the biomarker is 
captured and labeled on the nitrocellulose test strip. For alternative diagnostic strategies 
however, new methods of sample processing are desired. 
 Recently, it has been demonstrated that biomarkers such as RNA can be purified from 
complex mixtures using oil-liquid interfaces.
174-176
 The oil interface provides a barrier 
between the complex reaction solution and the elution chamber, preventing mixing of the 
chambers. Using a functionalized magnetic particle, the biomarker of interest can be 
specifically captured by the particles and transferred through the oil interface to an 
elution chamber, with minimal contamination from the biological sample solution. In 
general, these devices rely on the dominance of surface tension over gravity at the 
microscale to keep oil and aqueous phases indefinitely separated. This enables sequential 
loading of aqueous chambers separated by an oil interface (or valve), which is not 
disrupted by gravitational effects.    
As noted in Chapter IV, one of the principle targets for Plasmodium falciparum 
malaria RDT’s is pfHRP-II, a 67kDa protein dimer that contains histidines assembled in 
multiple repeats of AHH (51 total) and AHHAAD, which comprise ~85% of the total 
amino acids.
177
 It is an attractive biomarker for current malarial rapid diagnostic tests 
(RDTs), because 97% of the protein is released into the host’s blood during red blood cell 
rupture.
178
 In vitro, pfHRP-II coordinates as many as 50 heme molecules per dimer 
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through bis-histidine axial ligation.
179
 Ni(II) and Zn(II)NTA agarose affinity columns 
have been used to selectively isolate pfHRP-II from blood or serum samples containing 
human serum albumin, transferrin, 2-macroglobulin, and histidine-rich 
glycoprotein.
177,180
  
Ni(II) nitrilotriacetic acid (NTA) chelation has become a widely adopted technology 
for the isolation and purification of hexahistidine-tagged recombinant proteins.
180-182
 One 
advantage of Ni(II)NTA chelation is its high affinity to histidine, with an approximate 
dissociation constant (Kd) in the micromolar range.
183
 Chelation occurs between the 
imidazole side chain of histidine and one of the two available coordination sites of Ni(II) 
(Figure 39). In addition, other divalent metals such as Co(II), Zn(II), and Cu(II) can also 
be used as chelators to histidine.
177,184
 Consequently, pfHRP-II represents an attractive 
target for Ni(II)NTA chelation within a complex biological mixture.  
 
Figure 39. Coordination of histidine-rich targets to Ni(II)NTA ligands. NTA is a tetradentate ligand that 
coordinates with four of the six available binding sites on Ni(II) or other divalent transition metals. The 
remaining two binding sites are hydrated until they coordinate with the side chains of histidine. 
89 
 
In low resource settings, stability of reagents is a significant concern in the design of 
any diagnostic device component. For that reason, processing platforms are desired that 
do not require any biochemical or enzymatic reactions. Instead chemical and physical 
processes, such as Ni(II)NTA chelation, must be highlighted in an extraction cassette. 
This sample processing technology is designed to be a sample collection, concentration 
and preparation component for integration with downstream detection components to 
form a general diagnostic platform suitable for low resource environments. This chapter 
highlights the development of a low resource extraction device that isolates pfHRP-II 
from complex solutions using surface tension valves. The device utilizes the histidine-
specific chelation properties of Ni(II)NTA magnetic agarose beads to selectively capture 
pfHRP-II, isolate and purify using the separation properties of surface tension valves. The 
protein-bead conjugate is then delivered to a small volume elution solution, which serves 
to release and concentrate the protein. This device aims to improve the overall limit of 
detection of diagnosis, irregardless of the downstream diagnostic strategy. The extraction 
and concentration efficiency was demonstrated in simple (buffer) and complex (serum 
and whole blood) solutions and quantified using ELISA. The purity of the protein from 
biological interferents such as histidine-rich glycoprotein and hemoglobin were also 
analyzed.  
 
Experimental 
Materials and Reagents: Ni-NTA Magnetic Agarose Beads (Cat # 36111) were 
purchased from Qiagen Inc. Human Whole Blood (A+) collected in Na Heparin (Cat # 
HB1050), Human Plasma (A+) collected in CPD (Cat # HP1013), and whole Human Red 
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Blood Cells (A+) collected in CPD (Cat # HP1002A) were all purchased from Valley 
Biomedical Inc. Human Histidine Rich Glycoprotein ELISA kit (Cat # SEK10836) was 
purchased from Sino Biological Inc. Antibodies used in the pfHRP-II ELISA assay (Cat # 
ab9206 and ab30384) were purchased from Abcam Inc. TMB One solution (Cat # 
G7431) was purchased from Promega Corporation. D6 strain of P. falciparum malarial 
cultures were graciously provided by WRAIR. Recombinant HRP-II (Cat # AGPF-55) 
was purchased from Immunology Consultants Laboratory Inc. A 2” x 1” x ¼” 
neodymium magnet used in this study was purchased from Emovendo LLC. All other 
reagents were purchased from Sigma Aldrich Inc. or Fisher Scientific Inc. 
Culturing of Malarial Parasites: The D6 strain of P. falciparum obtained from WRAIR 
was cultured in A+ blood following the protocol described by Trager and Jenson.
185
 
When cultures reached a parasitemia > 5%, they were counted and frozen @ -80
o
C until 
further use. For limit of detection studies, cultures were synchronized to >95% rings 
using the method described by Lambros and Vanderberg.
186
 pfHRP-II content of the 
cultures was quantified by ELISA using the recombinant HRP-II as a standard. 
Design and Preparation of the Extraction Device: The extraction device was first 
prepared by cutting 1/16 inch inner diameter 1/32 inch thickness Tygon® tubing (Fisher 
Scientific, Cat # 14-169-1B) into 12 inch length pieces. Next, a PCR eppendorf tube was 
prepared by first puncturing a hole using a 27 ½ gage syringe needle in the top of the lid 
to serve as an air valve. The bottom of the tube was cut off (~1-2 mm) using a razor, 
leaving a hole for access to the Tygon tube. This tube was then placed into the Tygon 
tubing. To the opposite end of the Tygon tube, a 10 L solution of elution buffer (0.1 M 
phosphate buffer, pH 8.0, 300 mM NaCl, 500 mM imidazole, 0.05% Tween 20) was 
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added to the tube using a gel tip. The end of the tube was then sealed with the closed end 
of a melting temperature tube. Next, starting at the elution buffer end of the tube, valves 
(50 L of mineral oil) and chambers (100 L of 0.1M phosphate buffer, pH 8.0, 300 mM 
NaCl, variable concentrations of imidazole, and 0.05% Tween 20) are sequentially added 
to the device using a 27 ½ gauge syringe. Note: in older versions of the device, the 
loading chamber, wash chamber composition, and elution chamber will vary and will be 
noted in the text. 
Extraction Protocol of Samples: The extraction of samples was performed by first 
incubating the sample of interest (100 L) with a 100 L solution of 2x lysis buffer 
containing a final concentration of 0.1 M phosphate buffer, pH 8.0, 300 mM NaCl, 
variable concentrations of imidazole, and 1% Triton X-100 for 1 min in the PCR tube 
connected to the Tygon tubing. Next, a 10 L solution of Ni(II)NTA magnetic agarose 
beads (from stock, 9 x 10
-18
M beads) were added and protein binding was allowed to 
proceed while the sample was tumbling on a rotating rotisserie to ensure the beads 
remained suspended. After incubation, the agarose beads were collected using a donut 
magnet (250-300 mT in the center) and transferred into the first wash chamber. The 
beads were then diffused within the chamber for ~30 seconds and recollected before 
travelling into the next chamber. The overall time the samples remained in each wash 
chamber was ~1 min. This process was repeated until the beads reached the final 
chamber, where they were mixed manually for 10 minutes to ensure all protein was 
eluted from the beads. After elution, the magnetic beads were transported back into the 
adjacent oil valve and each chamber was cut out using a razor, collected in eppendorf 
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tubes and quantified for protein content. Note: in earlier studies, the extraction procedure 
will vary and will be noted in the text.  
ELISA Quantification of pfHRP-II: A 100 L solution of IgM anti-HRP-II (ab9206) in 
1x PBS (1 g/mL) was added to each well of an Immulon 2 HB 96-flat well plate and 
either incubated for 1 hour at room temperature or sealed with Para film and stored @ 
4
o
C overnight. After incubation, the wells were washed three times with 1x PBS 
containing 0.1% Tween 20 (PBST). Next, a 300 L solution of PBST containing 5% 
BSA (by weight) was added to each of the wells and incubated at room temperature for 1 
hour. After washing 3x with PBST, 100 L aliquots of diluted sample and controls in 
PBST with 0.1% BSA were added and incubated for 2 hours at room temperature. Note: 
the working range of the assay is 0-25 pM pfHRP-II. After washing the plate 5x w/ 
PBST, a 100 L solution (0.5 g/mL) containing IgG anti-HRP-II with HRP (ab30384) 
in PBST with 0.5% BSA was added and incubated at room temperature for 1 hour while 
protected from light. The plate was then washed 5x w/ PBST and a 100 L solution of 
TMB One solution was added and incubated for 20 minutes at room temperature under 
reduced light. The reaction was then quenched upon the addition of a 100 L solution of 
2M H2SO4. The plate was then measured spectrophotometrically at 450 nm using a Bio-
Tek Synergy HT multi-detection microplate reader. 
ELISA Quantification of HRG: ELISA plates and samples were prepared according to 
the kit procedures provided by Sino Biological with a few modifications. After loading 
the detection antibody and washing, analysis was performed by adding 100 L of the 
TMB One solution and incubating at room temperature under reduced light for 20 
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minutes. The reaction was quenched upon the addition of 100 L of 2M H2SO4 and the 
plate was measured spectrophotometrically at 450 nm. 
Hemoglobin Quantification: Hemoglobin concentrations were quantified by collecting 
reaction samples, measuring their absorbance at 414 nm, and calculating their 
concentrations by the molar extinction coefficient of hemoglobin. Note: the molar 
extinction coefficient of hemoglobin is 524,280 cm
-1
*M
-1
.  
Whole Protein Gel Analysis: Protein content of the chambers was evaluated using SDS-
PAGE gels either stained with Coomassie or silver stained. For silver staining, the gel 
was removed from its cassette and fixed for 1 hr in fix solution (50% MeOH, 12% acetic 
acid, and 0.0185% paraformaldehyde). Next, the gel was washed three times for 8 
minutes with 50% MeOH. After washing, the gel was incubated for 1 min in pretreatment 
solution (0.02% Na2S2O3) and washed three times for 20 seconds in water. The water was 
decanted, and the silver stain solution (0.2% AgNO3) was added and incubated with the 
gel for 20 min. After incubation, the silver stain was removed and the gel wash washed 
three times for 20 seconds in water. Next, the development solution (6% Na2CO3, 
0.0004% Na2S2O3, 0.0135% paraformaldehyde) was added and mixed with the gel until 
proper resolution was achieved. After incubation, the development solution was removed 
and the stop solution (50% MeOH and 12% acetic acid) was added. The gel was washed 
with water and analyzed for protein content. 
 
Results 
The proposed self-contained processing device captures pfHRP-II from complex 
biological matrices on the surface of a Ni(II)NTA magnetic agarose capture beads. These 
94 
 
beads then carry the biomarker through sequential washing solutions to reduce biological 
interferents and also concentrate the sample for improved diagnostic performance. The 
proposed device has several advantages: it (1) requires little or no power, (2) can be made 
suitable for an unskilled user, (3) have rapid time-to-extraction, (4) be low cost, and (5) 
be adaptable to multiple downstream detection designs. Currently, there is no known 
available low resource point-of-care extraction device that has the same level of 
simplicity, convenience, low cost and ease-of-use. Although the detector constraints 
downstream of the proposed component are undetermined, in general, detection of 
biomarkers of infection in patient samples is more easily achieved with a higher 
concentration of diagnostic biomarkers of interest and a lower concentration of 
interferents. 
 
Extraction Device Design and Physical Properties 
 In the generic extraction device outlined in Figure 40, surface tension valves are 
created when alternating solutions of processing buffer and oil are added to Tygon 
tubing. The oil “valves” serve as an immiscible phase filter between buffer “chambers”, 
which prevent mixing of the chambers. Each chamber can be composed of an aqueous 
buffer solution, where purification is achieved by simply processing the sample through 
the chambers in the presence of a magnetic field using magnetic capture beads. The 
chambers can also contain unique reagents, which allow for various processing steps to 
be conducted sequentially with minimal contamination from previous chambers. This 
extraction process requires two components: (1) a magnetic capture bead capable of 
binding an antigen of interest and traversing through the oil valve and (2) a magnet with a 
95 
 
strong enough magnetic field to overcome the surface tension of the oil/water interface. 
The modularity of this design allows for the addition of a sample preparation chamber 
and an elution chamber. Depending on the application, these chambers can also be added 
to the extraction device to create an all-in-one sample preparation device or diagnostic. 
 
  
 The surface tension in the small diameter tubing holds each of the solutions in place, 
and individual solutions remain largely undisturbed when the magnetic beads pass 
through the oil valves from one aqueous chamber to the next. The stability of the valve 
can be described by a physical property called the Bond number (β).187 Bond number is a 
Figure 40. General extraction device design using surface tension valves. Samples are prepared either 
prior to processing or pre-loaded into a sample preparation chamber. Processing is achieved through 
magnetic capture beads that are processed through wash chambers separated by oil valves. After 
processing, the samples are collected either in a final chamber or outside of the device for analysis or 
further processing. Bottom right: Visual image of the water/oil interface and quantification of surface 
tension properties.   
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measure of the importance of surface tension forces compared to body forces. It is 
described by the following formula: 
                                                        β=ΔρgR2/γ      (1) 
where β is the bond number, ρ is density, g is the gravitational force constant, R is the 
spherical cap radius, and γ is the surface tension. A large Bond number indicates that the 
system is relatively unaffected by surface tension effects; a low number (typically less 
than one is the requirement) indicates that surface tension dominates. Intermediate 
numbers indicate a non-trivial balance between the two effects. As noted in Figure 40, 
the calculated Bond number for an oil/water interface in 1/16” inner diameter Tygon 
tubing has been calculated to be 0.026, which indicates that surface tension between the 
water and the oil dominates over gravitational forces. Contact angle 163.7 + 3.5
o
 
Therefore, the valves should be stable under these conditions. 
 A second important measure of valve stability is defined by the capillary force on the 
valve. Capillary force is related to stability because solutions in the extraction cassettes 
must overcome the accelerative forces of handling to resist mixing. The capillary force is 
defined as
188
: 
      F=2πrγcosθ      (2) 
where F is the capillary force, r is the radius of the tube, γ is the surface or interfacial 
tension, and θ is the contact angle of the solution with the tube wall. With an 
experimentally determined contact angle of 163.7 + 3.5
o
, the capillary force was 
calculated to be -0.242 mN, indicating that the interface is stable and subsequently 
resistant to mixing.  
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 Although it has been determined that the oil/water interface is stable enough to be 
maintained in the tubing, it is not clear whether magnetic beads can successfully travel 
through the valves while maintaining the integrity of the valve. The process of entering 
and exiting an oil valve was analyzed for Ni(II)NTA-functionalized magnetic agarose 
beads (Figure 41). Visualization was performed by placing the tubing in glycerol and 
taking still-shots as the beads traverse through the surface tension valves. As the beads in 
the aqueous chamber approach the interface by magnetic movement, they begin to disrupt 
the surface tension of the valve. The particles begin to protrude beyond the interface and 
continue to travel on the tubing surface. The surface tension of the valve is eventually 
overcome and the valve retracts back to its original shape, releasing the beads into the oil 
valve. The beads remain hydrated, carrying a small volume of water with them in the 
valve. Although this does introduce some non-specific carryover of contaminating solutes 
and proteins, it is likely necessary that the bead-protein conjugate remains solubilized to 
retain the structural integrity of the protein for downstream diagnosis. As the beads in the 
oil valve make contact with the oil/water interface, the surface tension is again disrupted, 
and the water chamber “absorbs” the hydrated beads. After the beads are within the 
original dimensions of the aqueous chamber, the interface retracts back into its original 
shape. Although the process of entering and exiting the valves initially disrupts the 
oil/water interface, as long as the oil valve is sufficiently long enough that the two water 
chambers don’t make contact, the interfaces remain stable and return to their original 
conformation. 
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 We assume that the force required to transfer a functionalized bead or cloud of beads 
across a surface tension valve is related to the capillary force acting on the beads. This 
relevant force is analogous to the maximum attractive force of a sphere exiting a liquid 
surface through a liquid bridge. This force can be calculated by the following formula
189
:       
      F=4πrγcosθ     (3)  
where γ is the surface or interfacial tension, θ is the contact angle of the solution with the 
particle surface, and r is the radius of the bead. Ni(II)NTA agarose beads have an average 
Figure 41. Bead transport through water/oil interface. A. Ni(II)NTA magnetic agarose beads are pulled 
through an aqueous reaction chamber into an oil valve. B. Beads as they approach and enter an adjacent 
water chamber after transport through an oil valve. Images provided by Catherine Majors. 
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radius of 25 µm, the surface tension at the interface is 0.05 J/m
2
, and a contact angle of at 
the surface of water on the magnetic agarose bead is approximately 164° if we assume 
that Tygon has a contact angle to the agarose surface. The capillary force acting on a 
single bead is ~15 N. Interestingly, these beads do not readily travel through air valves, 
in contrast to the silica beads used during RNA processing.
176
 Based on the formula 
above, it is likely the size of the bead that inhibits them from travelling through the air 
interface.  
 The surface tension of the valve can be disrupted by the addition of surfactants such 
as Tween 20 and Triton X-100. Both of these surfactants are necessary with this system 
because Tween prevents that agarose beads from sticking the sides of the Tygon tube, 
and Triton is used to lyse the red blood cells. From our observations throughout this 
study, it appears that the addition of these surfactants does not significantly disrupt the 
valves, and the valves maintain their integrity throughout sample processing. This 
observation was also noted by Berry et al for their RNA processing strategy.
175
  
 The Ni(II)NTA magnetic agarose beads used for these studies are ~50 m in diameter 
(20-70 range), have a concentration of ~760 beads/L at stock concentration, and have an 
estimated binding capacity of 2 g of His-tagged protein per L of stock solution of 
beads. This corresponds to ~10 pmol of bound protein per L of beads for a 24 kDa His-
tagged protein. Based on estimates determined from the referenced literature
161,162,190-192
, 
the upper parasite load (i.e. 2000 parasites/L) contains ~1 nmol/L pfHRP-II, or 0.1 
picomoles per 100 L of parasite sample. Based on these calculations, the magnetic 
agarose beads, if added 1:100 to the sample, will be in 100-fold excess in terms of 
loading capacity. It is recommended however that 10 L of stock agarose bead 
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suspension be used per assay due to their settling velocity and size. Therefore, under all 
physiologically relevant conditions, the agarose beads will be in binding excess relative 
to pfHRP-II. In addition, the concentration of beads in a typical reaction (210 L) will be 
~36 beads/L.  
 
Optimization of Sample Processing Parameters 
 Initial studies focused on whether the oil valves would allow for the successful 
processing and recovery of the targets. Recovery of a peptide mimic of pfHRP-II was 
first investigated. The synthetic analog is a linear 27 amino acid containing three repeat 
motifs of AHHAHHAAD, and functionalized with an N-terminal TAMRA moiety. Initial 
experiments focused on comparing sample isolation between a standard eppendorf tube 
protocol and the extraction device. Extractions and controls were performed by first 
incubating a 90 L solution of TAMRA-HRP-II (10 M) in PBS with 0.025% Tween 20 
(PBST) with 10 L of Ni(II)NTA agarose beads. After 10 minutes of incubation on a 
rotisserie, the samples were either washed 3x with PBST in the tubes (controls) or 
processed through the extraction device (containing 5 chambers, 3 with PBST and 2 
sequential elution chambers containing PBST and 500 mM imidazole). Figure 42 shows 
the isolation efficiency of both methods. In both methods, over 50% of the protein is 
accounted for in the elution chamber. There is also no peptide detected in the post-elution 
chamber, suggesting that the elution time in the primary elution chamber is sufficient to 
collect all of the peptide from the beads. Extraction efficiency was also tested in the 
presence of 100 g/mL of fluorescein-labeled BSA. Extraction efficiencies are essentially 
maintained in the presence of the biological interferent. In addition, the amount of BSA 
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collected in the elution chamber is < 10% even in a non-blocking solution, suggesting 
that TAMRA-HRP-II binds preferentially over fluorescein-BSA.  
 
 
     
 Inspired by these promising results, extractions were performed against 
unsynchronized malaria parasite culture. A stock of freeze-thawed lysed culture (0.1% 
parasitemia, 3.25 nM pfHRP-II) diluted in water was extracted using the method 
described in the previous paragraph, but with the wash chambers containing 200 mM 
imidazole (It was determined that this is the maximum concentration before competitive 
blocking occurs). After 30 minutes of incubation, the sample was processed through the 
device and the wash chambers and elution were collected. It should be noted that the 
elution of the protein was achieved by transferring the beads out of the tubing into an 
eppendorf tube containing 100 L of elution buffer (Prototype design highlighted in 
Figure 43). ELISA analysis of the chambers determined that ~75% of pfHRP-II can be 
found in the elution chamber (Figure 43, left). In addition, analysis using a commercial 
Figure 42. Extraction efficiencies of TAMRA-HRP-II using the extraction device. Left: Extraction 
efficiency of the peptide in eppendorf tubing and the extraction device. Right: Extraction efficiency in 
the presence of a biological interferent.   
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RDT against pfHRP-II kit confirms that a majority of the protein is located in the elution 
chamber. 
 
 
  
 Although promising, sample processing time must be minimized to for a rapid 
diagnostic device. In addition, it is still not clear whether extraction efficiencies are 
maintained in the presence of complex biological samples. Extractions were performed 
by spiking 0.04% parasitemia unsynchronized culture (1.3 nM pfHRP-II) into 50% 
plasma and 50% whole red blood cells. For these studies, a lysis buffer containing 1% 
Figure 43. Early device design and extraction efficiencies of pfHRP-II from culture. A. Device design 
used in this study. The sample is reacted in an eppendorf tube prior to loading into the loading chamber. 
This chamber is capable of handling samples as large as 1 mL. Three wash chambers are separated by 
mineral oil valves. The elution buffer is independent of the device, allowing for simple handling. B. 
Extraction efficiency of pfHRP-II from culture. C. Representative RDT testing of the chambers of the 
device after processing. 
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Triton X-100 was used to lyse the red blood cells prior to processing. Protein recovery in 
the elution solution was 89.7 + 5.0% for plasma and 83.7 + 6.2% for red blood cells after 
30 minutes of incubation (Figure 44). At 10 minutes, recovery was a respectable 60.2 + 
1.4% for plasma and 47.6 + 1.6% for red blood cells. In addition, silver staining of an 
SDS-PAGE gel of the blood incubated for 30 minutes indicates that there is minimal 
contamination of interfering proteins in the elution chambers, highlighting the 
purification capabilities of this extraction process. 
 
 
 One of the advantages of this device is the ability to modify chamber size and 
composition without drastically affecting the fundamental properties of the surface 
tension valving. Previous work utilized a loading and elution chamber that was 
Figure 44. Extraction efficiencies in complex biological media at variable times. A. Extractions 
performed in 50% human plasma. B. Extractions performed in 50% lysed red blood cells. C. Silver 
stained gel extractions performed in 50% lysed red blood for 30 minutes. Lane 1: ladder. Lane 2: 
Sample loading chamber.   Lanes 3-5: Sequential wash chambers. Lane 6: Elution solution. 
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disconnected from the processing chambers. In a low resource setting, sample processing 
must be streamlined and simplified for ease of use. To address these needs, the sample 
and elution chambers were modified in such a way that they were contained in an all-in-
one device. In addition, the device design allows for the introduction of a much smaller 
elution chamber capable of significantly concentrating the antigen. It is not clear 
however, how elution within the device in a smaller volume affects the yield. Figure 45 
highlights the recovery capabilities of the all-in-one device. Ni(II)NTA magnetic agarose 
beads were pre-loaded with recombinant HRP-II and processed through the chambers 
into variable sized elution chambers. Changing the elution chamber volume didn’t affect 
the overall protein yield, and the smaller elution chamber (10 L) concentrated the 
sample nearly 10-fold. In addition, it was experimentally determined that elution of the 
protein from beads in a 10 L elution chamber with manual magnetic mixing yields 
significant protein after 2 minutes and most after 5 minutes.  
105 
 
 
 
Figure 45. Effect of elution chambers volume on recovery. A. Overall relative yield of HRP-II as an 
f(x) of elution volume. B. Effective concentration factor of the smaller elution chamber volumes. C. 
Time study to determine the optimal elution time with manual processing for a 10 L elution chamber.  
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Evaluation of the Current Extraction Design 
 
 
  
 Using all of the information gathered with the early prototypes designed above, the 
current extraction design format is outlined in Figure 46. This design consists of 5 
aqueous chambers separated by four mineral oil valves. The loading chamber contains a 
whole blood lysis buffer and imidazole to prevent any interfering protein interactions 
with the Ni(II)NTA agarose beads. The middle three chambers contain buffer with 
blocking concentrations of imidazole to prevent any binding of protein caught in the 
carryover volume of the beads. The final elution chamber has a high concentration of 
imidazole to ensure efficient elution of pfHRP-II. This chamber volume is minimized to 
concentrate the sample. The remaining studies all use the extraction protocol as described 
in the experimental section. 
 To determine the optimal imidazole blocking conditions, the binding efficiency of 
pfHRP-II was determined in the presence of varying concentrations of imidazole. Figure 
47 shows the loading efficiency of 1 nM pfHRP-II from unsynchronized parasite culture 
Figure 46. Self-contained sample processing design. 
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in the presence of imidazole after 30 minutes of incubation. Binding of pfHRP-II to the 
Ni(II)NTA magnetic agarose beads is not affected significantly until ~150 mM imidazole 
is present in solution. Complete blocking of pfHRP-II is achieved at concentrations above 
300 mM. Thus, optimal pfHRP-II binding can be achieved in conditions where the 
imidazole concentration is < 150 mM.  
 
 
 Extraction efficiency studies were performed under 125 mM imidazole blocking 
conditions with 10 minute incubation times at physiologically relevant concentrations in 
buffer, plasma, and pre-lysed whole blood. Figure 48 highlights the pfHRP-II yields 
determined under these conditions. Under all conditions, there was a 3-4.5 fold 
concentration of pfHRP-II in the elution chamber. At 1000 pM, which corresponds to the 
WHO upper range of infectivity, both the buffer and plasma samples have similar 
recoveries, while the whole blood sample has a 3-fold concentration in signal. At 100 
pM, plasma yields were similar to those at the higher concentrations, but there was a 
slight decrease in yield for the buffer and whole blood samples.  
Figure 47. Imidazole binding study to determine the optimal blocking conditions 
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 HRG is known to have a relatively strong affinity to Ni(II)NTA, and is commonly 
purified from plasma using Ni(II)NTA agarose purification strategies.
193
 Human plasma 
is reported to contain 100-200 g/mL of HRG, which corresponds to 1.3-2.7 M.194 
Blocking studies with human plasma were performed between 125-200 mM imidazole in 
eppendorf tubes to determine if there was any binding overlap between HRG and pfHRP-
II. Ni(II)NTA agarose beads were incubated with human serum for 30 minutes to allow 
for equilibrium to be established between free and bound HRG. After copious washing of 
the beads with wash buffer to remove any solubilized HRG, the remaining HRG was 
eluted in the presence of 500 mM imidazole and quantified using ELISA (Figure 49). At 
125 and 150 mM imidazole, significant amounts of HRG (~25% and ~6% of the total 
amount found in undiluted plasma, respectively) were recovered when eluted off of the 
agarose beads. At 175 mM imidazole, there is still ~0.25% of total HRG found bound to 
Figure 48. Comparison of extraction efficiencies of physiologically relevant concentrations of pfHRP-II 
in buffer, plasma and human whole blood.  
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the beads. Almost complete specific blocking of HRG was achieved at 200 mM 
imidazole.  
 
 
 To determine the recovery of HRG within the extraction device, control extractions 
were performed with plasma at 125 (“low blocking”) and 200 mM (“high blocking”) 
imidazole blocking conditions (Figure 50). Recoveries of HRG were similar to those 
conducted in eppendorf tubes. Under low blocking conditions, significant amounts of 
HRG (~17%) were recovered in the elution chamber. For the high blocking conditions, 
only ~0.013% of HRG can be accounted for in the elution chamber. When HRG recovery 
was compared between plasma and pre-lysed whole blood samples, there was no clear 
difference in overall recovery in the elution chamber, suggesting that the increased 
complexity provided by blood doesn’t lead to non-specific HRG contamination in the 
elution chamber.  
Figure 49. Quantification of HRG bound to Ni(II)NTA magnetic agarose beads in the presence of 
blocking conditions of imidazole.  
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 In addition to HRG, hemoglobin concentrations were also quantified using its molar 
extinction coefficient at 414 nm. Hemoglobin quantification serves to approximate the 
non-specific carryover of proteins from the sample loading chamber. It was determined 
that there was less than 0.1% of the original hemoglobin in the elution chamber under 
both conditions. Also, the high blocking conditions yielded ~50x less hemoglobin than 
the low blocking conditions. This suggests that either hemoglobin has a slight affinity to 
the Ni(II)NTA agarose or in general more interferents are being carried through under the 
low blocking conditions. A SDS-PAGE gel was prepared from the high blocking 
conditions and stained using Coomassie. Although whole blood contains significant 
amounts of protein (lane 3), the wash chambers and especially the elution chamber 
indicate that contaminating proteins remain primarily in the sample loading chamber. 
This highlights the utility of this method because the antigen of interest is being isolated 
with the same order of magnitude yield, while significantly reducing the biological noise.   
Figure 50. HRG purification efficiencies in the extraction device. Left: HRG contamination under low 
and high blocking conditions. Right: Effect of whole blood on HRG contamination. 
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Extraction Efficiencies below the WHOs Limit of Detection 
 One advantage of sample processing is the ability to concentrate pfHRP-II from a 
patient sample, which effectively lowers the limit of detection. Synchronized cultures 
were grown, counted, and lysed by freeze-thawing. Parasite loads at and below the 
WHOs recommended limit of detection were spiked into plasma and manually processed 
(Figure 52). At the low blocking conditions, 50% recovery of pfHRP-II was observed 
under all conditions, corresponding to an average 5-fold enhancement in signal. The high 
blocking conditions yielded 17-25% recovery, corresponding to a 1.7-2.5-fold 
enhancement in signal. Assuming that 200 parasites/L is the current LOD for the best 
RDTs on the market, it can be hypothesized that in conjunction with this extraction 
device, lower limits of detection can be achieved at 40-50 parasites/L. Furthermore, 
Figure 51. Quantification of contaminating proteins in the wash and elution chambers. Left: Recovery 
of hemoglobin at the low and high blocking conditions. Right: Coomassie stained SDS-PAGE gel of 
whole blood sample at high blocking condition. Lane 1: ladder. Lane 2 & 4: empty. Lane 3: sample 
loading chamber. Lane 5-7: sequential wash chambers. Lane 8: sample elution chamber.    
112 
 
when the reaction was performed at the low blocking conditions for 20 minutes, the 
recovery was improved to over 60% recovery (Data not shown). These results suggest 
that at the very least, this extraction technology could be used in conjunction with current 
RDT technology to improve the current LODs. 
 
 
Conclusions 
 A low resource device has been developed to extract and concentrate pfHRP-II from 
biological samples utilizing the properties of surface tension valves. This device was 
developed from the novel observation that for a small diameter tube, solutions separated 
by mineral oil valves are held in place by a capillary force. In fact, the capillary forces are 
so high that Ni(II)NTA magnetic agarose beads moving from one solution to the next 
pass through the oil valve entraining large volumes of the aqueous chambers. It has been 
demonstrated that sample processing of pfHRP-II from physiologically relevant parasite 
loads in complex media can lower the limits of detection by 5-fold at the cost of ~25 
Figure 52. Recoveries of pfHRP-II at and below the current WHO required limits of detection. Left: 
Total protein recovery for the low and high blocking conditions. Right: Fold concentration of pfHRP-II 
after processing. Note: for these studies the concentration of agarose beads was doubled to ~72 
beads/L. 
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minutes of processing. In addition, surface tension sample processing reduces biological 
noise by over 4 orders of magnitude. The device is fully self-contained and provides 
minimal sample handling, which eliminates the need for sophisticated equipment. The 
modularity of the device design allows for the preparation of a variety of sample volumes 
and compositions that can be tailored to the downstream application. Additionally, the 
technology is readily adaptable for the isolation of a variety of biomarkers, including 
other proteins, DNA, and carbohydrates. 
 
Future Directions 
 Studies are currently being conducted to demonstrate the limits of detection of the 
device with parasite samples prepared in whole blood. This is a more realistic condition 
that would be seen during sample processing of an infected patient in a low resource 
setting. In addition, processed samples are being analyzed by a commercially available 
RDT to determine how much amplification in signal can be achieved with this processing 
device. As mentioned above, alternative patient samples, including saliva, urine, and 
feces should also be investigated to determine the limits of detection in these complex 
samples. Also, it has yet to be determined whether the device exhibits long term stability 
at environmentally relevant temperatures and humidity.   
 Many parameters may have a significant effect on design performance including bead 
size, bead composition, tubing diameter, tubing material, and liquid characteristics. This 
modularity allows for a “plug-and-play” mentality, where different components can be 
modified to determine the optimal device composition. For example, 1 m Co(II)NTA 
magnetic beads are currently being investigated as an alternative capture bead. These 
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beads are advantageous because they not only traverse through oil valves they also travel 
through air valves. Air valves are preferred due to the reduction of overall cost of the 
device, and will likely be more stable than oil valves under environmentally relevant 
conditions. Previous work by the Haselton lab has shown that an air valve system works 
exceptionally well for an RNA processing device, with minimal contamination in the 
elution chamber.
176
  
 In addition to investigating the different valve and bead formats, the size and 
composition of the aqueous chambers can also be modified to improve efficiency, reduce 
overall reagent costs, and reduce processing times. The size and composition of the 
tubing can also be altered as well. Larger tubing is unlikely to work, due to loss in surface 
tension, leading to mixing of the chambers. However, smaller diameter tubing may prove 
to be advantageous because sample volumes can be reduced, again reducing costs. 
 Furthermore, the sample processing device will eventually need to be completely self-
contained and compatible with an assay for the detection of malaria to be useful in the 
field. As the various parameters are improved and the device is modified to become field 
ready, I believe that the utility of this device will become even more apparent and will 
catalyze the development of equivalent processing technologies for other biomarkers of 
interest. 
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CHAPTER VI 
 
DEVELOPMENT OF A COFFEE RING-BASED DIAGNOSTIC PLATFORM FOR 
THE DETECTION OF HISTIDINE-RICH PROTEINS 
 
Introduction 
Alternative diagnostic strategies for malaria detection are desired to circumvent the 
challenges faced in the developing world. Current diagnostics are used because they 
operate on premises that are well understood and established. Although this is commonly 
the standard by which device development should be performed, sometimes an “outside-
of the box” strategy provides the breakthrough needed to overcome the current 
limitations. In 1997, Robert Deegan published a letter in Nature describing the physical 
properties of how particles in coffee concentrate at the edge of a drying drop, leaving a 
visible stain.
195
 Termed the coffee ring phenomenon, this physical process capitalizes on 
the radial flow of a drying drop to replace evaporative losses at the pinned line (Figure 
53). The result is the concentration of colloidal particles into a well-defined ring, which 
can be easily visualized by naked eye. More recently, it has been demonstrated that this 
phenomenon can also be used as a nanochromatographic process where micro and 
nanoparticles form concentric rings that are separated based on their size.
196,197
 Unlike 
lateral flow assays, which utilize nanoparticles (2-5 nm) or dyes as the visible readout
21
, a 
radial flow assay could use particles such as nanoparticle aggregates or microparticles 
which would enhance the signal output. The following chapter highlights efforts toward 
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designing a radial flow malarial diagnostic that capitalizes on the physical properties of 
the coffee ring phenomenon. 
 
 
Physical Properties of Coffee Ring Formation 
The proposed assay is based on the physics of an evaporating drop. When a drop 
containing a homogeneous solution of colloidal particles is deposited onto a surface and 
allowed the dry, the particles are concentrated into a dense ring at the periphery. 
Complete ring formation is dependent on three essential requirements that must be met: 
(1) the solvent must dry, (2) the contact angle between the droplet and the surface must 
be > 0
o
, and (3) the contact line of the solvent must remain pinned to its initial position 
throughout the drying process.
195
 Interestingly, there are several physical properties 
commonly associated with solute transport that are negligible in ring formation. These 
properties include surface-tension gradients (i.e. the Marangoni effect), solute diffusion, 
Figure 53. Schematic of coffee ring formation. Colloidal particles such as gold nanoparticles or 
polystyrene microspheres are deposited at the drop edge due to radial flow induced by differential 
evaporation of the water at the liquid-surface interface. 
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electrostatic effects, and gravity effects. In fact, many of these properties are more likely 
to disrupt ring formation rather than to promote it. Instead, the microfluidic flow of the 
drop is the result of a geometric constraint imposed by the pinned contact line and 
differential evaporation rates between the drop edge and center.
198
 The free surface when 
constrained by the pinned contact line pushes the solvent outward to compensate for 
evaporative losses. The evaporative flux J(r) reduces the height h(r) at every point r. 
However, since the contact line must be maintained, solvent losses at the edges must be 
replaced by liquid in the interior. Therefore, a radial flow is obtained, carrying any solute 
molecules or particles from the center of the droplet to the edge, where they are deposited 
during evaporation of the solvent.  
The evaporation rate across the drop is heterogeneous, where the fastest rate of 
evaporation occurs at the drop edge.
198
 During evaporation, solvent molecules rapidly 
interchange with the gas phase at the gas-liquid interface. The rate of evaporation and 
subsequent diffusion is dependent on the partial pressures between the solvent vapor and 
the ambient gas phase. At the drop surface, the solvent vapor reaches equilibrium and 
diffuses away from the drop into the ambient air. At the drop edge, where the substrate, 
liquid, and gas all meet, the solvent is bounded by relatively more ambient air than at the 
drop center. This gives solvent vapor more volume to diffuse into, therefore promoting a 
faster rate of evaporation when compared to the drop center. 
Drop pinning is essential for ring formation, or the drop will recede during drying, 
leaving a deposition of particles on the surface with deposition densities relative to the 
initial height of the drop. Line pinning can be achieved by two mechanisms: (1) a rough 
surface due to physical or chemical heterogeneities provides enough drag force to hold 
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the particles in place or (2) the surface is functionalized with a capture agent, which binds 
the particles or particle-antigen conjugates when they come into contact with the surface.  
In the initial stages of drop deposition, particles are homogenously distributed 
throughout the sample. The particles nearest to the drop edge become quickly trapped at 
the liquid-gas-substrate interface due to surface tension interactions, or potentially 
captured by the surface ligands. These particles protrude from the drop, maintaining a 
larger contact angle that what would be observed with a drop without the particles. For 
pinning to occur, the overall change in the contact angle must be > 0
o
. Evaporation 
decreases the contact angle, while the deposition of particles on the edge increase the 
contact angle governed by the following equation
199
: 
      

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    (4) 
where R = drop radius,  = drag coefficient for a particle placed in a film through which 
there is a mean liquid flow, nc = # of particle chains, a = particle radius, h0 = height of the 
center of the drop, Ca = capillary # representing the strength of viscous forces compared 
to the interfacial tension forces, and  = volume fraction of the particles in solution.  
In general, smaller initial contact angles improve ring formation because they result 
in a drop with a larger radius, promoting faster radial flow. Ring formation is also 
governed by the solute or particle concentration, where higher concentrations improve 
line pinning and subsequent ring formation. In addition, ring formation is inversely 
related to particle size, where smaller particles induce better ring formation. As the 
particles increase in size, the capillary force driving the receding of the pinned line 
overcomes the drag force and/or the binding energy of the surface ligand-biomarker 
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interaction keeping the particles in place. The result is that the particles are dragged 
inward with the receding drop.  
Another important factor to consider is the settling velocity of a particle, or the 
amount of time it takes a particle to settle out of solution. This factor is governed by the 
Stoke’s law: 
      

Vs 
2
9
p  f 

gR2    (5) 
where Vs = settling velocity; p = particle density; f = fluid density;  = fluid viscosity; 
R = particle radius; and g = acceleration due to gravity. Particles with high densities or 
large diameters may settle on the substrate before they are able to travel to the drop edge. 
Depending on the assay format, this physical property can be advantageous, especially if 
it is necessary to isolate the biomarker in the center of the drop. 
 
Functional Gold Nanoparticles as Aggregation Reagents 
Gold nanoparticles represent an ideal coffee ring capture agent due to their unique 
physical and chemical properties. Gold is chemically inert and does not readily oxidize 
below its melting temperature, making it stable under ambient conditions. Although gold 
has a high density (19.3 g/mL), citrate-stabilized nanoparticles below ~50 nm remain 
suspended in aqueous solutions. In addition, gold exhibits a visible surface Plasmon 
resonance induced by the collective oscillation of electrons at its surface (Figure 54), 
making it useful as a diagnostic sensor.
200-204
 These electrons form an electron gas that 
moves away from its equilibrium position when perturbed by light energy. Collective 
electron movement creates an induced surface polarization charge that serves as a 
restoring force on the electron gas. This results in collective oscillatory motion of the 
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electrons, much like what is observed for the vibrations of a water surface.
205
 Unlike 
other metals which have a surface Plasmon resonance in the UV, gold resonates in the 
visible spectrum, giving gold its representative red color in aqueous solutions.
206
 With a 
molar extinction coefficient of 3.64 x 10
8
 M
-1
cm
-1
, gold nanoparticles are visible into the 
picomolar range, which is where the lower limit of detection for pfHRP-II is in current 
diagnostic strategies.
161
 
Since the nanoparticles have a high surface area to volume ratio, the Plasmon 
frequency is sensitive to the dielectric nature of its interface with the surrounding 
solution. As interparticle distances between the NPs are reduced to less than the average 
particle diameter (i.e. during aggregation), their surface Plasmon bands couple, resulting 
in visible red shifts in absorption.
207
 In addition, only small aggregates containing 2-10 
particles per cluster are required to drastically shift the Plasmon resonance.
208,209
  
 
 
Another advantage of gold substrates is their reactivity towards thiolated ligands. 
These molecules create a monolayer on the surface, allowing for the selective 
Figure 54. Surface Plasmon resonance of AuNPs. Left: The oscillating electric field of light induces a 
collective dipolar oscillation of the free conduction-band elections of the AuNP. This results in 
absorption of light at ~520 nm for 15 nm AuNPs (right, first vial). As two or more nanoparticles come 
into close contact with one another, their surface Plasmon resonance bands couple, resulting in a red 
shift that makes the visible color of the particles shift to purple (right, second vial). 
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functionalization of surface substrates. These substrates can be tuned to detect specific 
biological or synthetic targets. Surface substrates also serve to stabilize these 
nanoparticles in a variety of physiologically relevant conditions.
210
 Mirkin et al. have 
previously designed DNA recognition elements by conjugating complementary thiolated 
surface ligands (mercaptoalkyloligonucleotides) onto different gold nanoparticles that 
hybridize upon heating, inducing Plasmon coupling of the nanoparticles.
200
 Recently, this 
technology has been applied to the detection of single nucleotide polymorphisms.
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AuNPs functionalized with small alkanethiols, cysteine, dithiolthreitol, and glutathione 
have also been designed as colorimetric sensors against heavy metals such as Hg(II), 
Pb(II), Ag(I), Cu(II), As(III), and As(IV) with limits of detection in the nanomolar 
range.
212-214
 In addition, ligand-functionalized AuNPs have been used as colorimetric 
sensors of proteins.
215,216
  
This chapter highlights the progress towards the development of a low-cost diagnostic 
for the detection of malarial pfHRP-II based on the coffee ring phenomenon. The unique 
microfluidics present in an evaporating colloidal solution generates a characteristic 
“coffee ring” stain of gold nanoparticles visible with the naked eye. Ni(II)NTA 
functionalized gold nanoparticles were synthesized by assembling a monolayer of a 
PEGylated NTA thiol onto the surface of the metal particles. These particles serve as an 
in-solution capture agent that aggregates in the presence of histidine-rich targets. The 
functionalized particles were characterized using transmission electron microscopy 
(TEM), UV-visible spectroscopy, and dynamic light scattering (DLS). Aggregation 
behavior of Ni(II)NTA NPs in solution was evaluated in the presence of a number of 
poly-amino acids, pfHRP-II mimics, pHRP-II, BNT-II, and recombinant HRP-II in a 
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concentration and pH-dependent manner. The effects of long term storage at 
physiologically relevant temperatures on the aggregation behavior of the particles are 
evaluated. In addition, the particle behavior in the presence of common human serum 
proteins at physiological concentrations was investigated. Using a Ni(II)NTA 
functionalized glass surface, HRP-II-Ni(II)NTA AuNP aggregates selectively formed 
rings on the surface during drop drying. Optimizations of reaction parameters, including 
the utilization of glycerol to reduce non-specific binding, are investigated. In addition, a 
simple ring quantification technique that can be adapted to a Smartphone is investigated. 
  
Experimental 
Reagents: AuNPs were purchased from Ted Pella Inc. All peptide reagents were 
purchased from Aapptec Inc. Antibodies for HRG characterization were purchased from 
Abcam Inc. Pooled human serum was purchased from Cole-Parmer Inc. Human plasma 
was purchased from Valley Biomedical Inc. Western blotting reagents were purchased 
from Invitrogen Inc. Ni(II)NTA functionalized glass slides used during the ring assay 
were purchased from Xenopore Inc. All other reagents were purchased from Fisher 
Scientific Inc. or Sigma Aldrich Inc. and used without modification. 
Synthesis of Ni(II)NTA AuNPs: A 2.3 nM solution of citrate-stabilized AuNPs (15 nm) 
was incubated with excess NTA-thiol ligand (>0.1 mM) (7) overnight at room 
temperature. After the initial loading period, the particles were centrifuged (45 min, 7,200 
x g) to remove the unreacted thiols and washed three times with 0.1M HEPES buffer (pH 
7.4) with Tween-20 (0.1-0.25%). The resuspended particles were charged with Ni(II) 
upon the addition of excess metal chloride solution (0.2 mM) in water and incubated 
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overnight. Next, the particles were centrifuged and washed three additional times with the 
final suspension buffer (0.1 M HEPES, 0.025% Tween 20) before storage or use. For the 
pH studies, the final suspension buffer for pH 5.5 was 0.1 M MES buffer, 0.025% Tween 
20 and for pH 9.0 was 0.1 M CHES buffer, 0.025% Tween 20. 
Synthesis of Mixed Monolayer Ni(II)NTA AuNPs: A 2.3 nM solution of citrate-
stabilized AuNPs (15 nm) were initially centrifuged (10 min, 12,500 x g) and 
resuspended in 50:50 water:DMF with 0.1% Tween 20. Next, the thiolated ligands (7) 
and (8) were incubated with the particles overnight with a final thiol concentration of 0.1 
mM. Next, the particles were purified by centrifugation and washing three times with 0.1 
M HEPES pH 7.4 with 0.1% Tween 20. Note: the first centrifugation time was extended 
to 1 hr due to the inclusion of DMF in the reaction solution. After purification, the 
particles were charged with 0.2 mM nickel(II) chloride solution overnight and purified 
(same as above).  
Characterization of Ni(II)NTA NPs: All particles synthesized in this study were 
characterized by TEM using a Phillips CM20 microscope. The hydrodynamic diameters 
of the particles were determined using dynamic light scattering, and Zeta potentials of the 
particles were determined using a Malvern Nano ZS. Spectral characterization was 
performed on either an Agilent 8453 UV-Visible spectrometer or a Bio-Tek Synergy HT 
plate reader. 
Synthesis of Protein Mimics: All peptides were synthesized using standard FMOC solid 
phase synthesis methods using an Apex 396 peptide synthesizer (Aapptec). BNT-II was 
synthesized using previously established methods using a MAP resin containing four 
branches.
217
 All linear peptides were synthesized using a Rink amide resin. The N-
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terminus of each peptide was acylated using DCM:acetic anhydride (1:1). Cleavage was 
performed by treating the functionalized resins with Reagent R (90:5:3:2 
TFA:Thioanisole:Anisole:EDT) and precipitating the peptides in cold ether. Purification 
was performed using a reverse-phase HPLC (Waters Prep LC 4000) with a Waters 2487 
dual wavelength detector and C18 column. The purified products were characterized 
using MALDI-TOF, and tested for activity against a rapid diagnostic test specific for 
pfHRP-II (Malaria Antigen P.f, Standard Diagnostics, Inc.). 
Purification of Histidine Rich Glycoprotein (HRG): Human HRG was purified from 
plasma (Valley Biomedical) by Ni-NTA (Qiagen) affinity chromatography. Plasma (45 
mL) was loaded onto a pre-equilibrated column of Ni-NTA resin (5 mL) and incubated at 
4
o
C overnight with shaking. This reaction mixture contained 50 mM imidazole during 
incubation. After incubation, the resin was washed with 10 column volumes of 50 mM 
phosphate buffer, pH 8.0 with 500 mM NaCl and 50 mM imidazole. Next, the proteins 
were eluted using a gradient of imidazole up to 500 mM. After pooling fractions 
containing HRG, they were concentrated using Amicon centrifuge filtration units (30 kDa 
mw cutoff) and washed with 0.1 M HEPES, pH 7.4. The concentration of the protein was 
determined using the Bradford assay. Confirmation of the product was determined by 
SDS-PAGE using a 4-10% Bis-Tris gel.  
Western Blot of HRG: Western blotting was also performed by running HRG on SDS-
PAGE and subsequently transferring to a PVDF membrane (Invitrogen). The membrane 
was then blocked with 5% skimmed milk in 10 mM Tris, 0.15 M NaCl, pH 7.4, 0.1% 
Tween 20 (TBST) overnight at 4
o
C. Next, a 1:1000 dilution of HRG rabbit primary 
antibody (Abcam) was added and incubated for 1 hr at room temperature. After washing 
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5x with TBST, the membrane was incubated with 0.5 g/mL HRP conjugated secondary 
anti-rabbit IgG antibody for 1 hr. After subsequent washes with TBST, the image was 
developed using the ECL system (Invitrogen).        
Titration Assays: Aggregation behavior of Ni(II)NTA NPs was performed by titrating 
various amounts of targets with the particles. Briefly, targets were dissolved in water and 
diluted to appropriate concentrations. To these solutions, AuNPs were added to a final 
concentration of 2.3 nM and incubated for 15 minutes unless otherwise noted. 
Aggregation was monitored either by UV-Vis or DLS. Any variations in the protocol will 
be mentioned in the text as appropriate. 
Synthesis of Functional Glass Surfaces: Synthesis of functionalized glass slides was 
performed using a modified protocol from Goddard et al.
218
 Glass slides purchased from 
Fisher Scientific were placed into a 5 slide glass chamber. A solution of piranha solution 
(50 mL) was added to the slides and incubated for 1 hour. Note: piranha solution is very 
dangerous and should be handled with extreme caution! The slides were washed five 
times with DI water followed by a wash with 95% ethanol. The slides were then 
incubated with a 50 mL solution of 2% aminopropyltriethoxysilane (APTES) in ethanol 
and mixed on an orbital shaker (80 rpm) for 10 minutes. After incubation, the slides were 
washed three times with ethanol, followed by three washes in water. The slides were then 
dried and cured in an oven 80
o
C for a minimum of 4 hours. Next, 5 amine functional 
slides were placed into a 5 slide glass holder and incubated for 2 hours with shaking with 
a 50 mL solution of 10 mM glutaraldehyde and 10 mM sodium cyanoborohydride in 
PBS. After activation, the slides were washed three times with DI water. The activated 
slides were further functionalized with amine-terminated ligands by incubating the slides 
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in 50 mL of 10 mM ligand and 10 mM sodium cyanoborohydride with shaking overnight. 
After overnight incubation, the slides were washed 5 times with DI water and dried under 
N2 prior to analysis. Contact angle measurements were conducted using the sessile drop 
method using a goniometer located in the Jennings Lab.  
Coffee Ring Assay Method 1: An 8 L sample of recombinant HRP-II in water was 
incubated with 2 L of 10 nM Ni(II)NTA AuNPs with 50% NTA coverage for 15 
minutes. After incubation, a 0.5 L aliquot was collected and deposited onto a Ni(II)NTA 
functionalized glass slide (Xenopore Corporation) and allowed to dry overnight. After 
drying, the slide was visualized with microscopy under phase settings. Next, the slide was 
washed copiously with water, dried, and reanalyzed using microscopy. 
Coffee Ring Assay Method 2: An 8 L sample of recombinant HRP-II in water was 
incubated with 2 L of 10 nM Ni(II)NTA AuNPs with 50% NTA coverage for 15 
minutes. After incubation, a 2.5 L solution of glycerol in water was added to the 
reaction mixture. After mixing, a 1 L aliquot was collected and deposited onto a 
Ni(II)NTA functionalized glass slide (Xenopore Corporation) and allowed to dry for ~1 
hour. After drying, the slide was visualized with the fluorescence microscope under phase 
settings. Next, the slide was washed copiously with water, dried, and reanalyzed using 
microscopy. 
Image Processing: Images for visualization were background corrected using ImageJ. A 
light background was created using a rolling ball radius of 50 pixels.  
Image Analysis and Quantification: Each image was processed using identical 
functions and settings. All processing steps were performed with custom macros in Image 
Pro Plus (v. 7) for consistency and reproducibility. First, the images were inverted so that 
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the positive signal in the assay (the presence of gold nanoparticles) can be represented by 
an increase in intensity. Then the images were processed through a deconvolution 
algorithm to flatten the background and set the lowest intensity values to zero. This 
algorithm is essentially a high-pass filter applied independently to each image. Using a 
predefined Area of Interest (AOI) at each corner, four samples of “background” intensity 
were captured to ensure consistency across each image. Another predefined AOI was 
then centered on the drop region to measure the total intensity of the drop. The size of 
each AOI was held constant to prevent user-bias. The final signal value was produced by 
subtracting the mean background intensity from the drop intensity. This value represents 
a difference in intensity of the region occupied by the drop compared with the rest of the 
image. 
Synthesis of M(II)NTA Polystyrene Microspheres: A 200 L stock solution of 0.99 
m amine-functionalized polystyrene microspheres (Spherotech; Cat # AFP-0852-2; 1.87 
x 10
7
 particles/L) were centrifuged and washed with 0.1M phosphate buffer pH 7.8 (1 
mL). To this solution, a 100 L aliquot of 1 mg of bis[sulfosuccinimidyl] suberate (BS3) 
in 10 mM phosphate buffer pH 7.4 was added and incubated for 30 min. After incubation, 
the particles were washed twice with 0.1M phosphate buffer and a solution of NTA-
lysine in the same buffer was added and incubated for 2 hours. The reaction was 
quenched upon removal of the supernatant and addition of 1 mL of Tris buffer (50 mM, 
pH 8.0). This solution was incubated for 15 minutes. Next, the particles were washed 
with phosphate buffer three times and then the particles were split into three batches for 
metal charging. Each aliquot was incubated with NiCl2, CuCl2, or ZnCl2 for 2 hrs. After 
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incubation, the particles were washed with 10 mM phosphate buffer pH 7.4 three times 
before use. 
Incubation of M(II)NTA Polystyrene Microspheres with TAMRA-HRP-II: A 5 L 
aliquot of bead solution (1.87 x 10
7
 particles/L) was incubated with 5 L of 0.1 mg/mL 
TAMRA-HRP-II for 5 min. The reaction was quenched upon the addition of 150 L of 
10 mM phosphate buffer pH 7.4. The particles were centrifuged and the supernatants 
were collected for fluorescence (ex: 541/10 em: 595/35) and compared to a positive 
control of TAMRA-HRP-II. 
Synthesis of NTA-thiol Ligand: Synthesis of the NTA-thiol ligand (7) is summarized in 
Scheme 2. It follows procedures developed by Schmitt et al
219
 and Tinazli et al
220
. 
Briefly, 11-mercaptoundecanoic acid (1) was protected by treatment with zinc acetate to 
yield 11-acetyl-sulfanyl-undecanonic acid (2). Next, (2) was coupled to triethylene glycol 
using DCC coupling chemistry in DCM to afford (3). The terminal alcohol of (3) was 
then activated with carbonyldiimidazole (CDI) in DCM to generate the imidazolid 
intermediate (5). After purification, (5) was nucleophilically attacked with the NTA 
lysine moiety (4) synthesized using the method developed by Schmitt et al
221
 to yield the 
protected NTA product (6). Final deprotection of the NTA-thiol ligand (7) was achieved 
with hydrazine acetate in DMF. Total yield under these conditions was 44.7%. The 
backfill ligand (8) was synthesized by deprotecting (3) using hydrazine acetate in DMF, 
followed by silica column purification. 
S-Acetyl-MUA (2). 
11-mercaptoundecanoic acid (MUA) (5.00 g, 21.75 mmol, Sigma, 95%) (1) was 
dissolved in DCM (60 mL) and AcOH (60 mL). Subsequently, Zn (10 g) was added to 
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the reaction mixture and incubated for 15 minutes. The reaction mixture was then cooled 
to 0
o
C prior to the addition of 30 mL of acetyl chloride (425 mmol). After 2 hrs of 
incubation, the reaction mixture was warmed to room temperature, and the reaction 
solution was separated from the Zn by filtration. Next, the organic solution was washed 
twice with chilled 0.1 M HCl and the solvent was evaporated. The crude product was 
purified by silica chromatography. TLC: Rf = 0.54 (ethyl acetate). Yield 5.25 g (88 %). 
1H NMR (CDCL3): : 2.83(t, 2H), 2.32(t, 2H), 2.30(s, 3H), 1.5-1.62(m, 4H), 1.2-1.4(m, 
12H). 
S-Acetyl-MUA-PEG-OH (3) 
To a solution of (2) in DCM (5.25 g, 20.2 mmol), triethylene glycol (27.5 mL, 20.6 
mmol) and DMAP (0.52 g, 4.26 mmol) were added, followed by the addition of DCC 
(5.51 g, 26.7 mmol). The reaction mixture was stirred overnight. The reaction mixture 
was then filtered to remove any urea and the organic solution was washed with 0.1 M 
HCl. The aqueous layer was extracted once with DCM. The combined organic phases 
were dried over Na2SO4 and the solvent was evaporated. The crude product (3) was 
purified by chromatography using ethyl acetate as the elutent. TLC: Rf = 0.49 (ethyl 
acetate). Yield 5.7 g (72%). 1H NMR (CDCl3):: 4.22(T, 2H), 3.6-3.75(m, 10H), 2.86(t, 
2H), 2.32(t, 2H), 2.31(s, 3H), 1.5-1.62(m, 4H), 1.2-1.4(m, 12H). 
S-Acetyl-MUA-PEG-imidazolid (4) 
To a 20 mL solution of (3) in DCM (2.85 g, 7.27 mmol), 2.35 g of carbonyldiimidazolide 
(CDI, 14.5  mmol) was added and incubated for 4 hours. The imidazolid product (4) was 
then purified by silica column chromatography using first a gradient of 50:50 
hexane:ethyl acetate followed by ethyl acetate. Yield 3.00 g (84.7 %). TLC: Rf = 0.57 
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(ethyl acetate). 1HNMR (CDCl3) : 8.30 (s, 1H), 7.60(d, 1H), 7.06(d, 1H), 4.57(t, 2H), 
4.17(t, 2H), 3.85(t, 2H), 3.6-3.7(m, 6H), 2.84(t, 2H), 2.30(t, 2H), 2.29(s, 3H), 1.5-1.62(m, 
4H), 1.2-1.4(m, 12H). MS: 487 (ESI
+
) (MH
+
).  
S-Acetyl-MUA-PEG-NTA (6) 
N,N-Methylcarboxy-L-lysine (1.4 g, 5.34 mmol), synthesized according the method of 
Schmitt et al.
221
 was dissolved in 15 mL of water, and the pH was adjusted to 10 with 
concentrated NaOH. This solution was mixed with 650 mg (1.33 mmol) of (4) in 15 mL 
of DMF and incubated overnight. The reaction was quenched with 15 mL of water and 
the aqueous solution was extracted three times with ethyl acetate. The aqueous phase was 
then acidified to pH 1.5 with 0.1M HCl and extracted four times with ethyl acetate. The 
combined organic fractions were washed with saturated sodium chloride and dried over 
anhydrous Na2SO4. Finally, the organic solvent was removed by vacuum. Yield 970 mg 
(quant.). 1HNMR (MeOD) : 4.19(t, 2H), 4.15(t, 2H), 3.5-3.8(m, 13H), 3.11(t, 2H), 
3.07(m, 2H), 2.85(t, 2H), 2.32(t, 2H), 2.29(s, 3H), 1.5-1.62(m, 8H), 1.2-1.4(m, 14H). MS: 
681 (ESI
+
) (MH
+
Na
+
), 703 (ESI
+
) (MH
+
2Na
+
). 
MUA-PEG-NTA (7) 
Hydrazine acetate (140 mg, 1.5 mmol) was added to a 100 mg (0.15 mmol) solution of 
(6) in DMF under nitrogen. The reaction mixture was mixed overnight and the solvent 
was evaporated. The crude product (7) was resuspended in water and acidified until a 
precipitate formed (pH = 1.5). The precipitated product was then extracted three times 
using ethyl acetate. The combined organic fractions were dried using anhydrous sodium 
sulfate, and the solvent was evaporated. The final product was then resuspended in water 
and lyophilized overnight. Yield 79.6 mg (83.2%). 1HNMR (D2O) : 4.19(t, 2H), 4.13(t, 
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2H), 3.5-3.8(m, 13H), 3.11(t, 2H), 3.06(m, 2H), 2.67(t, 1H), 2.48(t, 2H), 2.32(t, 2H), 1.5-
1.65(m, 8H), 1.2-1.4(m, 14H). MS: 637 (ESI
-
) (M
-
), 639 (ESI
+
) (MH
+
), 661 (ESI
+
) 
(MH
+
Na
+
). 
S-MUA-PEG-OH (8)  
Hydrazine acetate (10 g, 107 mmol) was added to a solution of (3) in DMF under 
nitrogen. The reaction mixture was mixed overnight, and extracted three times with water 
and DCM. Organic fractions were collected, dried with Na2SO4, and rotovapped. The 
crude oil was then purified with silica column chromatography using a 50:50 ethyl 
acetate:hexanes loading mixture, followed by elution with 75:25 ethyl acetate:hexanes. 
Samples were pooled and rotovapped, yielding a clear oil. 1HNMR (CDCl3) : 4.25 (t, 
2H), 3.6-3.8 (m, 10H), 2.55 (q, 2H), 2.34 (t, 2H), 1.5-1.7 (m, 4H), 1.2-1.4 (m, 12H). MS: 
351 (ESI
+
) (MH
+
), 368 (ESI
+
)(MH2O
+
). 
 
Results 
The unique physical and chemical properties of gold nanoparticles make them 
powerful reagents for possible low-resource point of care diagnostics. Gold particles have 
a high molar extinction coefficient of their surface Plasmon resonance absorption (3.64 x 
10
8
 M
-1
cm
-1
), which allows for spectrophotometric detection of these monodisperse 
particles in the high picomolar range. Further, the energy gap of the Plasmon band in 
these particles can increase as aggregation occurs, resulting in a visible red shift in the 
absorption, which is spectrophotometrically and visibly detectable. This allows for the 
detection of targets which induce crosslinking of the particles in the nanomolar range of 
sensitivity.  
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The key to utilizing such nanoparticles is to endow them with significant selectivity 
through surface ligand design. The use of a Ni(II)NTA surface ligand was inspired by 
nickel affinity chromatography of His-tagged proteins and the realization that pfHRP-II is 
nothing if not a naturally occurring His-tagged protein. For this study, a modular 
synthetic NTA ligand was designed to include a module for surface functionalization in a 
well-ordered monolayer, a module to minimize binding of non-specific interferents, and 
one to specifically target histidine-rich proteins. The use of a modified alkane thiol ligand 
provides the functionality to coordinate to the Au surface,
222
 while providing a well-
ordered packing layer near the NP surface. A polyethylene glycol (PEG) spacer provides 
a shield between the biological target and NP surface, thus reducing non-specific 
interactions between the two.
210
 The NTA moiety is attached adjacent to the PEG spacer. 
To complete the recognition element, Ni(II) is used to charge the chelate to provide the 
necessary affinity to histidine targets.
183
 
The general diagnostic strategy is outlined in Figure 55. Initially, Ni(II)NTA gold 
nanoparticles are incubated with a sample solution containing pfHRP-II. The particles 
and protein crosslink, creating AuNP aggregates, which can be detected 
spectrophotometrically, Next, a small volume (0.5-5 L) of reaction solution is deposited 
onto a surface coated with Ni(II)NTA and allowed to dry on the surface. The Ni(II)NTA 
on the surface of the slide serves to capture the protein-gold aggregate as it is deposited 
onto the pin line of the drop. After washing to remove any non-specific binding, the slide 
can be analyzed by visible inspection or microscopy to determine whether a ring was 
formed. A positive result occurs when the protein-nanoparticle aggregate specifically 
binds to the functionalized surface and the drop edge, resulting in a visible ring. If 
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pfHRP-II is not present, the particles (1) will not aggregate and (2) not specifically bind 
on the drop edge. Therefore, after washing, there should not be any ring formed, 
indicating a negative result.  
 
 
Synthesis and Characterization of Ni(II)NTA Nanoparticles 
NTA functionalized Au nanoparticles were synthesized following modified 
procedures developed by Barton et al.
223
 The NTA-thiol ligand (7) and PEGylated 
backfill ligand (8) were synthesized (Scheme 2) following modifications of Schmitt et 
al
219
 and Tinazli et al
220
. Surface functionalization of the Au nanoparticles was performed 
Figure 55. General coffee ring assay procedure using Ni(II)NTA AuNPs. Ni(II)NTA AuNPs are 
incubated in the presence of pfHRP-II, where they interact and crosslinked into large protein-particle 
aggregates. The aggregates are then deposited onto a Ni(II)NTA functionalized glass slide where they 
bind to the surface, pinning the contact line. Radial flow during drying concentrates the particles into 
the drop edge, leaving a visible ring after drying. If the biomarker isn’t present, the contact line isn’t 
pinned and the ring doesn’t form. 
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by incubating particles overnight either with purified NTA-thiol ligand in water or the 
mixed thiol solution in a 50:50 solution of DMF/water, allowing for efficient packing of 
the ligand onto the surface of the particles (Scheme 3). After incubation, the NPs were 
centrifuged and washed three times with buffer (0.1 M HEPES buffer, pH 7.4 and 0.1% 
Tween 20) to remove any unreacted thiols.  
 Scheme 2. Reaction scheme for the synthesis of the NTA-PEG-Thiol and HO-PEG-Thiol ligand. 
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The functionalized particles show a minimal red shift (~5 nm) in their surface 
Plasmon absorption, which is consistent with the dielectric changes induced by the 
monolayer of the thiolated ligands on their surfaces (Figure 56).
223,224
 The AuNPs have 
an average hydrodynamic diameter of 23-25 nm, which is 4-6 nm larger than the citrate-
stabilized stock particles. This particle size increase is consistent with the addition of the 
thiolated ligands onto their surfaces. Although there is no measurable trend in particle 
size between the particles synthesized with the backfill PEG ligand and NTA, Zeta 
potential measurements of the particles in 0.1M CHES buffer pH 9.0 without Tween 
indicate a clear increase of surface potential from uncharged alcohol-terminated particles 
to the carboxylic acid coated NTA particles. It should be noted that the particles in the 
presence of Tween all have similar Zeta potentials, suggesting a close association of the 
surfactant with the surface of the particles. Due to the low Zeta potential of the particles 
with < 10% surface coverage, Tween is necessary to maintain the long-term stability of 
the particles. This could also explain the similar hydrodynamic diameter measured for the 
particles in the presence of Tween.     
Scheme 3. Modular design of the M(II)NTA functionalized AuNPs. 
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Charging of the particles with Ni(II) was achieved by incubating the particles in 0.1M 
HEPES buffer pH 7.4 with 0.1% Tween 20 overnight with a 0.2 mM solution of NiCl2. 
After purification, the particles were characterized by UV-Vis spectroscopy, DLS, and 
imaged with TEM (Figure 57). Although the total recoveries were different for each 
particle condition, they exhibited similar spectrophotometric behavior. In addition, their 
hydrodynamic diameters were between 24-27 nm, which is on average 1-2 nm larger than 
the NTA-functionalized AuNPs. This slight increase in particle hydrodynamic diameter is 
likely due to the addition of Ni(II) to the NTA moiety. The measured Zeta potential was 
~9 mV under all conditions, which is likely due to the combination of charging the 
surface with Ni(II) and the inclusion of Tween. The Zeta potential was measured in 0.1M 
CHES buffer pH 9.0 with 0.1% Tween 20 because the particles are unstable without 
Tween when charged. During the purification process, it was noted that the particles 
when centrifuged created a more tightly associated pellet than what was observed when 
the uncharged particles. This further suggests that the metal is associated with the surface 
Figure 56. UV-Visible spectra and table of particle diameters and Zeta potentials for NTA and mixed-
monolayer AuNPs. 
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of the particles. TEM analysis revealed that the particles are primarily monodisperse, 
suggesting that they do not aggregate during preparation. 
 
 
 
 
Figure 57. Characterization of Ni(II)NTA and mixed-monolayer AuNPs. Top left: UV-Visible spectra 
of the particles. Top right: Table containing particle size and Zeta potential information for the particles. 
Bottom: Representative TEM images of each of the particles.  
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Synthesis and Characterization of Functional Glass Slides 
For the proof of concept studies described in this chapter, commercially available 
Ni(II)NTA glass slides were used (Xenopore Inc). However, glass slides with variable 
Ni(II)NTA ligand densities were also synthesized to understand the effect of capture 
ligand density and contact angle on the overall drop dynamics. Glass slides were initially 
cleaned with piranha solution to hydroxylate the glass surface (Scheme 4). Next, an 
amine functionalized silane (APTES) was added, creating an amine-functionalized 
surface. To add specific functionality to the surface, the crosslinker glutaraldehyde was 
added, forming a Schiff base, which is reduced to a stable 2
o
 amine linkage in the 
presence of sodium cyanoborohydride. To complete the functional surface, a solution 
containing varying ratios of NTA-lysine and 3-aminopropanol were added in the 
presence of sodium cyanoborohydride, yielding a functional surface. For slides 
functionalized with NTA, charging can be achieved upon the addition of a solution of 
NiCl2. 
 
 
Scheme 4. Synthesis scheme for Ni(II)NTA functionalized glass slides.  
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Contact angle measurements were conducted for each of the slides (Figure 58). 
Piranha treated slides are completely hydroxylated, yielding a contact angle < 5
o
. When 
the amine surface is added, the contact angle increases drastically to 56.8 + 5.4
o
. 
Glutaraldehyde addition increases the contact angle to ~ 70
o
. The mixed monolayers of 
Ni(II)NTA and aminopropanol backfill ligand have variable contact angles dependent on 
the surface coverage of Ni(II)NTA. As the NTA ratio is increased, the contact angle 
increases. These results suggest that the surface properties of the glass can be tuned to 
accommodate the requirements of the ring assay. 
 
 
In general, the surface functionality of the glass slides can drastically change the 
physical properties of ring formation. For example, slides with a high contact angle will 
generate smaller diameter drops that take significantly longer to dry. The tradeoff is that 
the resulting ring in the higher contact angle slides will be more concentrated, yielding a 
Figure 58. Surface characterization of functionalized slides using contact angle measurements. 
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more profound ring. For example, the commercial Ni(II)NTA slides have an 
experimentally determined contact angle of 71.3 + 2.0
o
. The drying time of a 1 L drop 
on the surface is 15 minutes, as compared to 8 minutes on a glass slide. If the volume is 
increased to 3 L, then the drying time spikes to 45 minutes, whereas drops that are 3-4 
times larger on the glass slide yield the same drying time. It is important to understand 
how these parameters affect the overall ring formation, as well as the processing time 
needed for the assay.   
 
Reaction Properties of Ni(II)NTA AuNPs 
A number of factors influence the aggregation behavior of the nanoparticles.  These 
include the affinity of the coordinating ligand to the Ni(II), the pKa of the potential 
coordinating moiety, electrostatics, hydrogen bonding, and the size of the aggregating 
target molecule. A systematic investigation of single amino acids, poly-amino acids and 
malaria biomarker epitope mimics were used to investigate the aggregation behavior of 
the 100% Ni(II)NTA AuNPs. A series of acidic and basic monomeric amino acids, 
including histidine, were incubated with the Ni(II)-charged particles at pH 5.5, 7.4 and 
9.0. No aggregation behavior was observed for any of the single amino acids across the 
entire pH range, consistent with simple coordinative saturation of the Ni(II) binding sites. 
Previous work conducted by Bae et al. showed that 3-5 nm metal-free (uncharged) NTA-
NPs did aggregate in the presence of monomeric histidine at pH 9, presumably through 
hydrogen bonding and electrostatic interactions.
225
 When Ni(II) was titrated into their 
reactions, the aggregation was inhibited. Thus, those single amino acids coordinating to 
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Ni(II) simply saturate the coordination sites on the nanoparticle resulting in no cross-
linked aggregation.  
The aggregation behavior of the Ni(II)NTA AuNPs was also examined in the 
presence of commercially available poly-L-histidine. At pH 7.4, PLH induced 
aggregation of AuNPs. Highlighted in Figure 59 are UV-Vis spectra, DLS profiles, and 
representative TEM images for Ni(II)NTA AuNPs reacted with PLH over a concentration 
range of 0-440 nM. UV-Vis spectroscopy indicates a red shift caused by PLH-induced 
crosslinking of the nanoparticles. Significant peak broadening is observed for all 
concentrations and the absorption maximum shifts by ~30 nm to 555 nm for the highest 
concentrations for Ni(II)NTA AuNPs. DLS measurements indicated that the average 
hydrodynamic diameter of gold nanoparticle aggregates approached 500 nm as a function 
of time and target concentration. Aggregation occurs rapidly, as indicated by the minimal 
change in the UV-Vis after 2 minutes of incubation. TEM images further confirm that the 
particles form large aggregates as a result of Ni(II)NTA-PLH crosslinking.  
142 
 
 
 
Imidazole has been used extensively during Ni(II)NTA purification strategies due to 
its ability to block weakly bound proteins for binding to Ni(II)NTA, as well as its ability 
to elute His-tagged proteins at elevated concentrations. It was of interest to determine if 
imidazole could also be used to inhibit aggregation of the particles by PLH. Figure 60 
demonstrates the aggregation behavior of Ni(II)NTA and NTA-functionalized particles in 
the presence of 125 nM PLH and varying concentrations of imidazole. Under the non-
blocking conditions, both NTA and Ni(II)NTA particles aggregate in the presence of 
Figure 59. Aggregation behavior of Ni(II)NTA AuNPs in the presence of PLH at neutral pH. A.) UV-
Visible spectra of aggregating AuNPs. B.) DLS measured hydrodynamic diameters at variable PLH 
concentrations. C.) Spectral profile as a function of time for particles incubated in 44 nM PLH. D.) 
Representative TEM image of particles aggregated in the presence of PLH. 
143 
 
PLH. However, when 100 mM imidazole is included in the reaction, only Ni(II)NTA 
particles aggregate. In addition, peak broadening is observed even in the presence of 200 
mM imidazole. For, Ni(II)NTA, it is expected that histidine can coordinate to multiple 
ligands on multiple particles, inducing crosslinking. As the imidazole concentration is 
increased, the coordination between the PLH and Ni(II)NTA is disrupted, inhibiting 
aggregation of the particles. In the case of the uncharged NTA particles, aggregation is 
likely an electrostatic event, where a small percentage of the histidines on PLH remain 
positively charged at neutral pH. The inclusion of imidazole serves to disrupt this 
electrostatic interaction, inhibiting aggregation. The fact that aggregation is inhibited at 
different concentrations further confirms that the Ni(II)NTA particles are in fact charged.   
 
Figure 60. Effect of imidazole on the aggregation of Ni(II)NTA AuNPs in the presence of PLH at 
neutral pH. Top: UV-Visible spectrum of Ni(II)NTA and NTA AuNPs in the presence of 125 nM PLH 
and variable concentrations of imidazole (Legend is on bottom left). Bottom right: Bar graph 
representing aggregation of the particles. The ratio of absorbance (A600/A525) is used to quantify the 
amount of aggregation observed with the particles. 
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PLH induced aggregation of Ni(II)NTA AuNPs also demonstrated a pH dependence 
over a range of pH 4 to pH 9. It should be noted that the Ni(II)NTA particles are unstable 
at pH’s below 4. In addition, it is known that Ni(II) leaches from NTA at low pH (Acidic 
solutions are commonly used to strip Ni(II) from Ni(II)NTA purification columns). 
Aggregation of the nanoparticles was detected spectrophotometrically for PLH below pH 
9.0. Figure 61 demonstrates the aggregation behavior of the Ni(II)NTA AuNPs in the 
presence of PLH (200 nM) at variable pH (4-10). Titrations with PLH were also 
conducted at selected pH’s (5.5, 7.4, and 9.0) to determine the limit of detection of 
aggregation. The limit of detection for aggregation was 32.6 nM at pH 5.5 and 14.0 nM at 
pH 7.4. No significant aggregation was observed at pH 9.0 even at ~425 nM. 
 
 
In addition to PLH, the Ni(II)NTA AuNPs aggregate in the presence of the basic 
polymeric amino acids PLL and PLR, consistent with the idea that multivalent targets 
induce the required crosslinks for aggregation (Figure 62). Each of the basic poly-amino 
acid ligands induced aggregation of the nanoparticles at each of the pH’s tested, while 
poly-L-aspartic acid (PLD) did not. It is likely that the multivalent carboxylic acids 
Figure 61. pH dependence of PLH-induced aggregation of Ni(II)NTA AuNPs. Left: Aggregation as a 
function of pH. Right: Titrations of PLH at selected pH’s. 
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outcompete NTA for binding of the Ni(II) ion and subsequently leach it from the 
nanoparticle, much like EDTA strips Ni(II) from an Ni(II)NTA agarose column.
183
 As 
aggregation could be inhibited above pH 7 by high concentrations of imidazole, these 
poly-amino acids likely serve as coordinative crosslinks between nanoparticles. In 
addition, aggregation of the particles appears to be dependent on the size of the polymer. 
Titrations performed with variable sized PLL polymers at neutral pH suggest that larger 
polymers induce aggregation of the particles at lower concentrations. Since larger 
polymers have more binding groups per polymer, it is likely that they are able to 
coordinate to multiple particles, inducing crosslinking at lower concentrations. This also 
correlates well with the higher limits of detection observed for PLH, for the polymer is 
only ~8,000 g/mol. 
 
Figure 62. Aggregation behavior of Ni(II)NTA AuNPs in the presence of acidic and basic poly amino 
acids at variable pH. Titrations with PLD (A), PLR (B), and PLL (C). Note: polymer sizes are 12,500 
g/mol for PLD, 12,500 g/mol for PLR, and 55,600 g/mol PLL, respectively. D.) Effect of polymer size 
on aggregation of Ni(II)NTA AuNPs. 
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To understand how the gold interacts with a biologically relevant sample, the 
particles were tested for aggregation behavior in the presence of two peptide mimics of 
the malarial protein pfHRP-II. pHRP-II is a 27 amino acid linear peptide containing the 
antigenic repeat (AHHAHHAAD)3 targeted by many RDT’s. BNT-II is a functional 
dendrimeric mimic of pfHRP-II previously synthesized by Zeigler and coworkers.
217
 This 
peptide contains 4 branched repeats of (AHHAHHAAD)2, which provides 16 heme 
binding motifs (its natural substrate) and a more realistic globular structure. Much like 
PLH, both mimics induced aggregation of the nanoparticles at pH’s below 6.5, however 
no particle aggregation was observed at neutral pH or higher (Figure 63). Titrations of 
the mimic targets at pH 5.5 revealed that the limit of detection of pHRP-II is 616.6 nM. 
With the more realistic biological mimic BNT-II, the limit of detection is improved to 
189.7 nM.  
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When the smaller malaria mimics, pHRP-II and BNT-II were reacted with Ni(II)NTA 
AuNP’s, the aggregation behavior of the NP’s was very sensitive to the pH of the 
solution. Indeed, BNT-II and pHRP-II only induced aggregation at pH’s below 6, 
showing a marked decrease in aggregation at pH’s higher than the pKa of histidine. As 
noted above, the ~8,000 mw amino acid PLH polymer induced aggregation of the 
Figure 63. Aggregation of Ni(II)NTA AuNPs in the presence of the malarial mimics pHRP-II and BNT-
II. A.) pH dependence of aggregation. B.) Titration of the mimics at pH 5.5. C.) Photographic image of 
Ni(II)NTA AuNPs in the presence of variable concentrations of malarial mimics. 
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particles throughout the pH range tested. This difference suggests that the smaller, 
globular mimics are aggregating through a mechanism different than only simple 
coordinative crosslinking.  At the pKa of histidine, 50% of the imidazole rings are 
deprotonated and available to coordinate the Ni(II) within the functionalized NP’s. The 
other 50% are protonated and available for the formation of hydrogen bonds to 
deprotonated histidines on other mimic molecules or electrostatic crosslinks. The 
resulting composite is likely an aggregate of mimics coordinated to the Ni(II) of the NPs 
and cross-linked to other target mimic molecules through hydrogen bonding and 
electrostatic interactions. Similar pH dependent assembly of multi-valent histidine coated 
nanoparticles has been previously observed.
226
 At higher pH, the small peptide mimics 
simply saturatively coordinate the Ni(II) sites covering the nanoparticles, effectively 
blocking aggregation. Unlike the larger amino acid polymers, the small size of these 
mimics prevents particle-particle crosslinks due to repulsive particle-particle forces.  
Consequently, little aggregation is seen above pH 6. Consistent with this model is the fact 
that over the range of detectable aggregation the ratio of BNT-II to particles is ~80:1 at 
the LOD. 
In complex biological mixtures such as human blood or saliva, proteins such as 
transferrin (TF), histidine rich glycoprotein (HRG), human serum albumin (HSA), and -
2 macroglobulin (2) are at high concentrations and could act as interferents to the 
aggregation assay by inducing non-specific aggregation. Physiological concentrations of 
these proteins were incubated with the Ni(II)NTA AuNPs at pH 5.5 and 7.4 and no 
aggregation was observed. UV-Visible spectral profiles of Ni(II)NTA AuNPs in the 
presence of the protein targets indicated a slight 2 nm shift for the Plasmon absorption 
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without any significant peak broadening (Figure 64). This is in stark contrast to particles 
reacted with the histidine-rich targets, which showed dramatic shifts in their Plasmon 
absorption to longer wavelengths. Interferents can also inhibit aggregation by absorbing 
to the particles and reducing the binding sites available to bind to the target. To test the 
aggregation properties of PLH in the presence of a complex mixture, a 9% serum solution 
was spiked into a solution of Ni(II)NTA AuNPs and reacted against PLH at neutral pH. 
Aggregation of the particles by PLH was drastically perturbed and only began to show 
particle instability micromolar range, as compared to ~25 nM in buffer only. In addition, 
the inclusion of 75 mM imidazole as a blocking agent did not recover the aggregation 
behavior as well. This suggests that complex mixtures may inhibit or drastically reduce 
the aggregation capabilities of the particles.  
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A requirement for the ultimate application of these functionalized nanoparticles in 
diagnostic assays is that non-specific interactions between the nanoparticles and other 
components found in a complex biological matrix do not induce aggregation. Current 
RDTs for malaria target pfHRP-II in either whole blood or saliva from an infected 
Figure 64. Aggregation properties in the presence of interfering proteins. A.) UV-Visible spectra of 
Ni(II)NTA AuNPs in the presence of physiological concentrations of serum proteins at pH 5.5. B.) UV-
Visible spectra in the presence of variable concentrations of HRG at pH 7.4. C.) Titration profile of the 
particles in the presence of serum and imidazole. 
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patient.
21
 Within such complex mixtures are proteins (e.g. HRG, TF, HSA, and 2) 
which are known to have some affinity to M(II)NTA columns at neutral pH.
177
 For 
example, HRG is a 75 kDa protein (507 amino acids) found in relatively high 
concentrations in human serum (100-200 g/mL).227 Of the six domains that make up the 
HRG protein, only the 60 amino acid region of the histidine-rich region (HRR) contains 
tandem repeats of histidine.
194
 Within this region, there are conserved repeats of GHHPH, 
which serve as a Zn
2+
 and heme binding domains. Much like pfHRP-II, HRG has been 
readily purified from serum using Ni(II)NTA agarose affinity chromatography.
228
 
However, the experimental evidence suggests that neither HRG nor HSA induces 
aggregation of the particles at pH 5.5, where aggregation was observed for the pfHRP-II 
mimics. In the case of HRG, the localization of the histidine-rich site concentrated in a 
single protein domain, as opposed to the complete distribution of such sites in pfHRP-II, 
limits possible crosslinked driven particle aggregation.  Furthermore, at low pH, these 
control proteins will be protonated, thereby reducing their ability to coordinate with 
Ni(II)NTA. Similarly, the negative control HSA protein did not induce aggregation of the 
nanoparticles.  While these control serum proteins may show some slight affinity to the 
nanoparticles, they do not induce aggregation at normal physiological concentrations.  
One of the primary advantages of using metal chelation based molecular recognition 
is the avoidance of thermally sensitive reagents such as antibodies. The long-term 
stability of the particles was evaluated by storing the particles at room temperature and 
37
o
C for several weeks before testing their aggregation behavior with PLH. After four 
weeks of storage, the Ni(II)NTA AuNPs showed no indication of storage-induced 
aggregation and similar aggregation behavior in the presence of PLH, suggesting that 
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these particles are stable throughout the study (Figure 65). Therefore, Ni(II)NTA AuNPs 
demonstrate the potential thermal and storage stability required for further development 
in global health applications. 
 
 
Aggregation Properties of the Mixed-Monolayer Ni(II)NTA AuNPs with 
Recombinant HRP-II 
 
After all of the systematic studies were conducted using 100% Ni(II)NTA AuNPs, 
polymeric amino acids and malarial mimics, a recombinant HRP-II was obtained. This 
particular protein consists of a 30 kDa monomer of pfHRP-II tagged with a 25 kDa 
glutathione-S-transferase (GST) tag, which is used for protein purification. This protein 
mimic, although not a complete replicate of pfHRP-II, should induce aggregation of the 
particles. A systematic study was conducted to determine the ideal pH range for 
aggregation as well as the optimal NTA surface coverage of the particles (Figure 66). 
Using a 1 nM particle concentration, the particles with 25 and 50% coverage are the most 
sensitive toward aggregation in the presence of recombinant HRP-II (135 nM). Particles 
Figure 65. Thermal stability of Ni(II)NTA AuNPs. Left: UV-Visible spectra of the particles after 
multiple weeks of storage at room temperature and elevated temperatures. Right: Aggregation behavior 
of the particles in the presence of PLH after multiple weeks of storage. 
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that are completely coated with Ni(II)NTA are less sensitive to aggregation, likely due to 
the steric crowding associated with loading such a bulky ligand to the surface of the 
particles. As the surface coverage is lessened to 1-10% coverage, the particles aggregate 
much less, suggesting that there is insufficient Ni(II)NTA coverage to induce particle 
crosslinking. Particles with only the HO-PEG-Thiol did not aggregate under any 
conditions tested, confirming that the Ni(II)NTA moiety is necessary for aggregation to 
occur. Using the 50% Ni(II)NTA nanoparticles, the pH dependence was investigated. 
Much like the peptide mimics, aggregation is most prevalent around the pKa of the 
protein, confirming that the mechanism proposed for the peptide mimics also holds true 
for recombinant HRP-II. 
 
 
The limit of detection for recombinant HRP-II was determined at variable 
concentrations of AuNPs. Spectrophotometric limits of detection for AuNPs is ~100 pM, 
so titrations were performed for 0.1-2 nM nanoparticle concentrations (Figure 67). There 
is an aggregation dependence on particle concentration from 0.5-2 nM. At concentrations 
below 0.5 nM, the concentration of particles is so dilute that there is no difference in 
Figure 66. Aggregation properties of mixed monolayer Ni(II)NTA AuNPs in the presence of 
recombinant HRP-II. Left: Comparison of aggregation properties as a function of surface coverage. 
Right: pH dependence of aggregation using the 50% Ni(II)NTA AuNPs. 
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aggregation. Using a sigmoidal curve fit for the higher concentrations, the limits of 
detection were determined to be 32.6 nM, 56.7 nM, and 80.7 nM for 0.5 nM, 1 nM, and 2 
nM particles, respectively. As the particle concentration is increased, it takes more 
protein to destabilize the particles and induce aggregation.     
 
 
Development of the Coffee Ring Assay 
Ring formation was initially inspected by depositing reaction solutions containing a 2 
nM solution of 50% Ni(II)NTA AuNPs in the presence of recombinant HRP-II. A 2 nM 
solution was chosen because it is very difficult to visible detect aggregation of AuNPs at 
lower concentrations. The incubation of the particles was conducted for 15 minutes, after 
which a 0.5 L drop was deposited onto a Ni(II)NTA functionalized glass slide and 
allowed to completely dry. After drying, the slide was washed copiously with water to 
remove any weakly bound particles and residual salts and inspected with microscopy 
(Figure 68). Upon visual inspection of the samples, a clear, well defined ring is present at 
concentrations above 80 nM. At higher concentrations (>120 nM, not shown), the 
particles are largely aggregated, and likely precipitate out of solution before they are able 
Figure 67. Limits of detection of recombinant HRP-II in the presence of variable concentrations of 50% 
Ni(II)NTA AuNPs. Left: Titrations at variable concentrations of particles and target. Right: UV-Visible 
spectral profile of the titrations with 0.5 nM Ni(II)NTA AuNPs. 
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to travel to the drying drop edge. With a density of 19.3 g/mL, large gold aggregates are 
likely to precipitate and readily settle out of solution. Below the limit of detection, there 
is residual gold remaining on the slide, but the ring diameter is significantly reduced. It is 
likely that during the drying process, the contact line recedes until the overall 
concentration of gold remaining in solution is high enough to induce contact line pinning.  
 
 
The total signal of the ring was measured using a custom protocol in Image Pro Plus. 
First, the images were inverted so that the gold nanoparticle ring represents a positive 
signal. The images were then background corrected to flatten the image and set the 
background to zero. Next, a predefined Area of Interest (AOI) at each corner was 
Figure 68. Coffee ring formation induced by HRP-II induced pinning of Ni(II)NTA AuNPs during drop 
drying. Top left: UV-Visible titration of recombinant HRP-II in the presence of 2 nM Ni(II)NTA 
AuNPs. Top right: Corrected total signal of the drops deposited onto a Ni(II)NTA glass slide. The 
corrected signal is calculated by subtracting the total signal by the control without protein. Bottom: 
Representative images of coffee rings formed as a function of protein concentration. 
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measured for signal intensity to normalize any variation across the image. Another 
predefined AOI was then centered on the drop region to measure the total intensity of the 
drop. The final signal value was produced by subtracting the mean background intensity 
from the drop intensity. This value represents a difference in intensity of the region 
occupied by the drop compared with the rest of the image. For the titration above, the 
overall signal is visibly higher for images that contain well-defined rings.  
Even though there is a clear indication that the presence of recombinant HRP-II 
induces contact line pinning and subsequent ring formation, it is not clear whether 
interfering proteins would also induce ring formation. Using a 1 L drop, samples 
containing 48 nM human serum albumin (HSA) and glutathione-S-transferase (GST) 
were deposited on Ni(II)NTA slides, allowed to dry, and washed (Figure 69). Both 
control proteins produced partial ring structures that generated high signal values. 
Although the proteins do not induce the in-solution aggregation of the particles, their 
interaction with the particles in a confined space along the drop edge assists in pinning 
the particles.  
 
Figure 69. Coffee ring formation induced by interfering proteins. A solution of 2 nM AuNPs was 
incubated with 48 mM GST or HSA and spotted onto a Ni(II)NTA slide and dried. The addition of the 
proteins induced ring formation. 
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One way to reduce this interfering interaction is to include glycerol in the drop 
solution, which prevents complete drying of the drop. Glycerol at relatively high 
concentrations is commonly used to disrupt the coffee ring phenomenon by disrupting the 
pinning of the contact line in microarray applications.
229
 Since this assay relies on 
coordinative capture of the particles on the surface rather than surface heterogenaties, 
glycerol may actually be useful in disrupting non-specific interactions. Glycerol was 
included in the drop by first incubating the particles in the presence of the recombinant 
HRP-II, followed by addition of a small volume of glycerol prior to drop formation. 
Figures 70 and 71 show the ring profiles as a function of glycerol for both particles only 
and particles incubated with recombinant HRP-II. The overall signal of the control is 
reduced 4-fold with the addition 1% glycerol, whereas the positive control maintains 
~60% of its total signal. Ring formation is maintained up to 2.25% glycerol, with a steady 
decrease in signal. At 2.5% glycerol, ring formation is completely disrupted. Inspecting 
the control drops prior to washing revealed a trend in film behavior. Without glycerol, 
there is a film deposited onto the slide, likely from the salts found in the drops. As the 
glycerol concentration is increased, a small collection of fluid remains on the slide, 
consistent with increasing volumes of glycerol which will not dry. For the negative 
control, the contact line doesn’t pin above 1% glycerol and the particles appear to recede 
with the residual glycerol. For the positive control, the behavior of the pre-washed slide 
indicates that the contact line is initially pinned and remains until the final stages of 
drying. The decrease in overall signal may be partially a result of increasing volumes of 
liquid that doesn’t dry.   
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Figure 70. Effects of glycerol on ring formation. Solutions containing 2 nM particles and either 64 nM 
recombinant HRP-II or water were incubated for 15 minutes, followed by the addition of glycerol prior 
to drop deposition. Background interference is significantly reduced with 1% glycerol and rings are stil 
visible for the positive controls in the presence of 2.25% glycerol. 
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After determining that glycerol can reduce the non-specific signal generated by a 
negative control, titrations were performed with recombinant HRP-II and the two control 
proteins with 1.75% glycerol. Figure 72 shows the functionalized surfaces after 
incubation with Ni(II)NTA nanoparticles in the presence of recombinant HRP-II, GST, 
and human serum albumin (HSA). In this case, not only are rings formed for recombinant 
HRP-II, there is essentially no background signal for either of the control proteins. In 
addition, there appears to be detectable ring formation at 64 nM, which was not observed 
under the glycerol-free conditions. Glycerol not only prevents the drop from drying, it 
also likely slows down the rate of evaporation. Since the reaction was allowed to proceed 
longer, it is likely this extended period of time allows the aggregates longer periods of 
time to bind to the functionalized surface.     
Figure 71. Signal intensity calculated using the custom protocol on Image Pro Plus software. As the 
concentration of glycerol is increased, the amount of background signal is significantly decreased while 
the ring signal remains relatively strong. 
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Figure 72. Selective coffee ring formation induced by recombinant HRP-II induced pinning of 
Ni(II)NTA AuNPs during drop drying. Using 1.75% glycerol during drop drying, the particles were 
incubated with varying concentrations of recombinant HRP-II and the interfering proteins. The presence 
of glycerol inhibits ring formation for the interfering proteins, while rings readily form in a 
concentration dependent for HRP-II. Middle left: Signal calculated using the custom analysis protocol. 
Bottom and right: UV-visible spectra of the particles in the presence of the proteins. 
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Discussion/Future Directions 
Based on the above data, we have successfully employed Ni(II)NTA AuNPs to 
induce a colorimetric change upon aggregation with recombinant HRP-II. Through radial 
flow of an evaporating drop, the aggregated particles radially flow to the drop edge and 
selectively form purple rings detectable by microscopy. Although AuNPs maintain 
several advantages including a high coefficient of diffusion due to their size, facile and 
well-developed surface chemistry, and colorimetric sensitivity toward particle 
aggregation, there are several fundamental limitations with the current system. AuNP 
rings at lower limits of detection are difficult to see by eye, likely due to their small sizes. 
In addition, the current limits of detection with this system are in the nanomolar range, 
which are still 1-2 orders of magnitude above the desired limit of detection. Although this 
current design appears to lack the robustness to be applicable in the field, the built-in 
modularity of the technology allow for the modification of assay components to improve 
the limits of detection. 
One obvious approach is to increase the size of the capture bead so that it provides 
more signal on a per bead basis. Larger gold nanoparticles are likely poor candidates 
because of their rapid settling velocities above 50 nm, as well as the complete loss of 
their colorimetric properties. Instead, larger particles consisting of other materials, such 
as silica or polystyrene can be used instead. For example, a 1 m polystyrene particle has 
a density of 1.05 g/mL, which makes it essentially soluble in water during the drop 
drying process. Work is currently being performed involving overcoating polystyrene 
microspheres with a layer of gold, which allows for facile surface functionalization of 
thiolated ligands. Previously, it was demonstrated that polystyrene particles readily form 
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rings in aqueous solutions (Figure 73). In addition, preliminary work shows that 
M(II)NTA polystyrene microspheres synthesized by chemical crosslinking of NTA to 
amine-functionalized microspheres selectively capture TAMRA-HRP-II at neutral pH. In 
addition, protein can be recovered off of the beads upon the addition of an imidazole 
solution (Data not shown). Although there is no indication that the ring assay would in 
fact work with these beads, their ability to capture HRP-II mimics is a promising step 
toward modifying the ring assay. 
 
 
Another modification of the current assay is to rethink how the coffee ring 
phenomenon is utilized. Although it is attractive to utilize radial flow to capture the beads 
onto the drying drop edge, most other solute materials, including interfering proteins, will 
also travel to the edge. Instead, an alternative design strategy has been developed in the 
Haselton lab that capitalizes on the radial flow to process the sample. Termed the “3-
Figure 73. Demonstration of M(II)NTA polystyrene as an alternative capture bead in the coffee ring 
assay. Left: Polystyrene microspheres readily form coffee rings on glass substrates. Right: 
Demonstration of the selective binding of HRP-II mimics to M(II)NTA functionalized polystyrene 
microparticles.  
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bead” assay, this method utilizes three unique beads that serve specific functions (Figure 
74). A control bead is introduced that always flows to the drop edge, serving to pin it in 
place and provide a control ring for reference. The other two beads are functionalized 
with capture ligands that selectively bind to the biomarker. One of these beads is 
magnetic, which allows for magnetic separation into the center of the drop, concentrating 
it. If selective capture is achieved, then both the magnetic and non-magnetic bead will be 
isolated in the center of the ring, yielding a colored bulls-eye. 
 
 
With the modified assay strategy in hand, optimization of the various parameters can 
be conducted. For example, the surface chemistry of the substrate can be tuned to 
Figure 74. Three-particle coffee ring assay format. Two capture beads, one of which is magnetic are 
crosslinked in the presence of the biomarker. A control bead is also included to serve as a pinning agent 
and subsequent control ring. If the biomarker is present, the non-magnetic capture bead is entrained 
with the magnetic bead, generating a bulls-eye in the center of the drop. In a negative sample, the non-
magnetic capture bead travels to the drop edge via radial flow and is deposited at the ring edge. 
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optimize sample resolution and drying time. In addition, the composition of the capture 
agent on the beads can be adjusted by the addition of backfill ligands, which could 
improve the overall signal of the assay. It is important to remember that every adjustable 
parameter is an opportunity to improve the overall efficacy of the assay and should be 
evaluated thoroughly.  
 
Conclusions 
In its current format, the limit of detection against recombinant HRP-II is two orders 
of magnitude higher that what is needed to match current diagnostic strategies. In 
addition, human whole blood poses a challenge because it provides colorimetric 
interference, as well as a potential aggregation inhibitor. As a standalone assay, this 
method doesn’t meet the demands necessary of a low resource diagnostic. To circumvent 
these challenges, modifications of the assay are currently being developed that capitalize 
on the signal enhancement of a larger reporter bead and the concentration of the bead into 
a small central dot. These modifications will hopefully improve upon the limit of 
detection obtained in the current single AuNP capture bead strategy. In addition, it would 
be ideal if the coffee ring assay must was compatible with the sample processing 
technologies outlined in Chapter V. Together, this processing technology could be 
coupled with the coffee ring assay to detect pfHRP-II from whole blood in a simple and 
self-contained diagnostic for use in the developing world.  
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APPENDIX A 
 
CRYSTAL ENGINEERING: SOLVENT EFFECTS ON -HEMATIN FORMATION 
 
Introduction 
Blood feeding organisms implicated in malaria (Plasmodium), schistosomiasis 
(Schistosoma mansoni) and Chagas disease (Rhodnius prolixus) all digest large quantities 
of hemoglobin to meet their nutritional requirements.
230
 During the process, amino acids 
necessary for development and heme (Fe(III)PPIX) are released. In its free state, heme 
induces oxygen dependent free radical formation
231,232
, lipid peroxidation
233,234
,  and 
protein
235
 and DNA
236
 oxidation. To eliminate heme toxicity, these organisms have 
developed a detoxification mechanism that converts the toxic free heme into a non-toxic 
crystalline form known as hemozoin.
237,238
 Powder X-ray diffraction analysis of this 
crystal revealed a triclinic unit cell with a space group of Pī.239 With average sizes in 
microns, the crystal is composed of heme dimers formed through reciprocal iron-
carboxylate bonds
240
, where one of the two propionic side chains of a heme molecule 
coordinates with the axial Fe(III) of another. The remaining propionic acid group then 
hydrogen bonds with an adjacent dimer, forming an extended network of dimers.
239
 
Hemozoin has traditionally been a key target in antimalarial drugs because disruption of 
crystal formation results in accumulation of free heme in the parasite, leading to death. 
Understanding the molecular details of hemozoin formation could lead to novel 
antimalarial designs.  
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Acquisition of hemozoin from model animals is labor intensive, and the yields are on 
the milligram scale at best. Research focused on hemozoin has relied heavily on a 
synthetic analog of hemozoin known as -hematin. These crystals are chemically and 
structurally identical. Various synthetic routes have been widely used as synthetic routes 
for b-hematin formation, including benzoic acid
241
, acetic acid
242
, neutral lipids,
243-245
 
detergents
246
, and alcohol
247
 systems. All the mentioned methods require that soluble 
heme is introduced to a crystal mediating system. Although each method appears to 
generate crystals, limited data is available on the comparability of -hematin synthesized 
using these various systems. Hemozoin synthesized by the different parasites possesses a 
conserved molecular structure however; crystal morphologies differ significantly between 
the species. Crystals synthesized by Plasmodium are very regular in shape with well-
defined crystal faces.
248
 S. mansoni derived hemozoin is roughly spherical and 
heterogeneous in size, ranging from 50 nm to a few micrometers in diameter.
248,249
 
Hemozoin crystals extracted from R. prolixus exhibit irregular surface topography and 
are generally much larger than crystals obtained from Plasmodium.
248,250
 It is likely that 
the size and morphology differences between the species are directly related to the 
mediators used by the different species during in vivo crystallization.  
This study focuses on the controllability of crystal morphologies using various 
solvent systems. A solvent mediated approach is a valuable method for investigating the 
mechanisms of chemical reactions in solutions that lead to crystal nucleation. 
Correlations between crystal morphologies and solvents’ water miscibility and polarity 
properties are investigated. The controllability of crystal habits through the manipulation 
of solvent selection was also examined. My primary contribution to this study was to 
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synthesize -hematin in the presence of a variety of solvents and analyze the products via 
scanning electron microscopy (SEM). 
 
Methods 
Synthesis of b-hematin with organic solvents: Hemin porcine (7 mg) was dissolved in 
500 mL of solvent. The solid was dissolved by sonication. To this solution, 500 mL of 50 
mM citrate buffer pH 4.8 was added and the solution was incubated at 40oC for 10 days. 
After incubation, the resulting crystals were centrifuged and washed with several aliquots 
of water and 0.1M sodium bicarbonate until the crystals were clean. The products were 
then dissolved in acetone and spotted onto SEM pucks and dried. The samples were then 
analyzed by SEM.  
 
Results 
Unlike -hematin synthesized with other solvent systems251,252 which produce 
homogenous, bricklike crystals resembling hemozoin from P. falciparum 
248,253
, crystals 
produced in the current organic solvent/citrate buffer systems exhibited distinct 
morphologies that are dependent on the solvent conditions. Crystals formed by DMSO 
and acetonitrile exhibited morphologies that are regular in shape with the longest 
dimension being a few microns (Figures 169 & 173). These crystals are brick shaped 
with tapered ends that resemble hemozoin extracted from P. falciparum as reported by 
Sullivan et al. and Noland et al.
250,253
 Crystals formed in the DMF system were 
significantly striated, with many of the crystals being smaller than 300 nm in size.   
168 
 
Less size homogeneity was observed for crystals formed with chloroform and 
toluene. There are still tapering effects, although they are less frequent that what was 
observed for acetonitrile, DMF, and DMSO. Crystals formed under these solvents appear 
plate-like (Figures 169, 172, and 173). Crystals from the toluene system are very thin 
and extend approximately six times longer than those synthesized by the DMSO and 
DMF systems (Figure 174). -hematin from the DCM system exhibits some level of 
crystal thickness with a smooth surface (Figure 171). Both DCM and toluene are only 
slightly soluble in water, so the likely location for -hematin formation is at the aqueous-
organic interface. Hexanes were also investigated, but didn’t promote -hematin 
formation. It is thought that the solvents must be at least slightly soluble so that some 
heme can reside in the aqueous phase for crystal promotion to occur. 
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Figure 75. SEM Characterization of -hematin synthesized with acetonitrile. 
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Figure 76. SEM Characterization of -hematin synthesized with chloroform. 
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Figure 77. SEM Characterization of -hematin synthesized with DCM. 
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Figure 78. SEM Characterization of -hematin synthesized with DMF. 
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Figure 79. SEM Characterization of-hematin synthesized with DMSO. 
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Figure 80. SEM Characterization of -hematin synthesized with toluene. 
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Conclusions 
This study provides a systemic approach to β-hematin crystal engineering. The 
introduction of heme to an acidic citrate buffered system containing water miscible 
solvents (DMSO, DMF, and acetonitrile) increased heme solubility and promoted 
spontaneous β-hematin crystallization. Morphological analysis of these crystals 
demonstrated brick-like structures, resembling Hz produced in P. falciparum. Slightly 
soluble solvents (DCM, chloroform, or Toluene) formed β-hematin exhibiting plate-like 
structures, similar to hemozoin synthesized by P. vivax. These results suggest that crystal 
size and morphology can be controlled by the mediating solvent system. 
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APPENDIX B 
 
SYNTHESIS OF PEPTIDES FOR RANDOM STUDIES 
 
This appendix highlights the peptides I synthesized that have been used for various 
experiments during my graduate studies. Each peptide was synthesized using standard 
continuous flow FMOC solid phase peptide synthesis protocols on an Apex 396 Aapptec 
Automated Peptide synthesizer. Each peptide was purified by using a C18 reverse-phase 
column on a Waters Prep HPLC. Fractions were collected, lyophilized, and characterized 
using MALDI mass spectrometry. Table 6 lists all of the peptides that were used in 
various experiments. The level of effort on my part varied from simply synthesizing the 
peptide on the resin and giving the protected product to the project leaders for 
deprotection and purification to personally purifying the samples. Following Table 6 are 
several Figures (81 & 82) representing purification and characterization of the peptides I 
performed.   
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Table 6. Peptides synthesized using standard solid phase FMOC peptide synthesis. 
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Figure 81.Characterization of HRP-II peptide mimics. HPLC purification spectrum of pHRP-II and 
BNT-II used in titrations with Ni(II)NTA AuNPs. MALDI characterization of pHRP-II 
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Figure 82. Selected MALDI spectrum for synthesized peptides. 
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